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Alzheimer’s disease (AD) is characterised by neuropathological deposits of amyloid 
plaques and neurofibrillary tangles. In AD, tau is abnormally phosphorylated and forms 
aggregates which spread trans-synaptically throughout the brain. The non-receptor-
associated tyrosine kinase fyn is up-regulated in a subset of tangle-bearing neurons in 
AD brain and fyn also phosphorylates tau. Most tau is axonally located, where it 
promotes microtubule stability. Both tau and fyn are found in dendrites, where they 
stabilise receptor complexes at the post-synaptic density. Tau is also trafficked to the 
plasma membrane in a phosphorylation-dependent process that requires fyn. Tau is 
also present in the extracellular space, which could play an important role in the spread 
of tau pathology in AD. The function of tau at the membrane, and the precise role of fyn 
in tau trafficking are unclear, but they suggest that fyn could contribute to tau 
propagation.  
Here, the role of fyn in tau release was investigated in organotypic brain slices. The 
neurotoxicity of soluble β-amyloid oligomers was examined in organotypic brain slices 
to investigate their impact on tau release. Interactions between tau and SH2 and SH3 
domains of fyn were confirmed. Furthermore, the precise binding site between the 
proline-rich region of tau and the fyn-SH3 domain was identified. Lentiviruses 
containing tau mutations that alter the tau-fyn interaction were used to determine the 
downstream effects in organotypic brain slices. Changes in tau and fyn were 
investigated in human post-mortem brain tissue from individuals with AD and from 
unaffected controls.  
The results presented in this thesis characterise tau-fyn binding and provide insight into 
the functional implications of this interaction in relation to tau propagation. 
Understanding the basis of the molecular interactions between tau and fyn will improve 
our understanding of these important molecular entities and may lead to the discovery 
of new therapeutic targets for dementia.  
4 
 
Table of Contents 
Declaration .................................................................................................................. 1 
Acknowledgments ...................................................................................................... 2 
Abstract ....................................................................................................................... 3 
Table of Contents ........................................................................................................ 4 
List of Tables ............................................................................................................... 8 
List of Figures ............................................................................................................. 9 
Publications arising from this thesis ...................................................................... 11 
Abbreviations ............................................................................................................ 12 
Amino acid code ....................................................................................................... 16 
Chapter 1 Introduction ......................................................................................... 17 
1.1 Clinical overview of AD .............................................................................. 17 
1.2 Neuropathology of AD ................................................................................ 18 
1.3 Genetics of AD ............................................................................................ 20 
1.3.1 Genetic alterations of tau in neurodegenerative disease ........................ 22 
1.4 Amyloid beta ............................................................................................... 27 
1.4.1 Amyloid precursor protein processing .................................................... 27 
1.4.2 Species, toxicity, and aggregation of Aβ ................................................ 29 
1.5 Tau ............................................................................................................... 30 
1.5.1 Tau structure .......................................................................................... 30 
1.5.2 Tau function ........................................................................................... 34 
1.5.3 Tau phosphorylation and function in health and in neurodegenerative 
disease  .............................................................................................................. 36 
1.5.4 Tau toxicity and propagation .................................................................. 40 
1.5.5 Kinases and phosphatases of tau .......................................................... 42 
1.6 Fyn ............................................................................................................... 44 
1.6.1 Fyn structure and regulation of kinase activity ....................................... 44 
5 
 
1.6.2 Function of fyn ....................................................................................... 47 
1.6.3 Potential involvement of fyn in Alzheimer’s disease pathogenesis ......... 49 
1.7 Synergistic toxicity between tau and Aβ in Alzheimer’s disease ............ 51 
1.8 Aims and objectives of the thesis ............................................................. 54 
Chapter 2 Materials & Methods ............................................................................ 55 
2.1 Materials ...................................................................................................... 55 
2.1.1 General molecular biology reagents ...................................................... 55 
2.1.2 Site-directed mutagenesis ..................................................................... 57 
2.1.3 Transgenic mice .................................................................................... 61 
2.1.4 General cell biology reagents ................................................................ 63 
2.1.5 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE)  .............................................................................................................. 67 
2.1.6 General cell culture reagents ................................................................. 68 
2.1.7 Antibodies .............................................................................................. 71 
2.1.8 Sandwich ELISA .................................................................................... 74 
2.1.9 Post-mortem human brain ..................................................................... 75 
2.2 Methods ....................................................................................................... 80 
2.2.1 Breeding and maintenance of transgenic mice ...................................... 80 
2.2.2 Cell culture methods .............................................................................. 80 
2.2.3 Protein extraction and fractionation ........................................................ 82 
2.2.4 SDS-PAGE ............................................................................................ 83 
2.2.5 Colloidal Coomassie blue staining ......................................................... 84 
2.2.6 Western blotting ..................................................................................... 84 
2.2.7 GST fusion protein pull-down ................................................................. 85 
2.2.8 Co-immunoprecipitation ......................................................................... 85 
2.2.9 Sandwich ELISA .................................................................................... 87 
2.2.10 Cell toxicity assays ................................................................................ 87 
2.2.11 Immunocytochemistry ............................................................................ 88 
6 
 
2.2.12 Molecular biology methods .................................................................... 88 
2.2.13 Data analysis ......................................................................................... 95 
Chapter 3 Tau release from organotypic brain slices......................................... 97 
3.1 Results ...................................................................................................... 100 
3.1.1 Characterisation of wild-type and fyn-/- organotypic brain slices ........... 100 
3.1.2 Tau is secreted upon stimulation of neuronal activity in organotypic brain 
slices  ............................................................................................................ 106 
3.1.3 Investigating the uptake of extracellular tau ......................................... 109 
3.1.4 Characterisation of soluble Aβ oligomers ............................................. 112 
3.1.5 Effects of soluble Aβ treatment on organotypic brain slices ................. 115 
3.2 Discussion ................................................................................................ 119 
Chapter 4 Fyn binds to PXXP motifs in the proline-rich region of tau ............ 123 
4.1 Results ...................................................................................................... 126 
4.1.1 Tau binds to both SH2 and SH3 domains of fyn in vitro ....................... 126 
4.1.2 Site-directed mutagenesis of PXXP motifs in full-length tau ................. 129 
4.1.3 P213-219 of tau is important for tau binding to the SH3 domain of fyn . 133 
4.1.4 Generation of lentiviral plasmids expressing wild-type and PXXP mutant 
tau  ............................................................................................................ 135 
4.1.5 Expression of wild-type and PXXP mutant tau in organotypic brain slices 
and primary neurons .......................................................................................... 140 
4.2 Discussion ................................................................................................ 144 
4.2.1 Discussion and summary of results ..................................................... 144 
4.2.2 Limitations of lentiviruses expressing tau ............................................. 147 
Chapter 5 Investigating interactions between tau and fyn in brain tissue ...... 148 
5.1 Results ...................................................................................................... 150 
5.1.1 Optimisation of tau-fyn co-immunoprecipitation assays using lysates from 
primary neurons and brain tissue ....................................................................... 150 
5.1.2 Fyn expression in the human brain ...................................................... 156 
5.1.3 Alterations in tau and fyn expression during the progression of AD...... 160 
7 
 
5.1.4 Tau and fyn expression in the soluble fraction of human brain ............. 164 
5.1.5 Disease-related changes in tau and fyn in the human brain ................. 166 
5.2 Discussion ................................................................................................ 173 
Chapter 6 Discussion ......................................................................................... 176 
6.1 Regulation of extracellular tau release ................................................... 177 
6.1.1 The role of fyn in tau release ............................................................... 179 
6.1.2 Implications of activity-dependent tau release for AD ........................... 179 
6.1.3 Uptake of extracellular tau ................................................................... 181 
6.1.4 Extracellular tau as a therapeutic target ............................................... 186 
6.2 Association between tau and fyn in AD .................................................. 188 
6.3 Identification of the binding site between tau and fyn ........................... 190 
6.3.1 Inhibition of tau-fyn interaction: a viable therapy? ................................ 193 
6.4 Concluding remarks ................................................................................. 195 




List of Tables 
Table 1.1 Tau mutations and their associated clinical phenotype ................................ 24 
Table 2.1. Plasmids used in this thesis ........................................................................ 55 
Table 2.2. Forward and reverse primers used for site-directed mutagenesis of tau ..... 58 
Table 2.3. Primers to introduce stop codon in 2N4R tau in pcDNA3.1-V5-His-TOPO .. 60 
Table 2.4. Primers for genotyping fyn-/- mice ............................................................... 61 
Table 2.5. Primers for genotyping tau-/- mice ............................................................... 61 
Table 2.6. Primary antibodies used for western blots and enzyme-linked 
immunosorbent assay (ELISA) ................................................................................... 71 
Table 2.7. Secondary antibodies used for western blots and ELISA ............................ 74 
Table 2.8. Case details for control and late-stage Alzheimer’s disease post-mortem 
human temporal cortex ............................................................................................... 76 
Table 2.9. Case details for control and Braak I-VI Alzheimer's disease post-mortem 
human temporal cortex ............................................................................................... 78 
Table 2.10. PCR cycling parameters for site-directed mutagenesis ............................. 89 
Table 2.11. PCR cycling parameters for introduction of stop codon ............................. 91 
Table 2.12. PCR cycling parameters for genotyping of fyn-/- and tau-/- mice ................. 94 
Table 5.1 Conditions used for co-immunoprecipitation of tau and fyn ........................ 154 
Table 5.2 Summary of significance values from western blots of tau and fyn in control 
and AD brain tissue ................................................................................................... 169 
Table 5.3 Analysis of correlation between the amounts of tau and fyn in control and AD 




List of Figures 
Figure 1.1 Neuropathology of Alzheimer's disease ..................................................... 18 
Figure 1.2 Non-amyloidogenic and amyloidogenic processing of APP ........................ 28 
Figure 1.3 Isoforms of tau protein and their domains .................................................. 31 
Figure 1.4 Amino acid sequence of 2N4R tau ............................................................. 32 
Figure 1.5 The paperclip model of tau ......................................................................... 33 
Figure 1.6 Phosphorylation sites on tau ...................................................................... 37 
Figure 1.7 Structure of fyn kinase. .............................................................................. 44 
Figure 1.8 Active and inactive conformations of fyn .................................................... 46 
Figure 3.1 Schematic of organotypic brain slice preparation. ...................................... 99 
Figure 3.2 Immunocytochemistry of organotypic brain slices .................................... 102 
Figure 3.3 Characterisation of organotypic brain slice cultures ................................. 104 
Figure 3.4 Tau release from organotypic brain slices from WT and fyn-/- mice ........... 108 
Figure 3.5 No detectable change in intracellular tau following exposure to KCl ......... 109 
Figure 3.6 Tau uptake by tau-/- organotypic brain slices .............................................. 111 
Figure 3.7 Characterisation of the soluble Aβ oligomeric preparation ........................ 113 
Figure 3.8 Aβ treatment of WT organotypic brain slice cultures ................................. 116 
Figure 4.1 Preparation and purification of GST fusion proteins ................................. 127 
Figure 4.2 Tau from primary cortical neurons binds to fyn-SH2 and fyn-SH3 ............ 128 
Figure 4.3 PXXP motifs in the proline-rich region of full-length tau ............................ 130 
Figure 4.4 Preparation and verification of mutant PXXP tau constructs .................... 132 
Figure 4.5 Identification of PXXP motifs critical for tau binding to fyn-SH3 ................ 134 
Figure 4.6 Schematic of protocol used to generate WT and mutant PXXP tau lentiviral 
constructs ................................................................................................................. 136 
10 
 
Figure 4.7 Transfection of tau-IRES and LV-tau in CHO cells ................................... 138 
Figure 4.8 Optimisation of LV-tau transduction in rat primary cortical neurons .......... 141 
Figure 4.9 Optimisation of LV-tau transduction in organotypic brain slices ................ 143 
Figure 5.1 Co-immunoprecipitation of fyn from rat cortical neurons .......................... 153 
Figure 5.2 Optimisation of antibodies against fyn ...................................................... 157 
Figure 5.3 Immunoprecipitation of fyn in human post-mortem brain tissue ................ 159 
Figure 5.4 Changes in tau phosphorylation over time in AD ...................................... 162 
Figure 5.5 Tau and fyn expression in soluble fractions of AD brain............................ 165 
Figure 5.6 Altered tau and fyn expression at late stages of AD (Braak stages V-VI) .. 168 
Figure 5.7 Correlation between disease-related changes in tau and fyn in AD brain . 171 
Figure 6.1 Potential mechanisms of tau secretion and uptake in neurons ................. 183 
Figure 6.2 Model of extracellular tau binding on M1 and modulation of NMDA receptors
 ................................................................................................................................. 185 
Figure 6.3 Interactions between tau and fyn-SH2 and SH3 domains ........................ 191 
11 
 
Publications arising from this thesis 
Lau, D.H.W., Pooler, A.M., Noble, W., and Hanger, D.P. Identification of the binding site 
between tau and fyn-SH3. (In preparation) 
Rodríguez-Martín, T., Pooler, A.M., Lau, D.H.W., Morotz, G., De Vos, K., Gilley, J., 
Coleman, M.P., and Hanger, D.P. Axonal mitochondrial number is reduced in neurons 
of mice expressing the P301L tau mutation associated with frontotemporal dementia. 
(In preparation) 
Hanger, D.P., Lau, D.H.W., Phillips, E.C., Bondulich, M.K., Guo, T., Woodward, B.W., 
Pooler, A.M., and Noble, W. Intracellular and extracellular roles for tau in 
neurodegenerative disease. (2014) J. Alzheimers Dis. 40:S37-45. PMID: 24595196 
Pooler, A.M., Phillips, E., Lau, D.H.W., Noble, W., and Hanger, D.P. (2013) 
Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 




aa Amino acid 
ABCA7 ATP binding cassette transporter 7 gene 
AD Alzheimer’s disease 
Aβ β-Amyloid 
AECM Albert Einstein College of Medicine 
AGD Argyrophilic grain disease 
AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA Analysis of variance 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
APS Ammonium persulphate 
BACE β-site APP cleaving enzyme 
BCA Bicinchoninic acid  
BIN1 Bridging integrator 1 gene 
BSA Bovine serum albumin 
bp Base pairs 
BME Basal medium Eagle 
BRET Bioluminescence resonance energy transfer 
CBD Corticobasal degeneration 
CD2AP CD2-associated protein gene 
CD33 Myeloid surface antigen CD33 gene 
Cdk5 Cyclin dependent kinase-5 
CHO Chinese hamster ovary 
CK1 Casein kinase 1 
CLU Clusterin gene 
CNS Central nervous system 
COS CV-1 in Origin with SV40 genes 
CR1 Complement receptor 1 gene 
13 
 
Csk C-src kinase 
C-terminus Carboxyl-terminus 
DIV Days in vitro 
DTT Dithiothreitol 
DMSO Dimethyl sulfoxide 
dNTP Deoxyribonucleotide triphosphate 
DSP Dithiobis[succinimidyl propionate] 
EBSS Earl’s balanced salt solution 
E.coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
EGFP Enhanced green fluorescent protein 
EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EPHA1 Ephrin receptor A1 gene 
ESLB Extra strong lysis buffer 
FAK Focal adhesion kinase 
FBS Foetal bovine serum 
FTD Frontotemporal dementia 
FTDP-17 Frontotemporal dementia and parkinsonism linked to chromosome 17 
g(av) Average gravitational force 
GFAP Glial fibrillary acidic protein 
GFP Green fluorescent protein 
GSK-3 Glycogen synthase kinase-3 
GST Glutathione-S-transferase 
GWAS Genome-wide association study 
HBSS Hank’s balanced salt solution 
HEK Human embryonic kidney cells 




iPSC Induced pluripotent stem cell 
IPTG Isopropyl-1-thio-β-D-galactopyranoside 
IRES Internal ribosome entry site 




LDH Lactate dehydrogenase 
LTD Long-term depression 
LTP Long-term potentiation 
MAP Microtubule-associated protein 
MARK Microtubule affinity-regulating kinase 
MAPT Microtubule-associated protein tau gene 
MCI Mild cognitive impairment 
MS4A Membrane-spanning 4-domains, subfamily A gene 
NMDA N-methyl-D-aspartic acid 
NR2b NMDA receptor subtype 2B 
NSE Neuron-specific enolase 
N-terminus Amino-terminus 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PBS-T PBS-Tween 
PCR Polymerase chain reaction 
PDL Poly-D-lysine 
PFA Paraformaldehyde 
PHF Paired helical filaments 
PICALM Phosphatidylinositol-binding clathrin assembly protein gene 
PKA Cyclic AMP-dependent protein kinase 
PP Protein phosphatase 
15 
 
PrPC Cellullar prion protein 
PSD-95 Post-synaptic density protein 95 
PS1 Presenilin-1 gene 
PS2 Presenilin-2 gene 
PSP Progressive supranuclear palsy 
OD Optical density 
RIPA Radioimmunoprecipitation assay 
rpm Revolutions per minute 
RPTPα Receptor protein tyrosine phosphatase-α  
rSAP Shrimp alkaline phosphatase 
sAPPα Soluble amyloid precursor protein α 
sAPPβ Soluble amyloid precursor protein β 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
S.E.M. Standard error of the mean 
SOC Super Optimal Broth with Catabolite repression 
SH Src homology 
STEP61 Striatal enriched phosphatase 61 
STS Staurosporine 
TAE Tris-acetate-EDTA 
TBS Tris-buffered saline 
TBS-T TBS-Tween 
TEMED N,N,N’,N’ tetramethylethylenediamine  
TMB 3,3’,5,5’-Tetramethylbenzidine 
TNE Tris-NaCl-EDTA 
TREM2 Triggering receptor expressed on myeloid cells 2 
TU Transducing units 




Amino acid code 
Alanine Ala A Methionine Met M 
Cysteine Cys C Asparagine Asn N 
Aspartic acid Asp D Proline Pro P 
Glutamic acid Glu E Glutamine Gln Q 
Phenylalanine Phe F Arginine Arg R 
Glycine Gly G Serine Ser S 
Histidine His H Threonine Thr T 
Isoleucine Ile I Valine Val V 
Lysine Lys K Tryptophan Trp W 




Chapter 1 Introduction 
1.1 Clinical overview of AD 
The first formal diagnosis of what is now known as Alzheimer’s disease (AD) was 
presented in 1906 by Alois Alzheimer (Alzheimer, 1907), who had examined a woman 
suffering from cognitive impairment that he had never seen before. His patient, Auguste 
Deter, was fifty years old when she was diagnosed with “senile dementia”, although in 
the present day she would most likely have received a diagnosis of early-onset AD. Her 
symptoms included aphasia, paranoia, rapid memory loss, auditory hallucinations, and 
disorientation. After she died, her brain tissue was obtained by Dr Alzheimer for 
histopathological analysis. In his findings, he noted the presence of significant cortical 
atrophy, leaving in its place characteristic fibrils that we now know as neurofibrillary 
tangles, composed of the tau protein. He also noted the deposition of “miliar foci” in the 
cerebral cortex, filled with a “peculiar matter” which is now known to be the β-amyloid 
(Aβ) protein of amyloid plaques (Strassnig and Ganguli, 2005). 
AD is the most common cause of dementia in the elderly population. The greatest risk 
factor for AD is age; typically, late-onset AD affects individuals aged 65 or above, 
whereas early onset forms of AD, usually caused by genetic mutations, are less 
common (Thies and Bleiler, 2011). Currently, the diagnostic criteria for AD are those 
proposed by the International Working Group for New Research Criteria for the 
Diagnosis of Alzheimer’s Disease (Dubois et al., 2014). The diagnosis of the early 
stages of AD has been refined due to improvements in technology and detection of 
early changes (Dubois et al., 2014). There are three stages of AD: preclinical AD, 
prodromal AD, and dementia due to AD, all of which display progressively worse 
symptoms. The first stage is asymptomatic in that there may be visible changes in 
biomarker profile, but the individual will not have developed any cognitive symptoms. 
Changes in biomarker profile include positive positron emission tomography scans 
using the Pittsburgh compound B (PiB-PET), which detects deposits of Aβ protein, or 
changes in levels of Aβ or tau in the cerebrospinal fluid (Dubois et al., 2010). 
Subsequently, individuals with prodromal AD display clinical symptoms, which include 
episodic memory loss characterised by low free recall, but these cognitive impairments 
do not affect the individual’s daily activities (Dubois et al., 2010). Cognitive testing is 
carried out using clinical tools such as the Mini-Mental State Exam which is a widely 
used screening test that measures several factors including orientation, memory, 
concentration, and language (Folstein et al., 1975). Finally, progression to the last 
stage of AD is typified by increasingly impaired episodic memory and impairment of 
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other cognitive functions, such as aphasia, apraxia, and agnosia with worsening of 
executive function (van der Flier et al., 2011). The progressive decline in cognitive 
function results in the individual eventually being unable to carry out daily tasks due to 
impaired judgment, disorientation, confusion, and problems with language and 
movement, therefore requiring full-time assistance. Those in the final stages of AD 
become extremely vulnerable to infections or complications due to immobility, 
ultimately leading to death. 
 
1.2 Neuropathology of AD 
 Morphologically, post-mortem brains from AD patients display severe brain atrophy 
compared to a cognitively normal individual (Holtzman et al., 2011). At the microscopic 
level, the hallmarks of AD pathology are characterised by neuronal loss and 
degeneration with intraneuronal neurofibrillary tangles, composed of the microtubule-
associated protein tau, and depositions of Aβ peptide in extracellular plaques (Figure 
1.1) (Holtzman et al., 2011).  
 
 
Figure 1.1 Neuropathology of Alzheimer's disease 
Aggregates of (A) Aβ protein and (B) tau protein are observed in brains of late-stage 
AD individuals. Extracellular Aβ plaques stained with an Aβ-specific antibody (A) and 
intracellular neurofibrillary tangles containing tau stained with an antibody specific for 




The inclusions of tau protein, in the form of pre-tangles, neurofibrillary tangles, and 
neuropil threads, occur long before the onset of clinical symptoms (Braak et al., 2013). 
Pre-tangles, which are composed of soluble but abnormally phosphorylated tau, start 
forming in the axon of diseased neurons, which then turn into neurofibrillary tangles 
positive for Gallyas silver iodide staining (Uchihara et al., 2001). Tangle-containing 
neurons can survive for several years, but following death of the neuron, extracellular 
“ghost tangles” can remain in the neuropil (Morsch et al., 1999). The formation of tau 
pathology follows a characteristic pattern of spreading throughout the brain during 
disease progression which is used to classify disease severity as Braak stages I-VI 
(Braak and Braak, 1991). At stages I and II, tau pathology is confined to the 
transentorhinal cortex. By stages III-IV, the pathology has progressed anatomically to 
involve the limbic region. In stages V-VI, severe tau pathology, including ghost tangles, 
is seen in the preceding regions and tau pathology finally consumes the isocortex 
(Braak and Braak, 1991; Braak et al., 2011). 
Isolation and purification of the amyloid constituent from the plaques revealed a 4 kDa 
polypeptide termed Aβ (Glenner and Wong, 1984; Masters et al., 1985). Aβ is derived 
from cleavage of the amyloid precursor protein (APP), which was isolated and 
sequenced in 1986 (Kang et al., 1987). Extracellular depositions of aggregated Aβ 
peptide, including species ranging from 39 to 42 amino acids in length, but 
predominantly 40 or 42 (Aβ40 or Aβ42, respectively) give rise to the accumulation of 
amyloid plaques in AD brain. Aβ42 is more abundant in AD brain due to its insolubility 
and propensity to fibrillise, compared to other species of Aβ (Serrano-Pozo et al., 
2011). Amyloid plaques are classified into two categories. Dense-core plaques stain 
positive for β-sheet dyes such as Congo Red and Thioflavin S, and are associated with 
toxicity of the surrounding neuropil, characterised by dystrophic neurites, loss of 
synapses and neurons, and activation of glial cells (Serrano-Pozo et al., 2011). On the 
other hand, diffuse plaques can be found in cognitively “normal” individuals as well as 
in AD brain and the Aβ that makes up the majority of the protein content in these 
plaques is not in a fibrillar form (Selkoe, 2011). Aβ plaques occur much later after the 
presentation of abnormal tau inclusions, generally in the fourth decade when pre-tangle 
pathology can already be observed (Braak et al., 2011; Braak et al., 2013). In AD, 
amyloid plaques preferentially appear in the cerebral cortex, particularly the isocortex 




1.3 Genetics of AD 
The relationship between plaques and tangles is not fully understood. However, it is 
generally accepted that Aβ accumulation in the brain initiates a pathological cascade 
triggering altered tau phosphorylation, resulting in the loss of neurons, eventually 
causing dementia. This is known as the amyloid cascade hypothesis (Hardy and 
Allsop, 1991; Hardy and Higgins, 1992). The strongest evidence for the amyloid 
cascade hypothesis came from the discovery of mutations in the APP gene on 
chromosome 21 in families with early-onset AD (Chartier-Harlin et al., 1991; Goate et 
al., 1991; Murrell et al., 1991; van Duijn et al., 1991). APP processing results in the 
production of both non-amyloidogenic products and several different Aβ species 
including those with 40 or 42 amino acids (Aβ40 and Aβ42) (O'Brien and Wong, 2011). 
The first mutations in APP were found in codon 717 which were point mutations that 
resulted in the substitution of valine with glycine, isoleucine, or phenylalanine (Chartier-
Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991; Naruse et al., 1991). 
Although these mutations are rare, they are not found in healthy individuals or in 
individuals with late-onset AD, indicating that APP 717 mutations, located just beyond 
the C-terminus sequence encoding Aβ, are pathogenic for early-onset AD. Additionally, 
another APP mutation, resulting in substitution of alanine by glycine at residue 692, 
was found in a Dutch family with “presenile dementia” (Hendriks et al., 1992). In 
support of the pathogenicity of APP mutations, transgenic mice expressing V717F 
mutant APP exhibit extracellular Aβ deposits, dystrophic neurites, gliosis, and synaptic 
loss consistent with AD (Games et al., 1995).  
Subsequently, a double mutation at residues 670/671 of APP, located in exon 16, was 
found in a large Swedish family with early-onset AD (Mullan et al., 1992). This mutation 
causes lysine-asparagine and methionine-leucine substitutions in the amino acid 
sequence of APP. In contrast to the APP 717 mutations, the 670/671 mutation resides 
at the N-terminus of the sequence encoding Aβ peptide. In cultured human embryonic 
kidney (HEK) 293 cells, overexpression of 670/671 mutant APP results in a six-to-eight-
fold increase in Aβ production compared to wild-type (WT) APP-expressing cells (Citron 
et al., 1992). Furthermore, mutation of codon 693 of APP (E693G), termed the Arctic 
mutation, also contributes to familial AD, resulting in decreased plasma Aβ levels but 
without affecting the ratios of Aβ40/Aβ42 (Nilsberth et al., 2001).  Overall, mutations in 
APP are rare, as they only account for a very small proportion of familial AD (Tanzi et 
al., 1992). Intriguingly, a recent mutation in APP (A673T) was discovered in an 
Icelandic cohort, with the finding that this mutated allele was actually protective for AD 
(Jonsson et al., 2012). This was suggested to be caused in part by altered processing 
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of APP by β-secretase enzyme, resulting in a decreased production of Aβ in transfected 
cells (Jonsson et al., 2012). However, a homozygous mutation at the same codon 
(A673V), is causative for AD and increases Aβ production and fibrillisation (Di Fede et 
al., 2009). 
Mutations were later discovered in the presenilin-1 (PS1) and presenilin-2 (PS2) genes 
on chromosomes 14 and 1, respectively, in families with early-onset AD (Clark et al., 
1995; Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995; Wasco et 
al., 1995). In particular, mutations in PS1 appear to be a frequent association in early-
onset familial AD individuals, while mutations in PS2 are rare in familial AD 
(Sherrington et al., 1996). In individuals with familial AD associated with mutations in 
PS1 or PS2, elevated Aβ42 was found in plasma compared to age-matched controls 
(Scheuner et al., 1996). Additionally, individuals bearing the E280A PS1 mutation were 
found to have significantly increased Aβ42 deposition when compared to sporadic AD 
individuals, indicating that these mutations enhance Aβ42 production (Lemere et al., 
1996). In further support of this suggestion, expression of PS1 mutations both in vitro 
and in vivo upset the ratio of Aβ40/Aβ42 production, leading to an elevation of Aβ42 which 
is more fibrillogenic than Aβ40 (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 
1997).  
There are also a number of genetic risk factors for AD. Most notably, the APOE gene 
has a significant effect on the risk of developing AD (Corder et al., 1993). There are 
three alleles in the APOE gene, APOE-ε2, APOE-ε3, and APOE-ε4. Individuals 
harbouring the ε4 allele have an increased risk of developing late-onset AD and this 
risk is further increased by homozygosity of the ε4 allele, whereas individuals with the 
ε2 allele have a reduced risk of AD or a later age of onset (Corder et al., 1993; 
Strittmatter et al., 1993; Chartier-Hariln et al., 1994; Blacker et al., 1997). Interestingly, 
the apolipoprotein E (ApoE) protein co-localises with neurofibrillary tangles as well as 
amyloid plaques, suggesting a pathogenic role of this protein in AD (William Rebeck et 
al., 1993; Benzing and Mufson, 1995), although its function in disease is not well 
understood. The presence of APOE alleles does not conclusively determine whether or 
not an individual will develop AD (Meyer et al., 1998). 
More recently, genome-wide association studies (GWAS) have provided evidence of 
several other genetic risk factors for sporadic late-onset AD, including CLU (encodes 
clusterin protein), CR1 (complement receptor 1), PICALM (phosphatidylinositol-binding 
clathrin assembly protein), BIN1 (bridging integrator 1), MS4A (membrane-spanning 4-
domains, subfamily A) gene cluster, EPHA1 (ephrin receptor A1), CD2AP (CD2-
associated protein), CD33 (myeloid surface antigen CD33), ABCA7 (ATP binding 
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cassette transporter 7), and TREM2 (triggering receptor expressed on myeloid cells 2) 
(Harold et al., 2009; Lambert et al., 2009; Corneveaux et al., 2010; Seshadri et al., 
2010; Hollingworth et al., 2012; Guerreiro et al., 2013; Jonsson et al., 2013). It is 
believed that these genes explain about 50% of late-onset AD, indicating there are 
remaining risk genes that have not yet been identified (Kamboh et al., 2012). 
Interestingly, the FYN gene, among others, has been flagged as a candidate gene in 
modulating APOE-ε4-dependent transcriptomic changes in AD (Rhinn et al., 2013). 
Although tau pathology is evident in the brains of individuals with AD, to date, no 
mutations causative for AD have been found in the gene encoding the tau protein, 
MAPT. A seminal finding was reported in 1998 (Hutton et al., 1998) when mutations in 
the tau gene were found to be causative for frontotemporal dementia and parkinsonism 
linked to chromosome 17 (FTDP-17), demonstrating that tau dysfunction alone was 
sufficient to cause neurodegeneration (Dumanchin et al., 1998; Hutton et al., 1998; 
Spillantini et al., 1998b; Rizzu et al., 1999). While no evidence for mutations in the 
MAPT gene in AD individuals has been established, tau mutations in FTDP-17 support 
the hypothesis that tau is causative for neurodegenerative dementias. 
 
1.3.1 Genetic alterations of tau in neurodegenerative disease 
The genetic basis of tau-mediated neurodegeneration is supported by the existence of 
two haplotypes at the MAPT locus on chromosome 17q21. H1, the more common 
haplotype, has been associated with several tauopathies, including corticobasal 
degeneration and progressive supranuclear palsy (PSP) (Baker et al., 1999; Houlden 
et al., 2001). There have been several sub-haplotypes identified within the H1 
haplotype, but it was later determined that only the sub-haplotype H1c is associated 
with PSP (Pittman et al., 2006). Conversely, the H2 haplotype is uncommon and 
involves a chromosomal inversion of ~900 kilobases, with a 238 base pair deletion in 
the intron upstream of exon 10 (Baker et al., 1999; Stefansson et al., 2005). It is 
negatively associated with PSP, suggesting that carriers of the H2 haplotype may be 
protected against disease (Baker et al., 1999). The H2 haplotype has been shown to 
be associated with increased expression of exon 3 of tau mRNA, especially in the 
frontal cortex (Caffrey et al., 2008; Trabzuni et al., 2012). The effect of MAPT haplotype 
on the risk of AD remains unclear. The H1c haplotype has been found to be associated 
with increased risk of AD (Myers et al., 2005; Myers et al., 2007), and a more recent 
study has provided more evidence for an association between the H1 haplotype and 
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AD (Gerrish et al., 2012). However, these studies need to be replicated with larger 
sample sizes. 
To date, several pathogenic mutations in MAPT have been discovered, including 
missense, deletion, silent, and intronic mutations (Table 1.1) (Spillantini and Goedert, 
2013). Although these mutations are pathogenic in tauopathies, none of them have 
been found to be causative for AD. Most of these mutations are coding mutations in 
exons 9-12 of MAPT. Mutations in tau are classified into two categories: mutations 
which act at the protein level and mainly affect microtubule binding or tau aggregation, 
and mutations which act at the mRNA level to influence the splicing of exon 10, 
therefore affecting the 3R to 4R tau ratio. For the most part, mutations which influence 
tau splicing tend to promote the inclusion of exon 10, resulting in over-production of 4R 
tau (Spillantini and Goedert, 2013). For example, evidence shows that tau containing 
frontotemporal dementia mutations such as P301L, R406W or ΔK280 tau accelerate 
aggregation of tau in vitro (Goedert et al., 1999; Nacharaju et al., 1999; Barghorn et al., 
2000). These mutations suggest that tau-mediated neurodegeneration stems from a 
gain of function rather than loss of function, as none of the mutations in tau have been 




Table 1.1 Tau mutations and their associated clinical phenotype  
Mutation Exon Clinical 
phenotype 
Reference 
R5H 1 FTD (Hayashi et al., 2002) 
R5L 1 PSP (Poorkaj et al., 2002) 
K257T 9 FTD (Pickering-Brown et al., 
2000; Rizzini et al., 
2000) 
I260V 9 FTD (Grover et al., 2003) 
L266V 9 FTD (Hogg et al., 2003; 
Kobayashi et al., 2003) 
G272V 9 FTD (Hutton et al., 1998) 
G273R 9 FTD (van der Zee et al., 
2006) 
-15, -10 Intron 9 FTD (Malkani et al., 2006) 
N279K 10 FTD (Wszolek et al., 1992) 
ΔK280 10 FTD (Rizzu et al., 1999; 
Momeni et al., 2009) 
L284L 10 FTD (D'Souza et al., 1999) 
L284R 10 PSP (Rohrer et al., 2011) 
ΔN296 10 PSP (Pastor et al., 2001) 
N296N 10 FTD (Spillantini et al., 2000) 
N296H 10 FTD (Iseki et al., 2001) 
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P301L 10 FTD (Dumanchin et al., 
1998; Hutton et al., 
1998; Spillantini et al., 
1998a) 
P301S 10 FTD (Bugiani et al., 1999; 
Sperfeld et al., 1999; 
Lossos et al., 2003) 
P301T 10 FTD (Llado et al., 2007) 
G303V 10 PSP (Ros et al., 2005) 
S305I 10 AGD (Kovacs et al., 2008) 
S305N 10 FTD (Iijima et al., 1999; 
Kobayashi et al., 2002) 
S305S 10 FTD, PSP (Stanford et al., 2000; 
Skoglund et al., 2008) 
+3, +11, +12, 
+13, +14, +16 
Intron 10 FTD (Hutton et al., 1998; 
Spillantini et al., 1998b; 
Yasuda et al., 2000; 
Miyamoto et al., 2001; 
Kowalska et al., 2002) 
+19 Intron 10 FTD (Stanford et al., 2003) 
L315R 11 FTD (van Herpen et al., 
2003) 
K317M 11 FTD (Zarranz et al., 2005) 
S320F 11 FTD (Rosso et al., 2002) 
P332S 11 FTD (Deramecourt et al., 
2012) 
G335S 12 FTD (Spina et al., 2007) 
G335V 12 FTD (Neumann et al., 2005) 
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Q336R 12 FTD (Pickering-Brown et al., 
2004) 
V337M 12 FTD (Sumi et al., 1992; 
Poorkaj et al., 1998) 
E342V 12 FTD (Lippa et al., 2000) 
S352L 12 Other tauopathy (Nicholl et al., 2003) 
S356T 12 FTD (Momeni et al.) 
V363I 12 FTD (Munoz et al., 2007; 
Anfossi et al., 2011) 
P364S 12 FTD (Rossi et al., 2012) 
G366R 12 FTD (Rossi et al., 2012) 
K369I 12 FTD (Neumann et al., 2001) 
G389R 13 FTD (Murrell et al., 1999; 
Pickering-Brown et al., 
2000) 
R406W 13 FTD (Reed et al., 1997; 
Hutton et al., 1998) 
N410H 13 CBD (Kouri et al., 2014) 
T427M 13 FTD (Giaccone et al., 2005) 
This table lists the known pathogenic mutations in MAPT and where they are located 
within the sequence (intron or exon). The clinical phenotype caused by each mutation 
is shown as well as the primary references. FTD, frontotemporal dementia. PSP, 




1.4 Amyloid beta 
1.4.1 Amyloid precursor protein processing 
APP is a transmembrane protein located in neurons that can be alternatively spliced 
into three major isoforms: APP695, APP751, and APP770, of which the shortest form 
APP695 is specifically expressed in the brain (Kang and Müller-Hill, 1990; O'Brien and 
Wong, 2011). Cleavage of APP can occur by two mutually exclusive pathways (Figure 
1.2). In the non-amyloidogenic pathway, APP is first cleaved by α-secretase within the 
Aβ domain, releasing an extracellular soluble fragment, sAPPα. Subsequently, γ-
secretase cleaves the remaining C-terminal fragment in the membrane (APP-CTFα) to 
produce the p3 fragment (Haass and Selkoe, 1993). In the amyloidogenic pathway, β-
secretase, which was subsequently identified as β-site APP cleaving enzyme (BACE), 
cleaves APP and releases a soluble fragment called sAPPβ (Vassar et al., 1999). 
BACE cleavage releases a C99 membrane-bound fragment, which can be further 
cleaved by γ-secretase to generate Aβ (Vassar et al., 1999). γ-secretase is a complex 
composed of at least four proteins, including presenilin 1 (PS1) or its homologue 
presenilin 2 (PS2), nicastrin, anterior pharynx-defective-1 (APH-1), and presenilin 
enhancer-2 (PEN-2) (Kimberly et al., 2003). The Aβ peptide generated from γ-
secretase cleavage of C99 at multiple sites ranges from 38-43 residues in length. 
Predominantly Aβ40 (90%) is produced, followed by Aβ42 (10%) which is believed to be 





Figure 1.2 Non-amyloidogenic and amyloidogenic processing of APP 
Cleavage of APP occurs on two mutually exclusive pathways: non-amyloidogenic and 
amyloidogenic. In the non-amyloidogenic pathway, APP is cleaved by α-secretase into 
sAPPα and CTF-α. CTF-α is then cleaved further by γ-secretase to release p3. In the 
amyloidogenic pathway, APP is first cleaved by β-secretase to produce sAPPβ and 
C99, which is retained in the membrane. C99 is subsequently cleaved by γ-secretase 




1.4.2 Species, toxicity, and aggregation of Aβ 
The amyloid cascade hypothesis postulates that Aβ plays a critical role in the 
pathogenesis of AD, driven by accumulation of toxic Aβ in neurons (Hardy and Selkoe, 
2002). However, contrary to this hypothesis, the number of Aβ plaques in the brains of 
AD individuals does not correlate well with disease severity (Arriagada et al., 1992; 
Gómez-Isla et al., 1997; Giannakopoulos et al., 2003; Nelson et al., 2009), and 
transgenic mouse models of AD overexpressing mutant APP or presenilin do not 
exhibit a correlation between the amount of Aβ plaques and severity of 
neurodegeneration (Benilova et al., 2012). Therefore, attention has shifted to studying 
the intermediate forms of Aβ species that accumulate prior to the formation of Aβ 
plaques. 
Soluble oligomeric Aβ extracted from brains of AD patients is a better correlate of 
disease progression than the presence of Aβ plaques (McLean et al., 1999; Mc Donald 
et al., 2010). Extracts of soluble Aβ oligomers, but not insoluble Aβ plaques, are able to 
induce synaptotoxicity in cultured rodent neurons, further supporting the idea that 
soluble species of Aβ are toxic while plaques are relatively inert (Shankar et al., 2008). 
Soluble Aβ resolves into several assemblies of various sizes on electrophoretic gels, 
but the smallest species that exert toxicity were proposed to be Aβ dimers (Shankar et 
al., 2008). 
However, caution must be used in interpreting studies using Aβ oligomers, as it is 
difficult to determine whether the assemblies of Aβ studied in different laboratories are 
identical. Aβ oligomers can be generated synthetically (Lambert et al., 1998), extracted 
from AD brain tissue (Shankar et al., 2008), or purified from mammalian cells (Shankar 
et al., 2007), but depending on the origin, the toxicity of the Aβ species can be highly 
variable. Synthetic Aβ oligomers have been suggested to be less neurotoxic than Aβ 
oligomers derived from cells expressing mutant forms of APP (Townsend et al., 2006). 
Other studies have since confirmed the variability of Aβ toxicity and the relatively 
weaker potency of synthetic Aβ oligomers compared to human brain-derived Aβ (Jin et 
al., 2011). The exact nature of the toxic species of Aβ is still elusive and the reality may 
be that a mixture of oligomeric Aβ assemblies exert neurotoxicity at varying potencies 
in vivo, although reproducing this is difficult due to the heterogeneity of Aβ species 




1.5 Tau  
1.5.1 Tau structure 
Tau is a microtubule-associated protein ubiquitously expressed in the brain (Binder et 
al., 1985) which binds to microtubules to promote their assembly and stabilisation. Tau 
protein is encoded by the MAPT gene on chromosome 17q21 and contains 16 exons 
(Neve et al., 1986; Andreadis et al., 1992). Alternative mRNA splicing gives rise to six 
possible isoforms of tau in the central nervous system (CNS), resulting from the 
inclusion or exclusion of exons 2, 3, and 10 (Cleveland et al., 1977; Couchie and 
Nunez, 1985; Goedert et al., 1989b). Alternative splicing of exon 10 gives rise to tau 
protein containing either three or four tandem repeat domains at its C-terminus (3R or 
4R tau, respectively) (Goedert et al., 1989a). At the N-terminus, exons 2 and 3 each 
encode inserts of 29 amino acids, resulting in three possible combinations of tau: 0N, 
1N, or 2N, in which exon 3 only appears if exon 2 is translated (Goedert et al., 1989b). 
Correspondingly, the combination of exons 2, 3, and 10 generate six isoforms of tau in 
the adult human brain, ranging from smallest to largest: 0N3R, 0N4R, 1N3R, 2N3R, 
1N3R, 2N4R with molecular weights of 48 to 67kDa (Figure 1.3) (Goedert et al., 1989b; 
Goedert and Jakes, 1990). In addition to these isoforms, a 110 kDa isoform of tau (also 
known as big tau) is found specifically in the peripheral nervous system. The sequence 
of big tau is identical to that of CNS tau, but big tau has an additional insert of 254 
amino acids at the N-terminus (Goedert et al., 1992). 
All six isoforms of tau are present in adult human brain, but the pattern of isoform 
expression is developmentally regulated. Foetal tau is mostly comprised of 3R tau, but 
the ratio of 3R to 4R tau gradually reaches a 1:1 ratio in adults (Goedert et al., 1989a). 
Additionally, the inclusion of exons 2 and 3 is observed only in adult human brain; 
during foetal development, only the shortest isoform, 0N3R tau, is expressed (Goedert 
et al., 1989b). 
The protein sequence of tau can be divided into distinct regions with differing functions. 
The N-terminus of tau, known as the projection domain, is overall negatively charged 
due to the high concentration of acidic residues (Himmler et al., 1989; Goedert et al., 
1991). The negatively charged residues suggest that the N-terminus of tau can 
protrude from the microtubule surface, which act as cross-bridges between 
microtubules and may determine the amount of spacing between microtubules 
(Hirokawa et al., 1988; Chen et al., 1992). In transfected PC12 cells, expression of an 
N-terminal fragment of tau (aa 1-202, excluding the microtubule binding domain) did 
not result in microtubule binding; instead, this region of tau localised to the plasma 
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membrane (Brandt et al., 1995). Moreover, the N-terminus of tau plays an important 
role in mediating interactions between tau and plasma membrane-associated proteins 




Figure 1.3 Isoforms of tau protein and their domains 
There are six main isoforms of tau that arise from alternative splicing of exons 2, 3, and 
10 (denoted E2, E3, and E10, respectively). Tau is comprised of distinct regions: the N-
terminal projection domain, the proline-rich region, the microtubule-binding repeat 
region, and the C-terminus (C-term). The different isoforms (2N4R-0N3R) denote the 
presence or absence of the alternatively spliced exons in the N-terminal (N) or 
microtubule-binding repeat (R) domains. 
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Tau also contains a proline-rich region at residues 151-243 (Figure 1.4) (Kolarova et 
al., 2012), which is required for both microtubule bundling and the association between 
tau and microtubules (Kanai et al., 1992). Within the proline-rich domain, there are 
seven overlapping sequences of PXXP motifs, where P is proline and X is any other 
amino acid (Figure 1.4). These PXXP motifs, located between residues 176-236 of tau, 
are highly conserved candidate SH3 binding domains, indicating that tau can associate 
with proteins containing SH3 domains, such as fyn, phosphatidylinositol 3-kinase, and 
phospholipase Cγ1 (Cheadle et al., 1994; Sparks et al., 1994; Lee et al., 1998; 
Reynolds et al., 2008; Usardi et al., 2011).  
 
 
MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT 
PTEDGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG 
TTAEEAGIGD TPSLEDEAAG HVTQARMVSK SKDGTGSDDK KAKGADGKTK 
IATPRGAAPP GQKGQANATR IPAKTPPAPK TPPSSGEPPK SGDRSGYSSP 
GSPGTPGSRS RTPSLPTPPT REPKKVAVVR TPPKSPSSAK SRLQTAPVPM 
PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHV 
PGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV 
QSKIGSLDNI THVPGGGNKK IETHKLTFRE NAKAKTDHGA EIVYKSPVVS 










Figure 1.4 Amino acid sequence of 2N4R tau 
The amino acid sequence of the longest isoform of tau, 2N4R, is shown. Amino acid 
numbering is in the right hand column. The proline rich region (residues 151-243) in the 
N-terminal part of tau is underlined. The seven PXXP motifs are highlighted in yellow.  
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The C-terminal half of tau contains the microtubule binding domain, which comprises 
three or four imperfect repeats, dependent on the presence or absence of the 
alternatively spliced exon 10. In contrast to the acidic nature of the N-terminus, the C-
terminus of tau is basic and therefore the terminal ends of tau have opposing net 
charges (Mandelkow and Mandelkow, 2012). A paperclip model for the structure of tau 
has been proposed, whereby the N- and C-terminal ends are brought together near the 
microtubule repeat region (Figure 1.5) (Jeganathan et al., 2006). Interestingly, the 
repeat domain alone has more propensity to aggregate than full-length tau (Wille et al., 
1992). Additionally, two hexapeptide motifs (VQIVYK and VQIINK) in the repeat region 
of tau from 275-280 and 306-310 residues of tau, respectively, are essential for 
aggregation of tau, which is observed in AD and other tauopathies (von Bergen et al., 




Figure 1.5 The paperclip model of tau 
The paperclip model of tau folding has been proposed, whereby the N- and C-terminal 
ends of tau are brought towards the centre of the repeat domain (R1-4). This folding 
back of N- and C-terminals is thought to be transient but becomes more stable in 




1.5.2 Tau function 
The main function of tau protein is to promote the assembly and stabilisation of 
microtubules (Weingarten et al., 1975; Cleveland et al., 1977; Mitchison and Kirschner, 
1984; Drubin and Kirschner, 1986). In cultured neurons, tau binds to the most dynamic 
microtubules at the distal axon, towards the growth cone (Kempf et al., 1996). Tau 
knockout mice survive, but they display decreased microtubule number and density in 
axons as well as decreased microtubule stability in small-calibre axons (Harada et al., 
1994). Tau-deficient mice also exhibit some muscle weakness and impaired motor 
coordination (Ikegami et al., 2000). The lack of a more severe phenotype due to loss of 
tau-dependent microtubule function appears to be indicative of a compensatory 
mechanism from other microtubule-associated proteins, particularly microtubule-
associated protein 1A (MAP1A) (Harada et al., 1994), raising the possibility that tau 
may have functions other than microtubule stabilisation. To investigate whether tau was 
important in neuronal maturation, tau knockout mice were created by replacement of 
exon 1 with a neomycin expression cassette to disrupt translation of tau protein 
(Dawson et al., 2001). Neurons from these tau-/- mice exhibited delayed axonal 
elongation during development, but otherwise the mice were viable and displayed no 
overt phenotype. There was also increased MAP1A expression in knockout mice at 
birth but this decreased to comparable levels with WT mice after 12 months, 
suggesting that although MAPs other than tau may be upregulated to compensate for 
loss of tau, it is not sufficient to restore the role of tau in axonal extension. The 
upregulation of MAP1A has also been described in an additional tau knockout mouse 
line (Fujio et al., 2007). 
Tau is also thought to play a role in regulating axonal transport by interfering with 
dynein and kinesin motility on microtubules, thereby affecting their ability to transport 
cellular cargoes (Dixit et al., 2008). However, examination of a third tau knockout 
mouse which produces a fusion protein of the first 31 amino acids of tau fused to 
enhanced green fluorescent protein (EGFP) and which does not display any overt 
phenotype when compared to WT mice (Tucker et al., 2001), showed that in this line, 
the loss of tau did not significantly affect axonal transport rates (Yuan et al., 2008). This 
is contrast to the findings of Dixit et al. (2008) and suggests that tau does not play a 
major role in axonal transport in vivo. To determine whether these findings are due to 
developmental defects caused by absence of tau, a conditional knockout mouse where 
tau expression is suppressed in adulthood could resolve the question of whether tau is 
required for neuronal function. 
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In addition to microtubule binding and stabilization, tau can also interact with actin 
filaments and this was shown in vitro and in vivo in Drosophila brain tissue (Fulga et al., 
2007). Purified tau incubated with polymerised actin filaments was shown to increase 
bundled F-actin in a sedimentation assay, which was abolished by immunodepletion of 
tau. Upon treatment with an actin-depolymerising drug, actin filaments pre-incubated 
with tau were more resistant to depolymerisation than in the absence of tau (Fulga et 
al., 2007). Using electron microscopy, pre-incubation of actin filaments with tau induced 
actin bundling as observed by closely packed parallel fibres (Fulga et al., 2007). The 
interaction of tau with actin is thought to be mediated by the microtubule-binding 
domain and the proline-rich domain (Yu and Rasenick, 2006; He et al., 2009). Although 
the proline-rich domain binds to actin with a lower affinity than the microtubule binding 
alone, this study demonstrates that multiple domains can promote actin bundling (He et 
al., 2009).  
Tau has also been detected in the nucleus in both neuronal cells and human brain 
tissue (Loomis et al., 1990; Wang et al., 1993; Brady et al., 1995; Liu and Götz, 2013), 
thereby suggesting a role for tau involving DNA interactions. Moreover, tau protein can 
form complexes with DNA in vitro, and heat stress was able to induce DNA damage in 
tau knockout neurons but not in WT neurons, indicating that tau has a neuroprotective 
role in maintaining DNA integrity (Sjöberg et al., 2006; Wei et al., 2008; Sultan et al., 
2011). Indeed, overexpression of tau in tau knockout neurons rescued heat-induced 
DNA damage (Sultan et al., 2011). Studies focusing on the functions of nuclear tau are 
sparse, but evidence appears to suggest that the proline-rich domain of tau has more 
propensity to interact with DNA (Wei et al., 2008). Interestingly, rod-like tau deposits in 
the nucleus were recently reported in the brains of individuals with Huntington’s 
disease and AD but rarely in control brain (Fernandez-Nogales et al., 2014). Moreover, 
neuroblastoma cells expressing truncated 4R tau (151-391) displayed nuclear 
localisation of transfected tau, in contrast to endogenous and full-length 2N4R tau 
which were predominantly localised to the cytoplasm (Paholikova et al.). As the tau 
protein encoded by this exogenously expressed tau included the proline-rich domain 
and the microtubule-binding domain, but excluded the N-terminus, this study suggests 
that the N-terminus of tau is not required for nuclear localisation. 
In recent years, there has been a concentration of studies investigating the function of 
dendritic tau. Tau localisation at the dendritic spine and at synapses has been 
demonstrated in WT mice, and dendritic tau can co-immunoprecipitate with PSD-95 
(postsynaptic density 95), a postsynaptic scaffolding protein (Ittner et al., 2010; 
Mondragon-Rodriguez et al., 2012; Frandemiche et al., 2014; Kimura et al., 2014). 
Thus the presence of tau at the synapse under normal, non-pathogenic conditions 
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indicates that there may be a physiological role of tau in synaptic function. Tau 
knockout mice show mislocalisation of the dendritic protein fyn to the neuronal cell 
body, and reduction of N-methyl-D-aspartate (NMDA) receptor stabilization (Ittner et al., 
2010). NMDA receptor-induced long-term depression (LTD) results in a transient 
increase of tau phosphorylation at several epitopes (S199, S202, T205, T231, S235, 
S396, S404) without increasing total levels of tau (Mondragon-Rodriguez et al., 2012). 
Induction of long-term potentiation (LTP) and NMDA receptor activation also induced 
translocation of tau, PSD-95, fyn, and actin into the postsynaptic density fraction of 
cultured neurons, suggesting that tau is important in synaptic remodelling following 
synaptic plasticity (Frandemiche et al., 2014). Stabilisation of actin with an actin-
polymerising compound also resulted in tau translocation to dendritic spines, indicating 
that tau can respond to actin-dependent spine remodelling (Frandemiche et al., 2014). 
In another study, tau was demonstrated to be required for LTD induction in the 
hippocampus, and LTD also caused phosphorylation at S396/S404 of tau (Kimura et 
al., 2014). Taken together, these data provide evidence for the hypothesis that tau 
plays an important role at the synapse. 
Increasing evidence supports the idea that tau may also act as a signalling molecule. 
Several signalling molecules have been reported to interact with tau, including src 
family tyrosine kinases, phospholipase C γ, phosphatidylinositol 3-kinase, Grb2, 
histone deacetylase 6, and 14-3-3 (Jenkins and Johnson, 1998; Agarwal-Mawal et al., 
2003; Reynolds et al., 2008; Perez et al., 2009; Usardi et al., 2011). More specifically, 
tau has been found to bind to and target the non-receptor-associated tyrosine kinase 
fyn to the postsynaptic site to act as a protein scaffold in dendrites (Ittner et al., 2010). 
In oligodendrocytes, tau binds to fyn and promotes outgrowth of oligodendrocytes by 
tethering tau to microtubules (Klein et al., 2002). In cultured cells, tau facilitates src-
mediated actin remodelling induced by growth factor stimulation (Sharma et al., 2007). 
Whilst the function of membrane-associated tau remains to be fully elucidated, the 
presence of tau at the neuronal membrane supports the growing evidence for the 
involvement of tau as a signalling molecule at this site (Brandt et al., 1995; Maas et al., 
2000; Reynolds et al., 2008; Pooler et al., 2012). 
 
1.5.3 Tau phosphorylation and function in health and in 
neurodegenerative disease 
Phosphorylation is the most common post-translational modification of tau, and 
abnormal phosphorylation of tau is observed in many tauopathies, including AD. There 
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are 85 serine, threonine, and tyrosine residues along the tau protein sequence, and 
approximately 19% of these sites are phosphorylated in normal brain, increasing to 
more than 50% in AD brain (Figure 1.6)(Hanger and Noble, 2011; Noble et al., 2013). 
Many of these phosphorylatable residues are clustered in the proline-rich domain of tau 
and phosphorylation at these sites is likely to play a role in modulating structure and/or 
tau function.  
 
Figure 1.6 Phosphorylation sites on tau 
Schematic of the longest isoform of tau and the relative positions of the 
phosphorylation sites on tau in Alzheimer brain. There are 85 serine, threonine, and 
tyrosine residues of tau which can be phosphorylated by kinases and are clustered 
around the proline-rich domain and the regions surrounding the microtubule binding 
domain. Image from Noble et al. (2013). 
 
There is substantial evidence that phosphorylation of tau in and around the C-terminal 
repeat region can influence its ability to bind to microtubules. Overexpression of 
microtubule affinity-regulating kinase (MARK), a kinase which phosphorylates tau at 
KXGS motifs including S262, S324 and S356 in microtubule-binding repeats 1, 3 and 4 
in tau, results in its detachment from microtubules and decreased microtubule stability 
(Drewes et al., 1997). Additionally, phosphorylation at these sites is protective against 
tau aggregation into paired helical filaments (Schneider et al., 1999). Phosphorylation 
at S214 also leads to the dissolution of tau binding to microtubules in vitro (Illenberger 
et al., 1998). Furthermore, phosphorylation of tau at T231 by glycogen synthase 
kinase-3β (GSK-3β) also decreases the association between tau and microtubules 
(Cho and Johnson, 2003). In contrast, tau phosphorylated at T231 can bind to prolyl 
isomerase Pin1, which restores its ability to bind to microtubules, illustrating the 
complex nature of the coupling of tau phosphorylation and function (Lu et al., 1999). 
As tau phosphorylation is a key regulator of its interaction with microtubules, tau 
phosphorylation can also affect axonal transport of cellular cargoes. In transgenic mice 
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expressing the tau mutation K369I, which is causative for frontotemporal dementia, 
hyperphosphorylated tau has impaired interaction with c-Jun N-terminal kinase-
interacting protein 1 (JIP1) (Ittner et al., 2009). This leads to the translocation of JIP1 
from the axon to the cell body, which impedes the ability of JIP1 to mediate binding of 
cargoes to kinesin, thereby altering axonal transport (Ittner et al., 2009). Mitochondrial 
transport also appears to be regulated by tau phosphorylation. Phosphorylation of tau 
at S199, S202, and S205 by mutating each serine to aspartic acid in order to mimic 
phosphorylation, reduced the movement of mitochondria in neurite processes in PC12 
cells as well as in axons of primary cortical neurons (Shahpasand et al., 2012). The 
phosphorylation of tau can also modulate tau transport along microtubules. Inhibition of 
GSK-3, a tau kinase, reduces tau phosphorylation. GSK-3 inhibition in primary rat 
cortical neurons expressing tau fused to EGFP reduced the rate of axonal tau transport 
(Cuchillo-Ibanez et al., 2008). Expression of pseudophosphorylated tau at 18 or 27 
sites by substituting serine/threonine residues with glutamic acid significantly increased 
the rate of axonal tau transport, which was not due to differences in tau concentration 
(Cuchillo-Ibanez et al., 2008). In contrast, expression of a non-phosphorylatable tau 
mutant where 18 serine/threonine residues were mutated to alanine decreased the rate 
of tau transport (Cuchillo-Ibanez et al., 2008). This is thought to be mediated by the 
interaction between tau and kinesin-1, which is facilitated by GSK-3-induced 
phosphorylation of tau (Cuchillo-Ibanez et al., 2008). 
The structure of tau is also tightly linked to its phosphorylation state, as evidenced by 
studies showing that tau phosphorylation precedes its aggregation. In vitro experiments 
with pseudophosphorylated tau at S396/S404 by mutation of serine to glutamic acid 
show that phosphorylation at these sites significantly potentiates rates of tau assembly 
into filaments (Abraha et al., 2000). Pseudophosphorylation at other residues in the C-
terminal region of tau also resulted in enhanced propensity to aggregate into fibrils, 
whereas phosphorylation of N-terminal residues did not alter the self-aggregation of tau 
(Haase et al., 2004). These studies show that phosphorylation of tau differentially 
regulates its structure, dependent on the phosphorylated residue(s).  
In pathological conditions, evidence suggests that aggregation of tau is preceded by its 
phosphorylation. Phosphorylated tau isolated from AD brain self-assembles into paired 
helical filaments (PHFs), and in vitro phosphorylation of recombinant tau was sufficient 
to induce self-assembly into PHFs (Alonso et al., 2001). Moreover, it has been shown 
in transgenic mouse models of tauopathy that increased tau phosphorylation occurs 
prior to the onset of tau PHFs (Sahara et al., 2002; Andorfer et al., 2003; Oddo et al., 
2007; Delobel et al., 2008; Mastrangelo and Bowers, 2008). Likewise, lithium-mediated 
inhibition of GSK-3, a tau kinase, was able to decrease tau phosphorylation at specific 
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epitopes and reduce tau aggregation in a mouse model of tauopathy (Noble et al., 
2005). These data imply that tau phosphorylation may play a role in the formation of 
tau aggregates under pathological conditions. 
The subcellular localisation of tau may also be regulated by phosphorylation. For 
instance, membrane-associated tau is dephosphorylated at epitopes that are typically 
abnormally phosphorylated in AD (Arrasate et al., 2000; Maas et al., 2000; Pooler et 
al., 2012), whereas cytosolic tau contains a mixture of both dephosphorylated and 
phosphorylated tau. Furthermore, phosphomimetics of tau where residues at the N-
terminal half of tau were mutated to mimic phosphorylation, were shown to result in a 
reduction in the amount of tau associated with the plasma membrane. However, 
mimicking phosphorylation of residues in the C-terminal half of tau by amino acid 
substitutions did not affect the proportion of membrane-associated tau (Pooler et al., 
2012). The data agree with a previous report showing that pseudophosphorylation of 
tau at sites affected by AD, which are primarily in the C-terminal half of tau, reduces the 
binding of tau with the membrane in PC12 cells (Maas et al., 2000). Furthermore, 
phosphorylation of tau at tyrosine residues by pervanadate, which inhibits the activity of 
protein tyrosine phosphatases, also increases the association of tau with neuronal 
detergent-resistant membranes, or lipid rafts (Usardi et al., 2011). The interaction of tau 
with plasma membranes and lipid rafts is regulated by the presence of fyn, and the 
phosphorylation status of tau has also been shown to alter its binding with fyn (Usardi 
et al., 2011; Pooler et al., 2012). This suggests that tau phosphorylation at serine, 
threonine and tyrosine residues can regulate the association of tau with the plasma 
membrane, and its interactions with membrane-associated proteins, which could have 
further downstream effects on tau function. 
Recent findings suggest that extracellular tau may also play a role in both health and 
disease, but it remains to be seen whether phosphorylation may alter the function of 
extracellular tau. Similar to intracellular membrane-associated tau, extracellular tau 
secreted from primary neurons and non-neuronal cells is dephosphorylated at epitopes 
typically associated with AD (Plouffe et al., 2012; Pooler et al., 2013a). It is unclear 
whether the phosphorylation status of intracellular tau is directly related to that of 
extracellular tau. However, there is some evidence that phosphorylation of intracellular 
tau can affect the process of tau release. In HeLa cells overexpressing a construct of 
human tau mutated to mimic phosphorylation at 12 sites, tau release was significantly 
increased compared to cells expressing WT tau (Plouffe et al., 2012). In contrast, 
neuroblastoma cells overexpressing tau containing mutations associated with 
frontotemporal dementia secrete significantly less tau when compared to cells 
expressing WT tau (Karch et al., 2012). Additionally, these authors also reported that 
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extracellular tau from neuroblastoma cells expressing human tau is phosphorylated at 
T181 (Karch et al., 2012). These studies indicate that phosphorylation of tau may 
modulate neuronal tau release, which could have an effect on the spread of tau 
pathology or other undiscovered roles of extracellular tau in cell-cell signalling.  
 
1.5.4 Tau toxicity and propagation 
Spreading of protein aggregates found in neurodegenerative disorders is a common 
mechanism, as evidenced by studies of α-synuclein in Parkinson’s disease, and 
superoxide dismutase-1 in motor neuron disease (Spillantini et al., 1998a; Desplats et 
al., 2009; Münch et al., 2011). However, the mechanisms underlying the spread and 
uptake of tau from one brain region to another remains to be fully elucidated. This 
spread of pathological tau is termed “prion-like” propagation, since the propagation of 
pathology could involve the transfer of toxic proteins between cells that induce self-
assembly when taken up by neighbouring cells, despite not being infectious. 
In AD, the spread of tau pathology follows a specific, pre-defined characteristic pattern 
(as described above) that is defined by Braak staging from stage I to VI, which 
indicates the progression of disease. To provide an explanation for this spread of 
pathology, several studies support the hypothesis that tau pathology spreads via a 
trans-synaptic mechanism, whereby neuronal connectivity, not proximity, is the key 
determinant of the spatial localisation of pathology.  
In vitro studies have shown that extracellular, exogenous tau aggregates can be taken 
up by neurons to induce oligomerisation of intracellular tau, which can then be released 
and transferred to adjacent or synaptically connected neurons (Frost et al., 2009; Guo 
and Lee, 2011; Kfoury et al., 2012; Wu et al., 2013). These studies indicate that tau 
pathology may be seeded by an initial event that causes the oligomerisation of tau, 
following which tau seeds may be released and this extracellular tau taken up by 
connected neurons. Such a mechanism provides a template through which further tau 
oligomerisation is induced in the recipient neurons, enabling the spread of tau 
pathology. 
Recently, a series of studies carried out by independent groups has provided 
substantial evidence that tau pathology spreads throughout the brain in vivo. In one 
study, the authors took brain extract from transgenic mice which express mutant P301S 
tau, an FTD-causing mutation, and injected these extracts into mice overexpressing 
WT human tau (Clavaguera et al., 2009). The recipient mice would not normally 
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develop tau aggregates, but injection of the P301S brain extract induced the formation 
of tau filaments, and these were confirmed to be of both human and murine origin 
(Clavaguera et al., 2009). Several months after injection, tau pathology was not 
confined to the injection site, but had spread to neighbouring brain regions that were 
anatomically connected. The spread of tau pathology could not be explained by 
diffusion of the brain extract alone as a result of the extensive distance from the 
injection site.   
In other studies, a model of tau transmission was created by generating a transgenic 
mouse where expression of mutant P301L tau was limited to layer II neurons of the 
medial entorhinal cortex, where tau pathology is first observed. As these mice aged, 
tau pathology was first observed only in the entorhinal cortex, and over time, the 
pathology spread to interconnected hippocampal regions, indicative of a trans-synaptic 
spread of tau (de Calignon et al., 2012; Harris et al., 2012; Liu et al., 2012). The lack of 
significant amounts of human tau mRNA in neurons that had taken up mutant tau 
showed that the source of the spreading tau pathology was the mutant tau originally 
expressed in the entorhinal cortex. Interestingly, the recipient transgenic mice did not 
display cognitive defects or neurodegeneration (Clavaguera et al., 2009; Harris et al., 
2012), suggesting that the supposedly pathological tau species that propagates 
throughout the brain may not be toxic. Instead, there may be another, possibly soluble 
and/or oligomeric, tau species that could be responsible for neurotoxicity following the 
transmission of aggregated tau species.  
Until recently, the toxic species of tau was thought to be the mature neurofibrillary 
tangles, but recent studies have shown that it is likely that soluble phosphorylated 
forms of tau are toxic to neurons. For instance, synapse loss and impaired synaptic 
function occurs in transgenic mice expressing mutant P301S tau, and this occurs 
several months before neurofibrillary tangles are detectable (Yoshiyama et al., 2007). 
Interestingly, in the rTg4510 inducible mouse model of tauopathy expressing mutant 
P301L tau, turning off the tau transgene resulted in recovery of memory impairment 
and prevented further loss of neurons, despite continued accumulation of neurofibrillary 
tangles (SantaCruz et al., 2005). Synapse loss in rTg4510 mice also precedes 
significant neurofibrillary tangle accumulation in regions of synaptic loss (Kopeikina et 
al., 2013). Moreover, injection of synthetic tau oligomers into WT mice, but not 
monomers or fibrils, results in impaired memory, loss of synapses, and mitochondrial 
dysfunction at the area of injection (Lasagna-Reeves et al., 2011). Furthermore, the 
visual response function of tangle-bearing neurons from rTg4510 mice is not impaired 
when compared to neighbouring neurons that do not contain tangles (Kuchibhotla et 
42 
 
al., 2014). These studies strongly suggest that soluble, oligomeric species of tau are 
responsible for neurotoxicity. 
 
1.5.5 Kinases and phosphatases of tau 
Several candidate kinases that phosphorylate tau have been identified, including GSK-
3, cyclin-dependent kinase-5 (cdk5), cyclic AMP-dependent protein kinase (PKA), 
casein kinase 1 (CK1), prostate-derived sterile 20-like kinases, as well as several 
members of the mitogen-activated protein kinase family (Noble et al., 2013; Tavares et 
al., 2013). In addition, the five tyrosine residues on tau can be phosphorylated by 
tyrosine kinases including Lck, c-src, Syk, c-Abl, and fyn (Lee et al., 1998; Derkinderen 
et al., 2005; Reynolds et al., 2008). These kinases can be split into three 
classifications: proline-directed kinases, non-proline-directed kinases, and tyrosine 
kinases. There are also several phosphatases that dephosphorylate tau, including 
protein phosphatase (PP) 1, PP2A, and PP5 (Liu et al., 2005). These kinases and 
phosphatases work in concert to regulate tau phosphorylation, and it is believed that 
abnormal phosphorylation of tau in pathological conditions stems from an imbalance of 
kinase and phosphatase activity. 
Phosphorylation of tau is negatively regulated by phosphatase activity. PP1, PP2A, 
PP2B, and PP5 dephosphorylate tau at overlapping sites (S202, T205, T212, S214, 
S235, S262, S396, S404, S409) in vitro, but have some specificity for other 
serine/threonine residues (Liu et al., 2005).Total PP activity in AD brain is reduced by 
approximately 50% compared to control brain tissue, with PP2A accounting for the 
majority of the phosphatase activity (Liu et al., 2005). PP2A has also been shown to 
dephosphorylate tau through regulation of other tau kinases, such as GSK-3 (Qian et 
al., 2010).  
GSK-3 has two isoforms, GSK-3α and GSK-3β. GSK-3β (also known as TPK1, tau 
protein kinase I (Ishiguro et al., 1993)) is thought to be a key kinase of tau, and has 
been shown to phosphorylate tau at multiple sites in vitro and in vivo that are 
abnormally phosphorylated in AD (Hanger et al., 1992; Ishiguro et al., 1992; Lovestone 
et al., 1994; Zheng-Fischhöfer et al., 1998). GSK-3β-mediated phosphorylation of tau 
results in altered tau-microtubule binding and microtubule rearrangement (Wagner et 
al., 1996), and overexpression of GSK-3β in mouse models causes abnormal 
phosphorylation of tau and mislocalisation of tau from the axon to the somatodendritic 
area (Lucas et al., 2001). Lithium chloride, a non-specific inhibitor of  GSK-3, has been 
shown to decrease tau phosphorylation at GSK-3β sites in mice expressing P301L 
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mutant tau as well as reducing insoluble tau aggregates and ameliorate axonal 
degeneration (Noble et al., 2005), supporting the role of GSK-3β in mediating tau-
dependent neurodegeneration. A specific inhibitor of GSK-3, AR-A014418, also 
reduced the amount of insoluble tau in P301L mice, further supporting this conclusion 
(Noble et al., 2005). 
Cdk5 is another major kinase of tau (Baumann et al., 1993). Cdk5 activity is regulated 
by interaction with its activator proteins p25, p35, and p39 (Noble et al., 2003) and 
multiple studies have shown the relevance of cdk5 phosphorylation of tau at disease-
related epitopes (Michel et al., 1998; Patrick et al., 1999; Liu et al., 2002). Similar to 
GSK-3β, overexpression of cdk5 in mice results in abnormally phosphorylated tau and 
accumulation of tau pathology (Bian et al., 2002). When mice with elevated cdk5 
activity were crossed with mice expressing mutant tau, the double transgenic mice 
displayed increased tau hyperphosphorylation and exacerbated the progression of 
pathology (Noble et al., 2003). Additionally, the activity of GSK-3 was elevated in 
double transgenic mice, suggesting that GSK-3 and cdk5 may act in concert to 
promote abnormally phosphorylated aggregates of tau (Noble et al., 2003). A 
subsequent study further examined the relationship between GSK-3 and cdk5 on tau 
phosphorylation. Aged transgenic mice overexpressing p25 led to an over-activation of 
cdk5, resulting in elevated tau phosphorylation at several epitopes normally found in 
AD brain, whereas young mice did not exhibit the increased phosphorylation (Plattner 
et al., 2006). This discrepancy may be explained by differential regulation of GSK-3β by 
cdk5. Activity of GSK-3β was decreased in young transgenic mice with elevated cdk5 
activity, but this was reversed and activity was increased in aged mice. This difference 
in activity was proposed to be a result of inhibitory cross-talk between GSK-3β and 
cdk5, whereby cdk5 acts on protein phosphatase 1 and protein phosphatase 2A to 
regulate GSK-3β, thereby affecting tau phosphorylation (Plattner et al., 2006).  
Of the tyrosine kinases that phosphorylate tau, fyn increases tyrosine phosphorylation 
of tau in vitro, and subsequent experiments revealed that fyn phosphorylates residue 
Y18 of tau (Lee et al., 1998; Lee et al., 2004). Phosphorylation of tau at Y18 by fyn did 
not have a significant effect on microtubule binding, but tau phosphorylated at Y18 has 
been found in AD brain tissue, and insoluble tau fibrils from AD brain contain tau 
phosphorylated at Y18, suggesting the relevance of this site in pathogenic conditions 
(Lee et al., 2004). The interaction of the SH2, but not SH3 domain of fyn with tau is 
increased following phosphorylation of tau at Y18 (Usardi et al., 2011), and this was 
shown to be important for the localisation of tau to membrane microdomains. There is 
also evidence suggesting that fyn-mediated phosphorylation of tau may be protective 




1.6.1 Fyn structure and regulation of kinase activity 
Fyn kinase is a member of the src family of non-receptor-associated tyrosine kinases.  
Since the discovery of the initial src kinase, nine src family kinases have been 
identified, which are src, lck, hck, blk, lyn, fgf, yes, yrk, and fyn. All src family kinases 
share similar sequence homology and contain four distinct Src homology (SH) domains 
(SH1-SH4; Figure 1.7) (Boggon and Eck, 2004). The SH1 (kinase) domain is located in 
the C-terminus of src. This region is responsible for catalytic activity, which is regulated 
by tyrosine autophosphorylation at tyrosine residue Y420 which will be discussed 
further in this section. The SH2 domain contains a phosphotyrosyl recognition pocket 
alongside another pocket that binds hydrophobic residues adjacent to the 
phosphotyrosine, and hence recognises phosphotyrosine residues on interacting 
proteins with a preference for the motif pY-E-E-I (Boggon and Eck, 2004). The SH3 
domain recognises PXXP motifs in interacting proteins, such as those found in the 
proline-rich region of tau, which form a polyproline type II helix when bound to the SH3 
domain. The SH4 domain is located at the N-terminus and this region targets the 
protein to the membrane via lipid modification. This region is always myristoylated and 
sometimes palmitoylated at the consensus sequence M-G-C at the N-terminus which 
promotes anchoring of the kinase to the plasma membrane (Hof and Resh, 1997; Liang 
et al., 2004). Each src family kinase has a unique domain located between the SH4 
and SH3 domains at the N-terminus of the protein which distinguishes them from other 
src family kinases. 
 
 
Figure 1.7 Structure of fyn kinase. 
Schematic diagram of full-length fyn kinase. Fyn shares sequence and structural 
homology with other src family kinases, which all contain four SH domains. At the N-
terminus is the SH4 domain (orange), which is also called the unique domain as its 
protein sequence distinguishes it from other kinases in the family. This is followed by 
the SH3 domain (yellow), which is important for interactions with PXXP motifs on 
binding partners. The SH2 domain (blue) recognises phosphotyrosine residues, and 




Alternative splicing of fyn results in three isoforms. Inclusion of exon 7B results in the 
generation of the isoform Fyn-B (referred to here as fyn), which is expressed 
ubiquitously but expression of which is highest in the brain (Cooke and Perlmutter, 
1989; Resh, 1998). Isoform 2 (fyn-T) is expressed in hematopoietic cells, particularly T-
cells (Resh, 1998). Fyn-T has a role in cell growth and proliferation, platelet activation, 
T- & B-cell receptor signalling, and axon guidance (Saito et al., 2010). Isoform 3 
(FynΔ7) is less well characterised. It lacks exon 7 of full-length fyn and is expressed in 
hematopoietic cells, although other cell types have not been fully characterised 
(Goldsmith et al., 2002). In the brain, fyn expression has been demonstrated in the 
olfactory bulb, cortex, hippocampus, thalamus, and cerebellum, and it has been shown 
that fyn is expressed from embryonic day 8.5 to adulthood in mice (Yagi, 1999). 
The kinase activity of fyn is regulated by tyrosine phosphorylation. Phosphorylation of 
tyrosine residue Y420 up-regulates, and Y531 down-regulates, the kinase activity of 
fyn, such that these two phosphorylation sites work in concert to regulate fyn activity. 
Upstream targets of fyn include C-terminal src kinase (Csk), which phosphorylates 
Y531 of src family kinases, resulting in kinase inactivation (Nada et al., 1991; Nada et 
al., 1993). This leads to a conformational change in fyn so that the SH2 domain binds 
to the C-terminal tail, and the SH3 domain binds to the linker located between the SH2 
and the SH1 domain (Figure 1.8) (Superti-Furga et al., 1993; Sun et al., 1998). 
Knockouts of Csk result in embryonic lethality, in conjunction with increased src family 
kinase activity, demonstrating the importance of Csk as a regulator of members of src 
family kinases (Engen et al., 2008).  
Activation of fyn is also regulated by receptor protein tyrosine phosphatase-α (RPTPα), 
which dephosphorylates Y531 (Bhandari et al., 1998; Sala and Sheng, 1999). This 
leads to a conformational change to the active conformation, resulting in 
autophosphorylation of fyn at Y420 and uncoupling of the SH2 domain to the C-
terminal tail. Signalling transduction of the prion protein (PrP) has also been shown to 
act upstream of fyn. In 2000, it was first demonstrated that PrP can activate fyn by 
signalling via calveolin-1 (Mouillet-Richard et al., 2000), and subsequently this was also 
shown to be mediated by neural cell adhesion molecule (Santuccione et al., 2005). PrP 
knockout mice do not display an age-dependent increase in fyn expression when 
compared to WT mice (Schmitz et al., 2014), and the amount of active fyn was reduced 
in PrP knockout mice compared to WT (Santuccione et al., 2005). In contrast, Y420 of 
fyn is dephosphorylated by striatal enriched phosphatase 61 (STEP61), which results 





Figure 1.8 Active and inactive conformations of fyn 
 (A) In the inactive conformation of fyn, Y531 is phosphorylated allowing for binding of 
the SH2 domain to the C-terminal tail, while the SH3 domain binds the linker segment 
between the SH1 and SH2 domains. Inactivity of fyn is regulated by Csk-mediated 
phosphorylation of fyn at Y531, and STEP dephosphorylation of fyn at Y420. (B) When 
fyn is in the active conformation, Y531 is dephosphorylated by protein tyrosine 
phosphatases such as RPTPα, leading to autophosphorylation of Y420. This results in 




1.6.2 Function of fyn 
Several substrates of fyn have been identified, including focal adhesion kinase (FAK) 
and the γ-aminobutyric (GABA)A receptor γ2 subunit. Reduction of fyn expression in 
transgenic mice led to reduced phosphorylation and decreased kinase activity of FAK 
(Grant et al., 1995). Moreover, fyn phosphorylation of the GABAA receptor γ2 subunit in 
the hippocampus supports a role for fyn in synaptic function (Jurd et al., 2010).  
Fyn has also been shown to phosphorylate some important tau kinases. For example, 
fyn phosphorylates cdk5 at the Y15 residue, thus regulating cdk5 kinase activity in 
semaphorin-mediated neuronal guidance (Sasaki et al., 2002). In another study, fyn 
was also shown to phosphorylate GSK3-β. Neuroblastoma cells treated with insulin 
displayed a transient activation of GSK-3β and concomitant tau phosphorylation. Fyn 
was shown to phosphorylate GSK-3β in vitro, which was further increased by insulin 
stimulation (Lesort et al., 1999). Tau itself is a known fyn substrate. Fyn phosphorylates 
tau at Y18 (Lee et al., 2004) and it was recently shown that fyn is necessary for 
phosphorylation-dependent trafficking of tau to the membrane (Pooler et al., 2012). It is 
clear that a multitude of signalling pathways converge on fyn which can then act on 
several targets, which involve either targeting to the membrane or activation of 
signalling pathways. 
In the brain, fyn is involved in neuronal growth and oligodendrocyte maturation 
(Sperber et al., 2001; Krämer-Albers and White, 2011). Mice lacking fyn protein are 
hypomyelinated, and mice expressing a kinase-dead mutant of fyn also show defects in 
myelination (Umemori et al., 1994; Sperber et al., 2001). In oligodendrocytes, fyn has 
been shown to interact with tau to promote process outgrowth (Klein et al., 2002), 
suggesting that this interaction is important for myelination. In addition, fyn and APP co-
localise and interact in the somatodendritic area of neurons. Targeting of APP and the 
adaptor protein Disabled1 (Dab1) to lipid rafts is dependent on fyn in mice (Hoe et al., 
2008; Minami et al., 2011). Cell surface expression of ephrin-A receptors is also 
dependent on fyn kinase activity which, in contrast to APP, negatively modulates 
expression (Baba et al., 2009). 
The NMDA receptor is also a substrate of fyn, whereby the Y1472 of the NR2b subunit 
is the major phosphorylation site for fyn, and phosphorylation of this site facilitates 
synaptic plasticity (Suzuki and Okamuranoji, 1995; Nakazawa et al., 2001). Indeed, 
transgenic mice expressing constitutively active fyn exhibit significantly increased 
phosphorylation of NR2b at Y1472 (Kojima et al., 1998; Xia and Gotz, 2014). Several 
studies have demonstrated that fyn plays an important role in synaptic function by 
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associating with NMDA receptors to increase receptor stabilisation and activity. NMDA 
receptors are important for long-term potentiation and synaptic plasticity, and are 
involved in learning and memory. Co-expression of an active mutant form of fyn 
(Y531F) with NR2a subunit of the NMDA receptor in 293T cells resulted in increased 
tyrosine-phosphorylated NR2a (Tezuka et al., 1999). This was further compounded in 
the presence of PSD-95 (postsynaptic density 95), which was necessary for the 
formation of a complex involving PSD-95, NR2a, and fyn (Tezuka et al., 1999). The 
association of PSD-95 with fyn is mediated through its SH2 domain (Tezuka et al., 
1999). Fyn is required for the dopamine D1 receptor-stimulated cell surface expression 
of NR2b-containing receptors (Dunah et al., 2004).  Additionally, fyn can also bind to 
PSD-93, which is also a binding partner of NMDA receptors (Sato et al., 2008). In a 
more recent study, Ittner and colleagues (2010) showed that the phosphorylation of 
NR2b at Y1472 was significantly decreased when fyn is unable to be targeted to the 
postsynaptic density by tau. Mislocalised fyn was unable to bind to PSD-95, 
consequently de-stabilising the association between PSD-95 and NR2b. The 
sequestration of fyn in the cell body also conferred protection from pentylenetetrazole-
induced seizures, suggesting that the presence of fyn at the PSD contributes to 
excitotoxic signalling through NMDA receptors (Ittner et al., 2010). Taken together, 
these data show that fyn stabilises the interaction between NR2b and PSD95, which in 
turn strengthens synaptic signalling.  
Depletion of fyn in mice results in impaired spatial learning and long-term potentiation 
(LTP), and introduction of a fyn transgene rescued the impairment of LTP (Grant et al., 
1992; Kojima et al., 1997). Interestingly, levels of src were increased in fyn knockout 
mice, suggesting that there may be compensatory mechanisms by other src family 
kinases which is not sufficient to rescue synaptic impairment (Kojima et al., 1997). In 
the cortex and hippocampus, there is an age-dependent decrease in dendritic spine 
density in fyn knockout mice (Babus et al., 2011). On the other hand, mice expressing 
a constitutively active form of fyn exhibit persistent tremor and increased hyperactivity 
when pups are separated from the rest of the litter (Xia and Gotz, 2014). 
Overexpression of active fyn in transgenic mice are also more susceptible to 
penthylenetetrazole-induced seizures (Kojima et al., 1998), suggesting that increases 
in fyn kinase activity can induce anxiety and hyperactivity. 
Fyn can be both myristoylated and palmitoylated, and these modifications target fyn to 
the plasma membrane (Hof and Resh, 1997). In primary neurons, fyn was found to 
localise to lipid rafts, specialised membrane microdomains thought to play an important 
role in cell signalling (Pereira and Chao, 2007; Usardi et al., 2011). Subcellular 
fractionation of brain tissue also revealed the presence of fyn in synaptosomes, 
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predominantly the PSD fraction, although a smaller fraction was localised to the non-
PSD fraction (Um et al., 2012). In hippocampal neurons, a small proportion of fyn can 
be seen in the cell body but it is predominantly localised to the dendrite (Ittner et al., 
2010), and fyn was also observed at dendritic spines from human AD brain (Larson et 
al., 2012). Fyn is also required for the dynamic trafficking of tau between the 
membrane and cytoplasm (Pooler et al., 2012). In addition, the phosphorylation state of 
neuronal tau regulates its localisation suggesting that roles of tau, distinct from its 
microtubule-binding functions, are influenced by its phosphorylation and the presence 
of fyn (Pooler et al., 2012). Taken together, there is substantial evidence supporting the 
localisation of fyn to lipid rafts at dendrites, consistent with its role in synaptic function 
and membrane trafficking. 
 
1.6.3 Potential involvement of fyn in Alzheimer’s disease pathogenesis 
The first evidence suggesting a role for fyn in the pathogenesis of AD came from 
studies of human post-mortem brain tissue. Fyn expression is increased in a subset of 
neurons from human AD brain; these neurons are also immunoreactive for abnormally 
phosphorylated tau, suggesting a possible association between tyrosine kinases and 
serine/threonine phosphorylation of tau in AD (Shirazi and Wood, 1993). In AD brain 
tissue, fyn was increased in the insoluble fraction but reduced in the soluble fraction, 
indicating that fyn may be sequestered into insoluble aggregates with progression of 
disease (Ho et al., 2005). Immunocytochemistry also revealed that fyn was decreased 
at synapses and mislocalised to the neuronal cell body in AD, where it co-localised with 
tau-containing tangles (Ho et al., 2005). Additionally, the decrease of soluble fyn 
displayed a significant correlation with the cognitive decline seen in AD patients (Ho et 
al., 2005). More recently, fyn activity was found to be increased in AD brains (Larson et 
al., 2012). 
Transgenic mice overexpressing mutant APP exhibit reduced synaptophysin-positive 
presynaptic terminals compared to WT mice, but this is exacerbated when crossed with 
mice overexpressing fyn (Chin et al., 2004), implying that fyn can increase Aβ-induced 
synaptotoxicity. The double APP/fyn transgenic mice are able to learn the location of 
the platform in the Morris water maze test, but 24 hours after training they perform 
poorly in the maze and spend significantly less time in the target quadrant when 
compared to single APP or fyn transgenic mice (Chin et al., 2005). Thus the addition of 
fyn results in worsened memory deficits in an APP mouse model. Interestingly, the 
authors found that while total fyn expression was increased in the double transgenic 
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mice, fyn kinase activity was reduced compared to single transgenic fyn mice (Chin et 
al., 2005). In accordance with reduced fyn activity, STEP, which dephosphorylates fyn 
at Y420 and therefore inactivates fyn, was increased in double transgenic mice (Chin et 
al., 2005). Thus the exacerbation of Aβ-induced synaptic impairments may be due to a 
temporal difference in the elevation of fyn and STEP activity.  
Behavioural studies also demonstrate that the synergistic effects of Aβ and fyn on 
exacerbating cognitive impairment in mouse models of AD that over-produce A are 
dependent on the presence of tau (Roberson et al., 2011). It has been shown in 
multiple studies that fyn can mediate Aβ toxicity. In cell culture, fyn deficiency confers 
neuroprotection from Aβ toxicity and synaptotoxicity (Lambert et al., 1998; Williamson 
et al., 2008). In addition, elevation of Aβ results in activation of fyn, an increase in 
tyrosine phosphorylated tau, and re-distribution of fyn and tau in neurons (Williamson 
et al., 2002; Williamson et al., 2008; Um et al., 2012). 
The interaction of tau and fyn has been under considerable scrutiny due to their 
synergistic roles in mediating Aβ neurotoxicity. Fyn phosphorylates tau at Y18, which is 
an epitope that is hyperphosphorylated in AD and is present in neurofibrillary tangles 
(Lee et al., 2004). In 2005, Bhaskar et al. (2005) showed that disease-related 
modifications in tau could affect tau-fyn binding in vitro. Phosphomimetics of tau at 
residues known to be phosphorylated in AD (T231, S235) reduced the binding between 
tau and fyn (Bhaskar et al., 2005). Interestingly, the authors found that the binding 
affinity of 3R tau to fyn was different to that of 4R tau. Mutation of S199/S202 and 
S396/S404 to aspartic acid, both of which are AD-related phosphoepitopes, resulted in 
pseudophosphorylation at these epitopes and an increase of the binding affinity of 4R, 
but not 3R, tau to fyn (Bhaskar et al., 2005). This suggests that the interaction of tau 
with fyn could be dependent on the association of tau with microtubules, which could 
be modified by phosphorylation of tau. 
Since ablation of either tau or fyn can confer neuroprotection from Aβ toxicity, Ittner and 
colleagues (2010) initiated a series of experiments to investigate how these proteins 
can mediate Aβ toxicity. Transgenic mice expressing a tau deletion construct that 
lacked the microtubule binding domain resulted in sequestration of tau and fyn to the 
neuronal cell body (Ittner et al., 2010). In turn, the interaction of NMDA receptors and 
PSD-95 in dendrites was destabilised. Tau mutant mice crossed with mutant APP mice 
rescued premature mortality and memory deficits observed in single APP transgenic 
mice (Ittner et al., 2010). Reduction of total tau alone also ameliorated these 
impairments, suggesting that the targeting of fyn to the postsynaptic density by tau can 
specifically promote Aβ-induced toxicity (Ittner et al., 2010). In support of this 
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hypothesis, reduction of tau in a double transgenic mouse overexpressing mutant APP 
and fyn prevented cognitive deficits and premature mortality (Roberson et al., 2011). 
Thus there is considerable evidence that tau-fyn interactions could play a role in AD. 
 
1.7 Synergistic toxicity between tau and Aβ in Alzheimer’s 
disease 
Synaptic loss is the best correlate of progressive cognitive decline in AD (DeKosky and 
Scheff, 1990; Terry et al., 1991), indicating that synaptotoxicity has a key role in the 
pathogenesis of disease. Both tau and Aβ have been shown to exert neurotoxic effects 
on synapses, raising the possibility that they might act in concert to synergistically 
promote synaptic loss in AD.  
Using array tomography, soluble Aβ oligomers have been observed at individual 
synapses in post-mortem human brain tissue, and the presence of oligomers correlates 
with shrunken and degenerated spines (Koffie et al., 2012). Application of soluble Aβ to 
neurons causes impaired long-term potentiation and facilitates long-term depression 
(Lambert et al., 1998; Li et al., 2009). Extracts of Aβ oligomers from AD human post-
mortem brain tissue also impairs synaptic plasticity and reduces dendritic spine density 
in neurons (Shankar et al., 2008). It has been suggested that Aβ exerts its synaptotoxic 
effects by acting on glutamatergic neurotransmitters receptors. The effect of Aβ on 
reducing levels of PSD-95 requires NMDA receptor activity (Shankar et al., 2007). Aβ 
oligomers also induce internalisation of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and NMDA receptors, triggering the loss of dendritic 
spines (Snyder et al., 2005; Hsieh et al., 2006). Importantly, the effects of Aβ are 
mediated by the presence of tau, as reduction of tau reduced the susceptibility to 
excitotoxic seizures caused by Aβ (Roberson et al., 2007; Ittner et al., 2010; Roberson 
et al., 2011). 
There is increasing evidence that tau can also exert toxicity on synapses. Synapse loss 
is evident in mouse models of tauopathy and precedes accumulation of tangles, 
indicating that soluble pre-tangle forms of tau can promote synaptotoxicity (Yoshiyama 
et al., 2007). Loss of spines is correlated with the missorting of tau in dendrites, 
suggesting that the mislocalisation of tau is linked to synaptic dysfunction (Zempel et 
al., 2010; Zempel and Mandelkow, 2014). Recent evidence suggests that accumulation 
of abnormally phosphorylated tau in dendritic spines mediates synaptic impairment in 
rTg4510 mice expressing mutant P301L tau (Hoover et al., 2010). Expression of 
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mutant tau is sufficient to cause impaired synaptic function and reduce the surface 
expression of AMPA and NMDA receptors (Hoover et al., 2010). Tau has also been 
observed at synapses and dendritic spines in both mouse models of tauopathy and in 
AD brain tissue (Tai et al., 2012; Kopeikina et al., 2013; Tai et al., 2014). 
The link between tau and Aβ toxicity at synapses may be mediated by fyn. Ittner and 
colleagues (2010) demonstrated that tau plays an important role in trafficking of fyn to 
dendrites. Dendritic localisation of tau was shown to be important for positioning fyn in 
dendrites, where it phosphorylates the NMDA receptor subunit NR2b, thereby 
regulating the interaction between the NMDA receptor and PSD-95 (Ittner et al., 2010). 
The interaction of tau with fyn can influence A-mediated neurotoxicity and excitotoxic 
seizures in mouse models of AD (Ittner et al., 2010). Therefore, the dendritic 
localisation of tau supports the hypothesis that AD pathology can be mediated by the 
interaction between fyn and tau. Another protein which has been recently found as a 
possible link between tau and Aβ is PrPC, the cellular form of the prion protein. It was 
previously shown that PrPC could bind to Aβ oligomers and that abolishing PrP 
expression blocked Aβ-induced synaptic impairment (Lauren et al., 2009). 
Subsequently, PrPC was shown to form a complex with Aβ and fyn, resulting in 
abnormal phosphorylation of tau (Larson et al., 2012). This complex also appears to be 
mediated by mGluR5, a metabotropic glutamate receptor, which could mediate 
downstream effects of Aβ and tau on synapses (Um et al., 2013). Thus, it appears that 
Fyn may play a major role in mediating the development and progression of AD 
through interactions with A and tau at synapses. 
In 2012, it was reported that PrPC acted as the receptor for Aβ, which then triggered 
activation of fyn kinase and subsequent downstream effects on tau (Larson et al., 
2012). Fyn was found to be activated by Aβ oligomers when these were applied to 
cultured neurons, but activation of fyn was abolished in PrPC knockout neurons or 
when PrPC was immunodepleted (Um et al., 2012). Aβ treatment also increased the 
association between fyn and PrP. As early as fifteen minutes following Aβ application, 
NR2b phosphorylated at Y1472 by fyn was transiently increased accompanied by 
activation of fyn, but without any changes in STEP. Three hours post-Aβ, levels of 
STEP were increased while NR2b phosphorylation and levels of active fyn decreased 
(Um et al., 2012). This could point to compensatory up-regulation of STEP to 
counteract the Aβ-induced activation of fyn. Cell surface expression of NMDA receptors 
was also transiently increased in response to Aβ treatment in this study, and this was 
also followed by reduction of expression to levels below baseline, changes which were 
not seen in the absence of PrPC or fyn (Um et al., 2012). The transient increase of cell 
surface NMDA receptor expression correlated with release of lactate dehydrogenase 
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(LDH), a measure of cell toxicity. Immunodepletion of PrPC prevented the Aβ-induced 
LDH release (Um et al., 2012). This interaction was further confirmed when Larson and 
colleagues (2012) co-immunoprecipitated fyn, PrPC, and soluble Aβ dimers from AD 
brain tissue, and these were found to co-localise at dendritic spines. Primary neurons 
treated with PrPC antibody showed reduced phosphorylation of tau at the fyn-specific 
Y18 site, suggesting that PrPC-dependent fyn activation can lead to downstream 
phosphorylation of tau (Larson et al., 2012). Furthermore, deletion of PrPC in APP 
mutant transgenic mice reduced fyn activity, and lowered tau accumulation in the 
membrane fraction (Larson et al., 2012). On the other hand, overexpression of PrPC in 
APP mutant mice resulted in an increased active fyn/total fyn ratio and potentiated the 
effects of APP on tau missorting and phosphorylation. Together, these studies provide 
evidence that links Aβ toxicity with PrPC, fyn, and tau as a mechanistic pathway 
important for the pathogenesis of AD. 
However, the role of fyn in AD is confounded by a study that showed reduction of fyn 
did not rescue AD-related impairments in vivo. 3xTg mice, which harbour mutations in 
APP, presenilin-1, and tau, are commonly used as models of AD. When crossed with 
fyn knockout mice, knockdown of fyn resulted in worsened spatial learning compared to 
controls (Minami et al., 2012). Similarly, genetic ablation of STEP, which leads to 
increased levels of active fyn, improved spatial learning and memory in the Morris 
water maze test, and enhanced LTP in the CA1 region of hippocampal slices from 3xTg 
mice (Zhang et al., 2010). These discrepancies clearly indicate that the role of fyn in 
AD is complex and requires further investigation. While the lack of fyn itself is sufficient 
to cause defects in synaptic plasticity and spatial learning (Grant et al., 1992), it 
remains possible that Aβ toxicity is mediated through specific functions of fyn, such as 
its association with tau or the PSD-95/NMDA receptor complex at the dendrite. These 
studies suggest that reduction of fyn alone may not be an appropriate therapeutic 
strategy for AD, but that it may be more beneficial to investigate downstream targets 
such as the association between tau and fyn. 
Currently, it is known that the SH3 domain of fyn can bind to specific proline-rich 
sequences within PXXP motifs in tau (Lee et al., 1998; Usardi et al., 2011; Cochran et 
al., 2014). However, it is not known which of the seven PXXP sequences in tau has 
most importance for this interaction. Serine/threonine phosphorylation sites within and 
around the PXXP motifs have been identified in AD brain, suggesting that 
phosphorylation at these sites may regulate binding of tau to fyn (Reynolds et al., 
2008). Given that tau-fyn binding can mediate phosphorylation-dependent trafficking of 
tau, and aberrant activation of fyn by Aβ leads to downstream pathological changes in 
tau, it is important to characterise the molecular mechanisms of tau-fyn interactions 
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with respect to normal and pathogenic conditions in order to find novel avenues for AD 
therapy. 
 
1.8 Aims and objectives of the thesis 
It is clear that tau and fyn are downstream of Aβ and that they are both able to 
modulate Aβ-induced neurotoxicity, but the mechanisms by which this occurs are 
unclear. Although studies have investigated tau-fyn interactions, the binding site for fyn 
on tau has yet to be fully defined. Moreover, the downstream consequences of such an 
interaction remain unclear. In addition, the role of fyn has not yet been investigated in 
the context of spreading of tau, either physiologically or pathologically. Therefore, the 
aims of this thesis are to: 
1) Investigate the release of tau in organotypic brain slices, in comparison to tau 
release from primary neurons, and to determine whether fyn is involved in 
modulating tau release in this model; 
2) Determine the effects of soluble Aβ oligomers on tau release; 
3) Identify the critical binding site on tau that enables its interaction with fyn, and to 
determine the effects of inhibiting tau-fyn binding on tau release; 
4) Determine whether there is any correlation between the presence of fyn and 
AD-related changes in tau in human post-mortem brain tissue.  
55 
 
Chapter 2 Materials & Methods 
2.1 Materials 
2.1.1 General molecular biology reagents 
All reagents used were from Sigma-Aldrich (UK) and ultrapure water (Elga Maxima 
system) was used in the preparation of all solutions, unless otherwise stated.  
Plasmids 
All of the plasmids used in this thesis are listed in Table 2.1. Plasmids encoding 
glutathione-S-transferase (GST), or GST fused to the N-terminus of the src homology 
(SH) 2 or 3 domains of fyn were a gift from by Dr S. Anderson (University of Colorado 
Anschutz Medical Campus, Aurora, CO, USA) (Burton et al., 1997). Human full-length 
(2N4R) tau was previously cloned into pcDNA3.1-V5-His-TOPO vector by Dr Pascal 
Derkinderen in this laboratory (Derkinderen et al., 2005). Plasmids encoding 2N4R tau 
containing proline to alanine substitutions at residues 216 (P216A) or 233 (P233A) of 
tau was previously generated by Dr Alessia Usardi in this laboratory (Usardi et al., 
2011). Plasmids pIRES2-EGFP and Lenti-GFP were provided by Dr Nina Balthasar 
(University of Bristol, UK). 
Table 2.1. Plasmids used in this thesis 
Plasmid Vector Source/Reference Protein encoded 
GST pGEX Dr S. Anderson  
(Burton et al., 1997) 
GST 
GST-fyn-SH2 pGEX Dr S. Anderson  
(Burton et al., 1997) 
SH2 domain of fyn 
fused to GST at the 
N-terminus 
GST-fyn-SH3 pGEX Dr S. Anderson  
(Burton et al., 1997) 
SH3 domain of fyn 




Dr P. Derkinderen 
(Derkinderen et al., 
Wild-type (WT) 
human 2N4R tau 
tagged with V5 and 
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2005) His tags at the C-
terminus 
pIRES2-EGFP pIRES2-EGFP Clontech 
Laboratories (Palo 









Lenti-GFP pTYF-SW-linker Dr N. Balthasar 
(Liu et al., 2006) 
EGFP under the 
control of human 






D. Lau  Tau containing 
individual proline to 
alanine 
substitutions at 
residues 176, 182, 
200, 206, 213, or 
219 of tau 
P216A, P233A pcDNA3.1-V5-His-
TOPO 
Dr A. Usardi 
(Usardi et al., 2011) 
Tau containing 
individual proline to 
alanine 
substitutions at 
residues 216 or 233 




Agarose gel electrophoresis of nucleic acids 
Tris-acetate-EDTA (TAE) buffer 40 mM Tris, pH 8.0 
20 mM acetic acid 
1 mM ethylenediaminetetraacetic acid 
(EDTA) 
DNA loading buffer 5X Green GoTaq® Reaction Buffer 
(Promega, Southampton, UK) 
Nucleic acid molecular weight marker Quick-Load® 1kb DNA Ladder (New 
England BioLabs, Hertfordshire, UK) 
Size (kb): 10, 8, 6, 5, 4, 3, 2, 1.5, 1, 0.5 
TriDye™ 100 bp DNA Ladder (New 
England BioLabs, Hertfordshire, UK) 
Size (bp): 1517, 1200, 1000, 900, 800, 
700, 600, 500/517, 400, 300, 200, 100 
Plasmid DNA preparation 
Plasmid DNA was prepared using the QIAprep Spin Miniprep Kit (Qiagen, Manchester, 
UK) and HiSpeed Plasmid Maxi Kit (Qiagen, Manchester, UK).  
 
2.1.2 Site-directed mutagenesis 
The QuikChange II XL Site-Directed Mutagenesis kit was purchased from Agilent 
Technologies, Cheshire, UK.  
Primers 
All primers were custom synthesised by Eurofins MWG Operon, Wolverhampton, UK. 
Primers used for site-directed mutagenesis are listed in Table 2.2. Full-length 2N4R 
human tau in pcDNA3.1-V5-His-TOPO was used as a template. The codons mutated to 




Table 2.2. Forward and reverse primers used for site-directed mutagenesis of tau 
Primer name Primer sequence 5’ to 3’ 
Forward P176A GATTCCAGCAAAAACCGCGCCCGCTCCAA 
Reverse P176A TTGGAGCGGGCGCGGTTTTTGCTGGAATC 
Forward P176A-2 AGCAAAAACCGCGCCCGCTCCAAAG 
Reverse P176A-2 CTTTGGAGCGGGCGCGGTTTTTGCT 
Forward P176A-3 AGCAAAAACCGCTCCCGCTCCAAAG 
Reverse P176A-3 CTTTGGAGCGGGAGCGGTTTTTGCT 
Forward P182A CGCTCCAAAGACAGCACCCAGCTCTGG 
Reverse P182A CCAGAGCTGGGTGCTGTCTTTGGAGCG 
Forward P200A GCTACAGCAGCGCCGGCTCCCCA 
Reverse P200A TGGGGAGCCGGCGCTGCTGTAGC 
Forward P200A-2 TACAGCAGCGCAGGCTCCCCAG 
Reverse P200A-2 TGGGGAGCCTGCGCTGCTGTA 
Forward P200A-3 TACAGCAGCGCAGGCTCTCCAGGCACTC 
Reverse P200A-3 GAGTGCCTGGAGAGCCTGCGCTGCTGTA 
Forward P206A GGCTCCCCAGGCACTGCCGGCAGC 
Reverse P206A GCTGCCGGCAGTGCCTGGGGAGCC 
Forward P213A GCTCCCGCACCGCGTCCCTTCCA 
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Reverse P213A TGGAAGGGACGCGGTGCGGGAGC 
Forward P219A CCCTTCCAACCCCAGCCACCCGGG 
Reverse P219A CCCGGGTGGCTGGGGTTGGAAGGG 
 
E.coli culture 
IPTG 10 mM isopropyl-1-thio-β-D-
galactopyranoside (IPTG) in H2O, sterile 
filtered 
X-Gal 20 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (Thermo Scientific, 
Waltham, MA, USA) 
Luria Bertani (LB) broth 20 g/l LB, sterilised by autoclaving 
For LB-ampicillin broth, 100 µg/ml 
ampicillin is added to sterile LB on day of 
use 
For LB-kanamycin broth, 50 μg/ml 
kanamycin is added to sterile LB on day of 
use 
LB agar 32 g/L LB agar, sterilised by autoclaving 
For LB-ampicillin agar, 100 µg/ml 
ampicillin is added  when agar is less than 
55°C 
For LB-kanamycin broth, 50 μg/ml 
kanamycin is added  when agar is less 
than 55°C 
Super Optimal Broth with Catabolite 
repression (SOC) medium 
1X SOC Outgrowth Medium (New England 




Primers to introduce stop codon in 2N4R tau in pcDNA3.1-V5-His-TOPO vector 
All primers were custom synthesised by Eurofins MWG Operon, Wolverhampton, UK. 
PCR primers containing a single base mutation (underlined) were designed to amplify a 
fragment of tau to introduce a stop codon at the 3’ end of the sequence encoding 2N4R 
human tau in pcDNA3.1-V5-His-TOPO (Table 2.3).  
Table 2.3. Primers to introduce stop codon in 2N4R tau in pcDNA3.1-V5-His-
TOPO 
Primer name Primer sequence 5’ to 3’ 
Tau BsrGI forward TGACCTTCCGCGAGAACGCCAAAGCCAAG 
Tau EcoRV reverse GTGCTGGATATCTGCAGAATTGCCCTTTGATCACAAACC 
 
Restriction enzymes All restriction enzymes and buffers were 
purchased from New England BioLabs, 
Hertfordshire, UK, unless otherwise 
stated. 
DNA purification Plasmid DNA was isolated for subcloning 
using the QIAquick Gel Extraction Kit 
(Qiagen, Manchester, UK). 
Blunting, ligation and dephosphorylation Quick Blunting Kit (New England BioLabs, 
Hertfordshire, UK) 
T4 DNA ligase (New England BioLabs, 
Hertfordshire, UK) 
Shrimp alkaline phosphatase (New 
England BioLabs, Hertfordshire, UK) 
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2.1.3 Transgenic mice 
Wild-type, fyn-/-, and tau-/- mice were obtained from The Jackson Laboratory, Maine, 
USA. Fyn-/- mice were maintained on a B6129SF2/J background, so this strain was 
used to provide wild-type controls for experiments involving fyn-/- mice.   
B6;129S7-Fyntm1Sor/J (fyn-/-) mice are viable and fertile without any overt phenotype. 
However, homozygous mutant mice have impaired T-cell receptor signalling and 
display a reduction in tyrosine-phosphorylated proteins. Neurological defects are also 
observed, including blunted long-term potentiation, impaired spatial learning, and 
altered hippocampal development.  
Mapttm1(EGFP)Kit/J (tau-/-) mice are viable and fertile without any overt phenotype. Tau-/- 
mice are maintained on a C57BL/6 background. The coding sequence of enhanced 
fluorescent green protein (EGFP) is knocked into the first exon, disrupting expression 
of the Mapt gene to produce the first 31 amino acids of tau fused to EGFP. 
Mouse genotyping 
Primers for genotyping fyn knockout (-/-) and tau-/- mice are listed in Table 2.4 and Table 
2.5, respectively. 
Table 2.4. Primers for genotyping fyn-/- mice 
Primer name (code) Primer sequence 5’ to 3’ 
Wild-type forward (10207) AGGCCCAAGTTGACTATCCA 
Common reverse (10208) GGCAGCCTGTCTCAAAAGTC 
Mutant fyn forward (oIMR9535) GGGAGGATTGGGAAGACAAT 
Table 2.5. Primers for genotyping tau-/- mice 
Primer name (code) Primer sequence 5’ to 3’ 
Human tau forward (oIMR3115) ACTTTGAACCAGGATGGCTGAGCCC 
Human tau reverse (oIMR3116) CTGTGCATGGCTGTCCACTAACCTT 
62 
 
Mouse tau forward (oIMR3092) CTCAGCATCCCACCTGTCAC 
Mouse tau reverse (oIMR3093) CCAGTTGTGTATGTCCACCC 
EGFP forward (oIMR0872) AAGTTCATCTGCACCACCG 
EGFP reverse (oIMR1416) TCCTTGAAGAAGATGGTGCG 
 
TEN9 buffer 15 mM Tris-HCl, pH 8.0 
35 mM Tris 
20 mM EDTA 
40 mM NaCl 
Proteinase K 50 mg/ml proteinase K in storage buffer: 
50 mM Tris-HCl, pH 8.0 
5 mM CaCl2 
50% (v/v) glycerol 
Digestion mix 1% (w/v) SDS 




2.1.4 General cell biology reagents 
Protein buffering and lysis 
Phosphate-buffered saline (PBS) 1 PBS tablet dissolved in 200 ml water  
Tris-buffered saline (TBS) 50 mM Tris-HCl, pH 7.4  
150 mM NaCl 
PBS-T PBS 
0.1% (v/v) Tween-20 
TBS-T TBS 
0.1% (v/v) Tween-20 
Hypotonic buffer 10 mM NaHCO3 
25 μg/ml DNAse 
Complete protease inhibitor cocktail 
without EDTA (Roche, West Sussex, UK) 
1% (v/v) Phosphatase inhibitor cocktail 2 
Bovine serum albumin (BSA) protein 
standards 
Serial dilutions of 2 mg/ml BSA in H2O 
were prepared in the appropriate lysis 
buffer to obtain concentrations of 125, 
250, 500, 750, 1000, and 1500 μg/ml. 
Extra strong lysis buffer (ESLB) 10 mM Tris-HCl, pH 7.5 
0.5% (w/v) SDS 
20 mM sodium deoxycholate 
1% (v/v) Triton X-100 
1 mM sodium orthovanadate 
1.25 mM sodium fluoride 
10 mM EDTA 
Complete protease inhibitor cocktail 
without EDTA (Roche, West Sussex, UK) 
1% (v/v) Phosphatase inhibitor cocktail 2 
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Radioimmunoprecipitation assay (RIPA) 
buffer 
50 mM Tris-HCl, pH 7.4  
1% (v/v) Triton X-100 
0.5% (w/v) sodium deoxycholate 
0.1% (w/v) sodium dodecyl sulphate 
(SDS) 
100 mM NaCl 
1 mM ethylenediaminetetraacetic acid 
(EDTA) 
10 mM iodoacetamide 
Complete protease inhibitor cocktail 
without EDTA (Roche) 
1% (v/v) Phosphatase inhibitor cocktail 2 
Hypotonic buffer for fractionation 10 mM NaHCO3, pH 7.4 
25 μg/ml DNAse 
Complete protease inhibitor cocktail 
without EDTA 
1% (v/v) Phosphatase inhibitor cocktail 2 
NETF buffer 100 mM NaCl 
2 mM ethylene glycol tetraaectic acid 
(EGTA) 
50 mM Tris-HCl, pH 7.4 
1% (v/v) Nonidet P-40 (BDH Laboratories) 
Complete protease inhibitor cocktail 
without EDTA 
1% (v/v) Phosphatase inhibitor cocktail 2 
 HEPES buffer 50 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
140 mM NaCl 
0.5% (v/v) Triton X-100 
Complete protease inhibitor cocktail 
without EDTA 
1% (v/v) Phosphatase inhibitor cocktail 2 
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TBS-EGTA buffer 50 mM Tris, pH 7.4 
150 mM NaCl 
2 mM EGTA 
Complete protease inhibitor cocktail 
without EDTA 
1% (v/v) Phosphatase inhibitor cocktail 2 
Glutathione S-transferase (GST) pull-downs 
Tris-NaCl-EDTA (TNE) buffer 25 mM Tris-HCl, pH 7.5 
100 mM NaCl 
1 mM EDTA 
Complete protease inhibitor cocktail 
(Roche, West Sussex, UK) 
GST pull-down lysis buffer 25 mM Tris-HCl, pH 7.5 
10% (v/v) glycerol 
0.5% (v/v) Triton X-100 
1 mM EDTA 
1 mM ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid 
(EGTA) 
150 mM NaCl 
Complete protease inhibitor cocktail 
(Roche, West Sussex, UK) 
1% (v/v) Phosphatase inhibitor cocktail 2 
GST pull-down wash buffer 50 mM Tris-HCl, pH 7.5 
2 mM EDTA 
0.5% (v/v) Triton X-100 
150 mM NaCl 
Complete protease inhibitor cocktail 
(Roche, West Sussex, UK) 





Immunoprecipitation beads Protein A agarose beads 
IC261 3-[(2,4,6-Trimethoxyphenyl)methylidenyl]-
indolin-2-one, SU5607 (IC261; 
Calbiochem) 
Crosslinker  Dithiobis[succinimidyl propionate] (DSP, 
Thermo Scientific) 
Bicinchoninic acid (BCA) protein assay 
BCA Protein Assay Kit (Thermo Scientific, 
Waltham, MA, USA) 
BCA Reagent A (containing sodium 
carbonate, sodium bicarbonate, 
bicinchoninic acid, sodium tartrate in 0.1M 
sodium hydroxide) 
 
BCA Reagent B (containing 4% cupric 
sulphate) 
Cell toxicity assays 
Lactate dehydrogenase (LDH) assay CytoTox 96® Non-Radioactive Cytotoxicity 
Assay (Promega, Southampton, UK) 
LIVE/DEAD assay LIVE/DEAD® Fixable Far-Red Dead Cell 
Stain Kit (Life Technologies, Paisley, UK) 
 
Immunocytochemistry 
Fixing solution 4% (v/v) paraformaldehyde (PFA) in PBS 
Hoescht 1 µg/ml Hoescht 33342 diluted in PBS  
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Mounting medium Fluorescence mounting medium (DAKO, 
Cambridgeshire, UK) 
2.1.5 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Laemmli sample buffer (2x) 25 mM Tris-HCl, pH 6.8 
4% (w/v) SDS 
20% (v/v) glycerol 
0.01% (w/v) Bromophenol blue 
100 mM dithiothreitol (DTT) 
Stock acrylamide (National Diagnostics, 
Hessle, UK) 
30% (w/v) acrylamide 
0.5% (w/v) bis-acrylamide (37.5:1) 
Resolving gel 10% (w/v) acrylamide (National 
Diagnostics, Hessle, UK) 
25% (v/v) resolving buffer, pH 8.8 (National 
Diagnostics, Hessle, UK) 
0.01% (w/v) ammonium persulphate (APS, 
National Diagnostics, Hessle, UK) 
0.1% (v/v) N,N,N’,N’ 
tetramethylethylenediamine  (TEMED, 
National Diagnostics, Hessle, UK) 
Stacking gel 4% (w/v) acrylamide 
25% (v/v) stacking buffer, pH 6.8 (National 
Diagnostics, Hessle, UK) 
0.075% (w/v) APS 
0.15% (v/v) TEMED 
Running buffer 25 mM Tris, pH 8.3 
192 mM glycine 
0.1% (w/v) SDS 
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Protein molecular weight markers Precision Plus Protein™ All Blue 
Standards (Bio-Rad, Hertfordshire, UK) 
Molecular weight (kDa): 250, 150, 100, 75, 
50, 37, 25, 20, 15, 10 
Colloidal Coomassie blue staining 
ProtoBlue Safe Working Solution 10% (v/v) ethanol 
90% (v/v) ProtoBlue Safe (National 
Diagnostics, Hessle, UK) 
Western blot (WB)  
Transfer buffer 25 mM Tris, pH 8.3 
192 mM glycine 
20% (v/v) methanol 
Blocking solution (WB) 5% (w/v) dried skimmed milk in TBS 
Antibody diluent (WB) 3% (w/v) dried skimmed milk in TBS 
 
2.1.6 General cell culture reagents 
Poly-D-lysine 10 µg/ml poly-D-lysine (PDL) 
Culture medium for primary neurons Neurobasal® medium (Life Technologies, 
Paisley, UK) without Phenol red, 
supplemented with: 
0.02% (v/v) B-27® (Life Technologies, 
Paisley, UK) 
2 mM L-Glutamine (GE Healthcare, 
Buckinghamshire, UK) 




100 µg/ml streptomycin (GE Healthcare, 
Buckinghamshire, UK) 
Papain solution (Worthington Biochemical 
Corporation, Lakewood, New Jersey, 
USA) 
20 U/ml papain 
1 mM L-cysteine 
0.5 mM EDTA 
in Earle’s Balanced Salt Solution with 
bicarbonate and phenol red (EBSS) 
DNase I (Worthington Biochemical 
Corporation, Lakewood, New Jersey, 
USA) 
2000 U/ml deoxyribonuclease in EBSS 
Albumin-ovomucoid protease inhibitor 
(Worthington Biochemical Corporation, 
Lakewood, New Jersey, USA) 
10 mg/ml ovomucoid inhibitor 
10 mg/ml albumin 
in EBSS 
Chinese Hamster Ovary (CHO) cells HyClone™ Ham’s Nutrient Mixture F-12 
(GE Healthcare, Buckinghamshire, UK) 
supplemented with: 
10% (v/v) foetal bovine serum (FBS, 
Biosera, Boussens, France) 
2 mM L-glutamine 
100 U/ml penicillin 
100 µg/ml streptomycin 
Trypsin Trypsin-EDTA (GE Healthcare, 
Buckinghamshire, UK) 
Organotypic mouse cortical brain slice culture 
All medium was sterile filtered (0.2 µm) and stored at 4°C prior to use. 
Dissection solution 1.25 mM KH2PO4, pH 7.4 
124 mM NaCl 
3 mM KCl 
8.19 mM MgSO4 
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2.65 mM CaCl2 
3.5 mM NaHCO3 
10 mM glucose 
2 mM ascorbic acid 
39.4 μM ATP 
Slicing medium Basal medium Eagle (BME) 
26.6 mM HEPES, pH 7.1 
19.3 mM NaCl 
5 mM NaHCO3 
511 μM ascorbic acid 
40 mM glucose 
2.7 mM CaCl2 
2.5 mM MgSO4 
1% (v/v) GlutaMAX (Life Technologies, 
Paisley, UK) 
0.033% (v/v) insulin 
50 U/ml penicillin 
50 μg/ml streptomycin 
25% (v/v) horse serum 
Serum-free medium Minimum essential medium Eagle (MEM), 
phenol red-free 
26.6 mM HEPES, pH 7.1 
19.3 mM NaCl 
5 mM NaHCO3 
511 μM ascorbic acid 
40 mM glucose 
2.7 mM CaCl2 
2.5 mM MgSO4 
1% (v/v) GlutaMAX (Life Technologies, 
Paisley, UK) 
0.033% (v/v) insulin 
50 U/ml penicillin 





Table 2.6. Primary antibodies used for western blots and enzyme-linked 



















1/10,000 1/1,000 DAKO, 
Cambridgeshire, 
UK 














1/5,000  Abcam, 
Cambridge, UK 

























at  S202 
Mouse 
monoclonal 
1/400  Peter Davies 
(AECM, NY, 
USA) 

























1/500  Abcam, 
Cambridge, UK 





1/500  Diane Hanger 
Fyn Fyn  Rabbit 
polyclonal 









1/500  Santa Cruz 
Laboratories, 









1/250  Santa Cruz 
Laboratories, 
Santa Cruz, CA, 
USA 




1/500  BD Transduction 
Laboratories, 
San Jose, CA, 
USA 
Fyn (CST) Fyn Rabbit 
polyclonal 




























N-terminal of the 




1/10,000  Abcam, 
Cambridge, UK 





























1/5,000  My Bio Source, 
San Diego, CA, 
USA 







1/5,000  Life 
Technologies, 
Paisley, UK 
GFP GFP Rabbit 
polyclonal 
1/5,000  Abcam 
GST GST Goat 
polyclonal 
1/2,000  GE Healthcare, 
Buckinghamshire
, UK 
4G8 Amino acids 17-










cleaved at D175 
Rabbit 
polyclonal 














Table 2.7. Secondary antibodies used for western blots and ELISA 
 
 
2.1.8 Sandwich ELISA 
Antibody  Dilution for 
western blots 
Source 
Alexa Fluor® 680 goat anti-mouse 1/10,000 Life Technologies, Paisley, 
UK 




Pottstown, PA, USA 
Horseradish peroxidase (HRP)-linked 
donkey anti-rabbit  
1/500 GE Healthcare, 
Buckinghamshire, UK 
Blocking solution (ELISA) StartingBlock (TBS) Blocking Buffer 
(Thermo Scientific, Waltham, MA, USA) 
Antibody diluent (ELISA) 20% (v/v) SuperBlock (PBS) Blocking 
Buffer (Thermo Scientific, Waltham, MA, 
USA) in TBS 
3,3’,5,5’-Tetramethylbenzidine (TMB) 1-Step Ultra TMB-ELISA Substrate 
Solution (Thermo Scientific, Waltham, 
MA, USA) 
Coating buffer 15.6 mM K2HPO4, pH 7.2 
25.6 mM KH2PO4 
136.9 mM NaCl 
1.27 mM EDTA 
0.05% (w/v) sodium azide 
Wash buffer 10 mM Tris-HCl, pH 7.4 
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2.1.9 Post-mortem human brain 
Post-mortem human brain temporal or frontal (marked with an asterisk) cortex was 
obtained from the Medical Research Council London Neurodegenerative Diseases 
Brain Bank at the Institute of Psychiatry, Psychology and Neuroscience, King’s College 
London. Case details are summarised in Table 2.8 and Table 2.9. 
100 mM NaCl 
0.05% (v/v) Tween-20 
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Table 2.8. Case details for control and late-stage Alzheimer’s disease post-











A011/06 F 82 43 Control Normal brain 
A140/07 F 81 17 I Mild ageing changes Braak I 
A153/06 F 92 17 Control Control brain with some tau deposition 
A134/00 M 86 6 Control Normal adult brain 
A358/08 F 55 12 
Control Minimal tau pathology consistent with 
HP-tau stage I 
A192/09 M 80 21 
Control Widespread acute infarcts and acute 
ischaemic changes; old infarcts 
A063/10 F 90 50 
Control Control brain - mild Alzheimer-type 
changes (modified Braak II) and mild 
amyloid angiopathy 
A047/02 F 87 22 Control Normal adult brain 
A048/09 M 81 18 I Control - old cerebral infarct (Braak I) 
A239/03 M 78 10 Control Ageing changes  (mild) 
A265/08 M 79 47 
II Early tau pathology Braak II, no neuritic 
plaques 
A040/07 F 82 13 
Control Argyrophilic grains low to moderate 
density 
A124/04 M 59 50 Control Normal adult brain 
A150/01 M 40 40 Control Normal adult brain 
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A141/07 M 80 41 
VI Alzheimer's disease: Braak VI with 
severe amyloid angiopathy 
A065/04 F 91 29 VI Alzheimer's disease: Definite Braak VI 
A094/04 M 88 46 VI Alzheimer's disease: Definite Braak VI 
A059/07 F 92 42 VI Alzheimer's disease: Braak VI 
A331/07 F 80 13 
V Alzheimer's disease: Braak V with mild 
amyloid angiopathy 
A191/07 F 69 16 VI Alzheimer's disease: Braak VI 
A210/07 F 84 <24 V Alzheimer's disease: Braak V 
A167/05 F 81 <72 VI Alzheimer's disease: Braak VI 
A058/07 M 81 74 VI Alzheimer's disease: Braak VI 
A187/07 F 82 69 
V Alzheimer's disease: Braak V with mild 
amyloid angiopathy 
A168/05 F 84 36 V/VI Alzheimer's disease: Braak V/VI 
A247/05 F 90 23 V/VI Alzheimer's disease Braak V/VI 
A350/09 F 98 3.5 
IV Alzheimer's disease BNE IV, CERAD 
probable 
A065/02 M 82 80 V/VI Alzheimer's disease definite Braak V/Vi 
A318/09 M 72 5 
VI Alzheimer's disease: Braak VI with 
marked amyloid angiopathy 
A181/09 F 89 15 
IV Alzheimer's disease (BNE stage IV) 
with amyloid angiopathy 
A240/06 F 97 12 V Alzheimer's disease: Braak V 
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A013/03 M 89 19 
V/VI Alzheimer's disease: definite Braak 
V/VI 
A122/04 M 86 26 
V Alzheimer's disease: Braak V with 
moderate amyloid angiopathy 
A332/07 F 87 48 
VI Alzheimer's disease: Braak VI with 
moderate amyloid angiopathy 
 
Table 2.9. Case details for control and Braak I-VI Alzheimer's disease post-
mortem human temporal cortex 







A047/02 F 87 22 Control Normal adult brain 
A134/00 M 86 6 Control Normal adult brain 
A124/04 M 59 50 Control Normal adult brain 
A150/01 M 40 40 Control Normal adult brain 
A239/03 M 78 10 Control Ageing changes (mild) 
A040/07 F 82 13 Control 
Argyrophilic grains low to moderate 
density 
A153/06 F 92 17 Control Control brain with some tau deposition 
A358/08 F 55 12 I 
Minimal tau pathology consistent with 
HP-tau stage I 
A140/07 F 81 17 I Mild ageing changes Braak I 
*A265/08 M 79 47 II 




*A063/10 F 90 50 II 
Control brain- mild Alzheimer-type 
changes (modified Braak stage II) and 
mild amyloid angiopathy 
*A073/05 M 93 ~33 II Mild Alzheimer’s type changes Braak II 
*A310/09 F 84 35 II 
Alzheimer changes Braak II consistent 
with normal aging 
*A276/05 M 92 11 III 
Mild Alzheimer’s type changes due to 
ageing Braak III 
*A209/08 F 70 38 III 
Possible Alzheimer's disease (CERAD) 
Braak III (limbic) BNE stage III 
*A045/12 M 86 52 III 
Ageing changes (AD modified Braak 
stage 3) - suitable as control 
*A097/13 M 82 28 IV 
Alzheimer's disease (modified Braak 
stage 4) with limbic TDP-43 pathology 
*A078/13 M 86 53 IV 
Alzheimer's disease (modified Braak 
stage 4) with extensive severe amyloid 
angiopathy 
*A223/12 F 83 22 IV 
Alzheimer's disease (limbic stage) 
(modified Braak stage 4) and moderate 
to severe amyloid angiopathy 
*A175/12 F 89 56 IV 
Alzheimer's disease HP tau stage 4 
severely affecting limbic system and 
moderately extending to neocortex. 
A331/07 F 80 13 V 
Alzheimer's disease Braak V with mild 
amyloid angiopathy 
A187/07 F 82 69 V 
Alzheimer's disease Braak V  mild 
amyloid angiopathy 
A122/04 M 86 26 V 
Alzheimer's Braak V with moderate 
amyloid angiopathy 
A168/05 F 84 36 VI Alzheimer's disease  Braak V/VI 
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A094/04 M 88 46 VI Alzheimer's disease: Definite Braak VI 
A059/07 F 92 42 VI Alzheimer's disease Braak VI 
A191/07 F 69 16 VI Alzheimer's disease Braak VI 
2.2 Methods 
2.2.1 Breeding and maintenance of transgenic mice 
Breeding of animals was performed with males at least 8 weeks of age, and females at 
least 6 weeks of age. All animal housekeeping and procedures were carried out in 
accordance with the UK Scientific Procedures (Animals) Act (1986) under the authority 
of Project Licence 70/7204 and appropriate personal licence. 
2.2.2 Cell culture methods 
Primary neuronal cell culture 
100 ng/ml PDL in sterile H2O was used to coat cell culture dishes. Dishes were 
incubated at 37°C for 1-24 h. Excess poly-D-lysine was removed immediately prior to 
plating of neurons and cell culture dishes were washed with sterile H2O.  
Isolation and papain dissociation of cortical neurons from embryonic rat brain  
Embryonic day 18 (E18) Sprague-Dawley rat embryos (Charles River Laboratories, 
UK) were used to prepare primary cortical neurons following removal of the midbrain, 
cerebellum, and meninges. Dissected cortices were placed in Hank’s balanced salt 
solution (HBSS) without calcium and magnesium. Papain dissociation was carried out 
according to the manufacturer’s instructions (Section 2.1.6). Briefly, cortices were 
incubated in 5 ml papain solution containing 0.005% (v/v) DNAse I for 20 min at 37°C. 
Following vigorous trituration and straining (70 µm cell strainer, BD Falcon), a single 
cell suspension was produced. The cells were pelleted by centrifugation at 300 g(av) for 
5 min at ambient temperature. The pelleted cells were resuspended in a solution of 2.7 
ml EBSS mixed with 300 µl albumin-ovomucoid inhibitor solution and 150 µl DNase I. 
The cell suspension was layered onto 5 ml albumin-ovomucoid inhibitor solution and 
centrifuged at 70 g(av) for 5 min at ambient temperature to remove membrane 
fragments. The supernatant was removed, and pelleted cells were resuspended in 1 ml 
supplemented Neurobasal® medium per embryonic brain and counted using a 
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haemocytometer. Typically, 10 x 106 neurons were obtained from each embryonic 
brain. 
Plating of primary rat cortical neurons 
Cells were plated at the following densities: 
200,000 cells/well in a 12-well plate 
1 x 106 cells/well in a 6-well plate 
4 x 106 cells/10 cm diameter dish  
Culture of Chinese hamster ovary (CHO) cells 
CHO cells were maintained in Ham’s F-12 (Section 2.1.6) at 37°C, 5% CO2. Cells were 
passaged when they reached 80-90% confluency. Cells were passaged by washing 
with HBSS without Ca2+/Mg2+ followed by adding sufficient volume of trypsin-EDTA 
solution to cover the cells and incubating at 37°C for 5 min until cells detached. Cells 
were resuspended in culture medium to inactivate the trypsin. 
Transient transfection of CHO cells 
CHO cells were transfected at 70-80% confluency using jetPEI® (Polyplus 
Transfection) according to the manufacturer’s instructions. Briefly, for each well of a 6-
well plate, 3 μg of DNA was diluted in 150 mM NaCl to a final volume of 100 μl. 
Separately, 6 μl of jetPEI® reagent was added to 150 mM NaCl to a final volume of 100 
μl. The jetPEI® solution was added to the DNA solution, vortexed, and incubated at 
ambient temperature for 15 min. Culture medium was removed from the CHO cells and 
replaced with 1 ml of fresh medium. 200 μl of the transfection mix was added dropwise 
to each well and cells were incubated for 24 h at 37°C. Cells were harvested 24 h post-
transfection.  
Long-term culture of mouse cortical organotypic brain slices 
Postnatal day (P) 9-10 pups were used to prepare mouse cortical organotypic brain 
slice cultures. Pups were sacrificed by decapitation and the bisected heads were 
transferred immediately into oxygenated ice-cold dissection solution (Section 2.1.6). 
Following removal of the hippocampus and striatum, each half brain was placed into 
ice-cold oxygenated dissection solution. The corresponding half brain was cut into 350 
μm coronal slices using a McIlwain tissue chopper. Three slices were plated into each 
well of a 6-well plate containing tissue culture inserts (0.4 μm, Millipore) and 1 ml 
slicing medium (Section 2.1.6) and incubated at 37°C in 5% CO2. Three h after plating, 
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the medium was replaced with 1 ml fresh slicing medium, and slices were incubated at 
37°C in 5% CO2. The medium was changed every two days thereafter. 
Lentiviral transduction of organotypic brain slices 
Two different methods were used to assess the efficiency of lentivirus transduction into 
organotypic brain slices: 
(1) Lentivirus was diluted to 1x109 transducing units (TU)/ml in slicing medium. On the 
day of plating the slices, 107 TU lentivirus was pipetted per slice at the time of the first 
medium change. 
(2) 1 µl lentivirus (approximately 107 TU) was injected into each slice using a Hamilton 
2.5μl syringe at 3 equidistant locations. 
(3) 20 multiplicities of infection (MOI) (approximately 107 TU) lentivirus was diluted 
directly into the culture medium. 
Lentiviruses were allowed to transduce the cultures for at least 2 weeks before 
harvesting the slices. 
2.2.3 Protein extraction and fractionation 
Preparation of mouse brain homogenate 
Mouse brain tissue was homogenised in 1 ml ice-cold lysis buffer (Section 2.1.4) per 
half brain using a Dounce homogeniser. The homogenate was rotated for 30 min at 
4°C before being centrifuged at 16,000 g(av) for 45 min at 4°C. The supernatant was 
collected and diluted into 2x Laemmli sample buffer prior to western blotting. 
Preparation of primary cortical neuronal cell lysate 
Tissue culture medium was removed from rat cortical neuronal cultures. Cells were 
washed in ice-cold PBS and scraped into 2x Laemmli buffer (100 µl for each well of a 
6-well plate or 400 µl per 10 cm diameter dish). 
Preparation of organotypic brain slice lysate 
Organotypic brain slices were washed with ice-cold PBS and scraped into PBS. Brain 
slices were centrifuged for 30 s at 16,100 g(av) at 4°C to pellet the slices, and 
supernatant was discarded. Extra strong lysis buffer (Section 2.1.4) was added prior to 
sonication with a Vibra-Cell™ (Sonics & Materials, Inc., Newtown, CT, USA) with 5 
pulses at 40% output. Sonicated brain slices were then centrifuged at 16,100 g(av) for 
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20 min at 4°C. The resulting supernatant (brain slice lysate) was stored at -20°C until 
required.  
Subcellular fractionation 
PBS-washed rat cortical neurons or mouse brain tissue, on ice, were lysed in 1 ml ice-
cold hypotonic buffer (Section 2.1.4) per 12 x 106 cells. Lysed cells were sonicated 
using a Vibra-Cell™ (Sonics & Materials, Inc., Newtown, CT, USA) with 5 pulses at 
40% output, then centrifuged at 720 g(av) for 5 min at 4°C to remove unbroken cells. 
The supernatant was centrifuged at 100,000 g(av) for 1 h at 4°C. The resulting 
supernatant (cytosol) and pellet (membrane) fractions were resuspended in RIPA buffer 
or 2x Laemmli buffer. 
Preparation of homogenates from human post-mortem brain tissue  
Frozen human post-mortem brain tissue was thawed on ice and homogenised at 100 
mg tissue/ml using a mechanical homogeniser (Ultra Turrax® T8, Werke GmbH & Co., 
Germany). To obtain total brain homogenates, tissue was homogenised in 2x Laemmli 
buffer. For isolation of soluble cytoplasmic proteins, brain tissue was homogenised in 
TBS-EGTA buffer (Section 2.1.4), and for immunoprecipitation, brain tissue was 
homogenised in extra strong lysis buffer (Section 2.1.4). All homogenates were 
sonicated briefly using a Vibra-Cell™ for 3 pulses of 3 seconds each at 40% output. All 
samples were centrifuged at 16,000 g(av) at 4°C for 20 min. The supernatants were 
collected and stored at -80°C until required. 
Bicinchoninic acid (BCA) protein assay 
Protein concentrations of cell lysates and tissue homogenates were determined using 
the BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA) (Section 2.1.4) 
according to the manufacturer’s instructions. Briefly, 25 µl of BSA protein standard or 
sample diluted in lysis buffer were pipetted in duplicate into a 96-well plate. Reagent A 
was mixed with Reagent B at a ratio of 1:50, and 100 µl of this solution was added to 
each well. After incubating the plate at 37°C for 30 min, the absorbance was read at 
595 nm. 
2.2.4 SDS-PAGE 
Samples were mixed with 2x Laemmli sample buffer, heated at 100°C for 5 min, and 
centrifuged for 5 min at 16,000 g(av). Samples and molecular weight standards were 
loaded onto 10% (w/v) acrylamide gels. Gels were electrophoresed at 150V until the 
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dye front reached the end of the gel. In some experiments, the dye front was allowed to 
run off the gel for a period of 20 min. 
2.2.5 Colloidal Coomassie blue staining 
Gels were washed three times in H2O for 5 min each wash. ProtoBlue Safe Working 
Solution (Section 2.1.5) was added to cover the gels, which were then heated to 100°C 
for 30 s in 10 second bursts. The gels were incubated on an orbital shaker for 5 min, 
rinsed several times with H2O and incubated in H2O with agitation until protein bands 
were visible. 
2.2.6 Western blotting 
All steps were performed at ambient temperature unless otherwise stated. SDS-PAGE 
gels were transferred onto nitrocellulose membranes (0.45 µm, Whatman, GE 
Healthcare, Buckinghamshire, UK) using a Bio-Rad (Hertfordshire, UK) wet transfer 
system. Nitrocellulose membranes, sponges, and filter papers (11 µm, Whatman) were 
soaked in transfer buffer prior to assembly in the blotting cassette as follows: 
Anode 
Sponge 
10 filter papers 
Nitrocellulose membrane 
Gel 
10 filter papers 
Sponge 
Cathode 
Blotting cassettes were placed in transfer buffer (Section 2.1.5) with an ice pack, and 
electroblotted at 100V for 60 min. 
Membranes were incubated in blocking solution (Section 2.1.5) for 1 h to minimise non-
specific binding of primary antibody. Membranes were then incubated overnight in 
primary antibody (Section 2.1.5) at 4°C. Membranes were washed three times in PBS 
prior to incubation in secondary antibody (Section 2.1.5) for 1 h. Finally, membranes 
were washed three times in PBS and antigens were visualised using the Odyssey 
Infrared Imaging System (LI-COR Biosciences).  
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2.2.7 GST fusion protein pull-down 
All steps were performed at 4°C unless otherwise stated. Cells in 6-well plates were 
washed with 100 µl per well of ice-cold PBS prior to lysis in GST pull-down lysis buffer 
(Section 2.1.4) and incubated on ice for 15 min with occasional vortexing. Lysates were 
centrifuged at 6,000 g(av) for 5 min to pellet cell debris. A 50% slurry of GST-beads was 
washed twice in GST pull-down wash buffer prior to use. To wash the beads, triple the 
bead volume of wash buffer was added to the beads, which were vortexed and 
centrifuged briefly. The supernatant was removed and washing step was repeated 
once. Each lysate was pre-cleared with 20 µl bead slurry by mixing for 1 h. The beads 
were pelleted by brief centrifugation. 20 µl of pre-cleared supernatant was collected, 
mixed with 20 µl 2x Laemmli sample buffer and stored at -20°C (total lysate). 
The remaining supernatant was divided in two equal fractions and each was incubated 
with 20 µl 50% GST-only, GST-fyn-SH2, or GST-fyn-SH3 beads (Section 2.1.3). 
Samples were rotated overnight and the following day, the beads were pelleted at 
6,000 g(av)  for 5 min. The supernatant was discarded, beads were washed twice with 
wash buffer and resuspended in 30 µl 2x Laemmli sample buffer. Samples were heated 
at 100°C for 10 min and centrifuged at 16,000 g(av) for 1 min before analysing on 
western blots.  
2.2.8 Co-immunoprecipitation 
Pharmacological treatment and lysis of primary rat cortical neurons for co-
immunoprecipitation 
Primary rat cortical neurons were either untreated, or treated with vehicle (DMSO) or 4 
µM IC261 for 2 h at 37°C, or crosslinked using DSP for 30 min at ambient temperature. 
Cells were washed in ice-cold PBS prior to lysis in the appropriate buffer (Section 
2.1.4). Cells were incubated on ice for 15 min with regular vortexing, before being 
centrifuged at 16,000 g(av) for 30 min at 4°C. The supernatant was collected and stored 
on ice for subsequent co-immunoprecipitation studies. 
Preparation of mouse brain homogenate for co-immunoprecipitation 
Fresh mouse brain tissue was homogenised in ice-cold lysis buffer (Section 2.1.4) 
using a Dounce homogeniser. The homogenate was rotated for 30 min at 4°C before 
being centrifuged at 16,000 g(av) for 45 min at 4°C. The supernatant was collected and 
stored on ice for subsequent co-immunoprecipitation studies. 
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Subcellular fractionation of mouse brain homogenate for co-
immunoprecipitation 
Fresh mouse brain tissue was homogenised in ice-cold hypotonic buffer (Section 2.1.4) 
using a Dounce homogeniser. Homogenised tissue was sonicated using a Vibra-Cell™ 
(Sonics & Materials, Inc., Newtown, CT, USA) with 5 pulses at 40% output, then 
centrifuged at 720 g(av) for 5 min at 4°C to remove unbroken cells. The supernatant was 
centrifuged at 100,000 g(av) for 1 h at 4°C. The resulting supernatant (cytosol) and pellet 
(membrane) fractions were resuspended in RIPA buffer prior to subsequent co-
immunoprecipitation studies. 
Pervanadate treatment 
50 µl of 200 mM sodium orthovanadate was mixed with 1.6 µl of 30% (v/v) hydrogen 
peroxide in a final volume of 1 ml H2O, and incubated for 5 min at ambient temperature. 
Excess H2O2 was removed by adding 2 µl of 20 µg/ml catalase, and incubated for an 
additional 5 min at ambient temperature. CHO cells were treated with vehicle (0.04 
µg/ml catalase) or 100 µM sodium pervanadate for 20 min at 37°C. Cells were washed 
in ice-cold PBS prior to lysis in the appropriate buffer (Section 2.1.4). Cells were 
incubated on ice for 15 min with regular vortexing, before being centrifuged at 16,000 
g(av) for 30 min at 4°C. The supernatant was collected and stored on ice for subsequent 
co-immunoprecipitation studies. 
Co-immunoprecipitation 
A 50% (v/v) slurry of Protein A agarose beads was washed twice with lysis buffer 
(Section 2.1.4) prior to use. To wash the beads, a volume of buffer equivalent to three 
times the settled bead volume was added to the beads, which were then then vortexed 
and centrifuged at 8,000 g(av) for 1 min at 4°C. The supernatant was removed and 
washing steps were repeated. Homogenised brain tissue, or cell lysate was pre-cleared 
with 50% (v/v) washed bead slurry by mixing for 30 min at 4°C. The beads were 
pelleted by centrifugation at 8,000 g(av) for 1 min at 4°C. An aliquot of the pre-cleared 
supernatant from the homogenised brain tissue, or cell lysate (input) was mixed with 2x 
Laemmli sample buffer (Section 2.1), heated at 100°C for 5 min and stored at -20°C 
until required. 
The remaining pre-cleared supernatant was incubated with 3 μg primary antibody for 
16 h at 4°C. As negative controls, lysates were also incubated with an irrelevant 
antibody raised in the same species, or incubated without primary antibody. 
Lysate/antibody mixtures were incubated with 50% (v/v) washed bead slurry for 2 h at 
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4°C prior to centrifugation at 6,000 g(av) for 1 min at 4°C. The supernatant was 
discarded and the pellet (immunoprecipitate) was washed twice with the appropriate 
lysis buffer. 2x Laemmli sample buffer was added to each immunoprecipitate prior to 
analysis on western blots as detailed in Section 2.2. 
2.2.9 Sandwich ELISA 
A 96-well plate was coated with DA31 antibody, diluted 1/500 in coating buffer (Section 
0), overnight at 4°C with shaking. The plate was washed three times with washing 
solution (Section 0) and incubated in 200 μl blocking solution (Section 0) for 1 h with 
shaking at ambient temperature. After washing five times with washing solution, 50 μl 
cell culture medium supernatant (culture medium which had been centrifuged at 16,100 
g(av) at 4°C to remove cell debris) was added to triplicate wells. 50 μl of anti-tau 
detection antibody (manufactured by DAKO), diluted 1/1,000 in antibody diluent 
(Section 0), was mixed with the medium and the plate was sealed and incubated 
overnight at 4°C with constant agitation.  
The plate was washed five times with PBS before and incubated in 100 μl 1/500 HRP-
conjugated anti-rabbit secondary antibody (GE Healthcare, Buckinghamshire, UK) for 1 
h with shaking. After washing five times in PBS, 100 µl TMB reagent was added and 
the plate was incubated for 5-10 min, before stopping the reaction with 100 µl 1N 
hydrochloric acid. Absorbance at 450 nm was read using a Victor3™ Multilabel Plate 
Reader (PerkinElmer Life Sciences, Waltham, USA). 
2.2.10 Cell toxicity assays 
Lactate dehydrogenase (LDH) assay 
Cell culture medium was centrifuged for 5 min at 16,100 g(av) at 4°C to remove cell 
debris (pellet). 50 µl cell culture medium or cell lysate, diluted in medium, was pipetted 
in a 96-well plate in triplicate, with cell-free medium as a blank. 50 µl LDH substrate 
(Section 2.1.4) was added to each well and the plate was incubated at ambient 
temperature, protected from light, for 30 min, after which the plate was read at 490 nm 
to estimate the degree of LDH release. 
LIVE/DEAD assay 
Cells in a 12-well plate were washed with PBS and incubated in 300 µl per well of 
LIVE/DEAD solution (Section 2.1.4), diluted in 1/1,000 in PBS. After incubation at 37°C 
in a humidified chamber with 5% CO2 for 30 min, cells were rinsed with PBS and fixed 




All steps were performed at ambient temperature unless otherwise stated. Culture 
medium was removed from organotypic brain slices and washed once with PBS. Slices 
were fixed in 4% (w/v) PFA in PBS (Section 2.1.4) for 15 min followed by three washes 
in PBS. To permeabilise, slices were incubated in 0.5% (v/v) Triton X-100 in PBS 
overnight at 4°C. The following day, slices were blocked in 20% (w/v) BSA in PBS for 4 
h, after which they were washed 3x in PBS. Primary antibodies diluted in 5% (w/v) BSA 
in PBS (Section 2.1.4) were incubated with slices overnight at 4°C. Following three 
washes in PBS, secondary antibodies diluted in 5% (w/v) BSA in PBS were applied for 
4 h, removed from light. Slices were washed three times in PBS and incubated in 
1µg/ml Hoescht 3342 in PBS for 3 min in the dark. Finally, slices were washed twice 
with PBS and mounted onto glass slides using mounting medium (DAKO, 
Cambridgeshire, UK). Mounted slices were stored at 4°C, protected from light, until 
required. Images were captured using Nikon Imaging Software Elements-Advanced 
Research (NIS-Elements AR) on a Nikon Eclipse Ni-E Upright microscope equipped 
with a CSU-X1 Spinning Disk Confocal scanning unit and Andor Ixon3 EM-CCD 
camera. 
2.2.12 Molecular biology methods 
Site-directed mutagenesis 
Polymerase chain reaction (PCR)-based mutant strand synthesis 
Site-directed mutagenesis was carried out using the QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent Technologies, Cheshire, UK) according to the manufacturer’s 
instructions. In brief, control and experimental reactions were prepared as shown 
below. PCR was used with cycling parameters listed in Table 2.10 in order to amplify 
the mutagenesis and control reaction.  
All reactions were comprised of the following reagents: 
5 µl 10x reaction buffer 
1 µl dNTP mix 
3 µl QuikSolution reagent 
1 µl PfuUltra HF DNA polymerase (2.5 U/µl) 
Control reactions contained: 
2 µl (10 ng) pWhitescript 4.5-kb control plasmid (5 ng/µl) 
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1.25 µl (125 ng) oligonucleotide control primer #1 (34-mer, 100 ng/µl) 
1.25 µl (125 ng) olignoucleotide control primer #2 (34-mer, 100 ng/µl) 
Experimental reactions contained: 
5 µl (10 ng) template DNA 
125 ng each (forward and reverse) mutagenesis primer 
H2O was added to a final volume of 50 µl. 
Table 2.10. PCR cycling parameters for site-directed mutagenesis 
Step Cycles Temperature 
(°C) 
Time 
1. Initial denaturation 1 95 1 min 
2. Denaturation, annealing, and 
elongation 
18 95 50 s 
60 or 68 50 s 
68 7 min 
3. Extension 1 68 7 min 
Dpn I digestion of the PCR product 
Following PCR cycling (Table 2.10), samples were placed on ice and 1 µl Dpn I (10 
U/µl) was added. Samples were mixed and incubated at 37°C for 1 h to digest parental 
DNA, leaving mutant DNA intact. 
Transformation of XL10-Gold ultracompetent cells 
45 µl XL10-Gold ultracompetent cells was mixed with 2 µl of β-mercaptoethanol and 
incubated for 10 min on ice. 2 µl Dpn I-treated DNA, or 0.01 ng pUC18 control plasmid, 
was added to the ultracompetent cells, which were incubated on ice for 30 min. The 
cells were heated at 42°C for 30 s and placed on ice for 2 min. 0.5 ml of preheated 
(42°C) LB broth was added to each tube, incubated at 37°C for 1 h with shaking at 
225-250 rpm. Transformed cells were plated onto LB-ampicillin agar plates, pre-spread 
with 10 mM IPTG and 20 mg/ml X-gal (Section 2.1.1), and incubated overnight at 37°C.  
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Preparation of plasmid DNA 
Individual bacterial colonies were used to inoculate 5 ml LB-ampicillin broth and 
incubated at 37°C for 16 h with shaking at 225-250 rpm. Plasmid DNA was isolated 
using the QIAprep Spin Miniprep kit (Qiagen, Manchester, UK) according to the 
manufacturer’s instructions. 
Restriction enzyme digestion 
5 µl plasmid cDNA was digested with 1 U BamHI and PmeI restriction enzymes in their 
corresponding buffers, according to the manufacturer’s instructions (Promega, 
Southampton, UK). After incubation at 37°C for 1-2 h, samples were mixed with DNA 
loading buffer and separated on a 1% (w/v) agarose gel containing 5% ethidium 
bromide at 120 V for 1 h. DNA was visualised in a GelDoc-It® (UVP, Upland, CA, USA) 
transilluminator at a wavelength of 302 nm. 
DNA sequencing 
Plasmid DNA was sequenced by Eurofins MWG Operon, Wolverhampton, UK using 
the T7 primer.  
Lentiviral tau plasmids 
Wild-type (WT) human tau (2N4R), along with mutant tau P213A, tau P216A, and 
P219A in pcDNA3.1-V5-His-TOPO were subcloned into Lenti-GFP (Table 2.1) in a 
multi-step process. It was necessary to first introduce a stop codon into the WT and 
mutant tau constructs, before subcloning into pIRES2-EGFP vector to allow for 
screening of viral transduction efficacy. Finally, Tau-IRES plasmids were subcloned into 
the lentiviral backbone. Refer to Chapter 4 for a diagram of cloning scheme. 
Introduction of stop codon in WT and mutant tau in pcDNA3.1-V5-His-TOPO 
Primers were designed (Table 2.3) to introduce a stop codon at nucleotide 2297, 
replacing A with T to produce the stop codon TGA. Primers were designed to amplify a 
230 bp fragment of tau flanking the stop codon, to include restriction sites for BsrGI and 
EcoRV. PCR was used with the cycling parameters listed in Table 2.11 using WT tau as 
template.  
The reaction  comprised the following reagents: 
10 µl 5x GoTaq Reaction buffer (Promega, Southampton, UK) 
2.5 mM dNTP mix (GE Healthcare, Buckinghamshire, UK) 
1 µl (100 ng) forward primer 
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1 µl (100 ng) reverse primer 
1 ng template DNA 
0.25 μl Taq polymerase (Promega, Southampton, UK) 
H2O was added to a final volume of 50 µl. 
Table 2.11. PCR cycling parameters for introduction of stop codon 
Step Cycles Temperature 
(°C) 
Time 
1. Initial denaturation 1 95 2 min 
2. Denaturation, annealing, and 
elongation 
20 95 50 s 
65 50 s 
72 7 min 
3. Extension 1 72 7 min 
The PCR reaction was resolved on a 1.5% (w/v) agarose gel and the 230 bp fragment 
(insert) was extracted using the QIAquick Gel Extraction Kit (Qiagen, Manchester, UK) 
according to the manufacturer’s instructions. Extracted insert DNA containing stop 
codon, and 1 µg of vector DNA (WT, P213A, P216A, P219A tau) was digested with 
BsrGI and EcoRV overnight at 37°C. Double-digested vector DNA was resolved on a 
0.7% (w/v) agarose gel and double-digested insert DNA was resolved on a 1.5% (w/v) 
agarose gel. Insert DNA fragment (169 bp) and vector DNA fragment (6718 bp) were 
extracted from the agarose gel and the following reaction was set up for ligation with T4 
DNA ligase using a 1:6 vector to insert molar ratio with a total of 100 ng DNA per 
ligation. Ligation reaction was incubated overnight at ambient temperature.  
100 µl of thawed DH5α E.coli competent cells were incubated with 1.2 ng ligated DNA 
on ice for 30 min and heat-shocked for 45 s at 42°C, then placed on ice for 2 min. 900 
µl of SOC medium was added to each reaction and incubated at 37°C for 1 h with 
shaking at 225-250 rpm. Finally, transformed cells were plated onto LB-ampicillin agar 
plates and incubated overnight at 37°C. Individual bacterial colonies were used to 
inoculate 5 ml LB-ampicillin broth and incubated at 37°C for 16 h with shaking at 225-
250 rpm. Plasmid DNA was isolated using the QIAprep Spin Miniprep kit according to 
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the manufacturer’s instructions to produce tau constructs containing a stop codon 
(pcDNA3.1-tau-stop). 
Generation of Tau-IRES 
pcDNA3.1-tau-stop was placed into a pIRES2-EGFP vector to enable GFP screening 
of lentiviral transduction. pcDNA3.1-tau-stop (insert) was cut out using EcoRI and 
EcoRV, while pIRES2-EGFP (vector) was cut with EcoRI and SmaI. Digested insert 
(1370 bp) and vector (5278 bp) DNA was resolved on a 0.7% (w/v) agarose gel and 
extracted. Vector and insert DNA were ligated overnight and used to transform DH5α 
cells as above. Plasmid DNA was isolated using the QIAprep Spin Miniprep kit 
according to the manufacturer’s instructions to produce Tau-IRES. 
Generation of LV-tau 
Tau-IRES was then transferred to a lentiviral backbone containing the human synapsin 
promoter. Lenti-GFP DNA was first digested with SpeI and NotI to remove the GFP 
transgene, which would then be replaced with tau-IRES. Following overnight digestion 
of Lenti-GFP with SpeI at 37°C, SpeI-cut Lenti-GFP was heat inactivated at 80°C for 20 
min and blunted with Quick Blunting Kit (New England BioLabs, Hertfordshire, UK) 
according to the manufacturer’s instructions.  
The blunting reaction contained: 
4 μg SpeI-digested DNA 
2.5 μg 10x Blunting Buffer 
100 μM dNTP mix 
1 μl Blunt Enzyme mix 
H2O to 25 μl 
The blunting reaction was incubated at ambient temperature for 15 min then heat 
inactivated at 70°C for 10 min. Blunt-SpeI-cut Lenti-GFP was resolved and extracted 
from a 0.8% agarose gel, then subsequently dephosphorylated using shrimp alkaline 
phosphatase (rSAP). 
The dephosphorylation reaction contained: 
1 pmol blunted DNA 
2 μl 10x rSAP Reaction Buffer 
1 μl rSAP (1 unit/μl) 
H2O to 20 μl 
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The dephosphorylation reaction was incubated at 37°C for 20 min and heat inactivated 
at 65°C for 5 min. Finally, blunt-SpeI-cut Lenti-GFP was digested with NotI and 
extracted from a 0.8% (w/v) agarose gel to produce the cut Lenti-GFP vector (8.1 kb). 
Tau-IRES was digested with AfeI and NotI to produce insert DNA size of 2.7 kb. Vector 
and insert DNA were ligated as above and transformed into SURE2 competent cells. 
100 µl of thawed SURE2 competent cells were incubated with 2 μl β-mercaptoethanol 
and incubated on ice for 10 min with mixing at 2 min intervals. 2 μl ligated DNA was 
added and cells were incubated on ice for 30 min. Cells were then heat-shocked for 30 
s at 42°C, then placed on ice for 2 min. 900 µl of LB broth was added and incubated at 
37°C for 1 h with shaking at 225-250 rpm. Finally, transformed cells were plated and 
bacterial colonies were used to inoculate 5 ml LB-ampicillin broth as above. Plasmid 
DNA was isolated as above to produce lentiviral constructs expressing tau-IRES-EGFP 
(LV-tau). 
Preparation of endotoxin-free lentiviral plasmid DNA 
Plasmid DNA used to produce lentivirus stocks must be endotoxin-free. LV-tau DNA 
was prepared using EndoFree Plasmid Maxi Kit (Qiagen, Manchester, UK) according to 
the manufacturer’s instructions. Briefly, a single colony was picked from plates and 
used to inoculate 5 ml LB broth containing the appropriate antibiotic. Bacteria were 
grown for 8 h at 37°C in a shaking incubator, after which 2.5 ml culture was diluted into 
250 ml LB broth containing the appropriate antibiotic. Bacteria were grown overnight at 
37°C in a shaking incubator before being pelleted by centrifugation at 6,000 g(av) for 15 
min at 4°C. Pellets were resuspended in 10 ml buffer P1, lysed with the addition of 10 
ml buffer P2 and incubated for 10 min at ambient temperature. The lysis reaction was 
stopped by addition of 10 ml buffer P3. The resulting lysates were passed through a 
QIAfilter® cartridge and incubated for 10 min at ambient temperature to allow the 
precipitate to separate. Using the plunger, lysates were filtered through the cartridges 
into 50 ml Falcon tubes, and 2.5 ml of endotoxin removal (ER) buffer was added to 
each tube in order to remove endotoxins. Lysates containing ER buffer were incubated 
for 30 min on ice, after which they were applied to equilibrated QIAGEN-tip 500® 
columns. Lysates were allowed to enter the resin by gravity flow. The columns were 
washed twice with 30 ml QC buffer. To elute the DNA, 15 ml of QN buffer was added to 
the columns and allowed to enter the resin by gravity flow. The eluted DNA was 
collected in 30 ml endotoxin-free tubes. 10.5 ml of isopropanol was added to the eluted 
DNA to precipitate the DNA, and immediately centrifuged at 15,000 g(av) for 30 min at 
4°C. The supernatant was removed, and the pellet was washed with 5 ml of endotoxin-
free 70% ethanol, before centrifuging at 15,000 g(av) for 10 min at 4°C. The supernatant 
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was carefully decanted, and the pellets were air-dried at ambient temperature for 5-10 
min. The DNA pellets were resuspended in 300-500 µl of endotoxin-free Tris-EDTA 
(TE) buffer and stored at -20°C until required. 
Preparation of lentiviruses 
Lentiviruses were prepared by Penn Vector Core, University of Pennsylvania, PA, USA. 
DNA extraction 
Ear punches from individual fyn-/- and tau-/- mice were incubated with 20 μl digestion 
mix containing proteinase K (Section 2.1.3) and incubated at 55°C for 20 min. Tubes 
were vortexed and incubated for an additional 20 min at 55°C. 80 μl of PCR-grade H2O 
was added to each sample and vortexed before heating at 100°C for 10 min to 
inactivate proteinase K and melt DNA strands. Finally, 20 μl of sample was diluted with 
60 μl of PCR-grade H2O and the DNA was then used for PCR genotyping. PCR cycling 
parameters are listed in Table 2.11. 
Genotyping 
PCR reaction contained: 
1 μl each primer (1.25 μM) (Section 2.1.3) 
1 μl DNA 
10 μl REDExtract-N-Amp PCR ReadyMix (Sigma) 
H2O was added to a final volume of 20 μl. 
 
 
Table 2.12. PCR cycling parameters for genotyping of fyn-/- and tau-/- mice 
Genotype Cycle 
Fyn-/- mice 94°C for 3 min (1 cycle) 
94°C for 30 s, 60°C for 45 s, 72°C for 45 s 
(35 cycles) 
72°C for 2 min (1 cycle), 4°C hold  
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Tau-/- mice 94°C for 3 min (1 cycle) 
94°C for 30 s, 60°C for 1 min, 72°C for 1 
min (35 cycles) 
72°C for 2 min (1 cycle), 4°C hold 
 
Preparation of recombinant GST fusion proteins 
Frozen glycerol preparations of E.coli containing GST- and GST-fyn-SH3-encoding 
plasmids were streaked across LB-ampicillin agar plates and incubated overnight at 
37°C. A single bacterial colony was used to inoculate 5 ml LB-amp broth and incubated 
overnight at 37°C with shaking. 2.5 ml overnight culture was then added to 250 ml LB-
amp broth and incubated for 2 h at 37°C with shaking until an optical density (OD) of 
0.6-1.0 nm was reached. IPTG was added to the cultures to a final concentration of 1 
mM and cultures were incubated for a further 2 h with shaking. The culture was then 
centrifuged at 20,000 g(av) for 15 min at 4°C to pellet the bacteria. The pellet was 
resuspended in 12 ml TNE buffer (Section 2.1.4) and homogenised by sonication for 
six 15 s bursts on ice. Triton X-100 was added to a final concentration of 1% (v/v), 
mixed, and the samples were centrifuged at 30,000 g(av) for 10 min at 4°C. The 
supernatant, containing GST-fusion proteins, was collected and stored on ice. 
Coupling of GST-fusion proteins to glutathione beads 
A 50% (v/v) slurry of glutathione-4B beads (GE Healthcare, Buckinghamshire, UK) was 
washed three times in TNE buffer (Section 2.1.4) to remove ethanol. 750 μl 
glutathione-4B beads was added per 10 ml supernatant and rotated for 90 min at 4°C, 
then centrifuged at 3,300 g(av) for 1 min at 4°C to pellet the beads. Beads coupled to 
GST-fusion proteins were washed three times with TNE buffer and resuspended to a 
50% slurry with TNE buffer. 
2.2.13 Data analysis 
Statistical analyses were performed using Microsoft Excel and GraphPad Prism 5. Data 
were tested for normal distribution using D’Agostino-Pearson normality test. When 
comparing two groups, Student’s unpaired t-test was used to determine statistical 
significance. When comparing more than two groups, one-way analysis of variance 
(ANOVA) with Tukey’s post-hoc test was used to determine differences between 
groups. For non-normally distributed data, Mann-Whitney test or Kruskal-Wallis test 
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was used to analyse comparisons between two or more than two groups, respectively. 
Spearman’s rank correlations were used to determine correlations between proteins. 




Chapter 3 Tau release from organotypic brain slices 
Tau has a well-established role as a microtubule-binding protein, but more recently, 
evidence has shown that tau may have novel functions related to its positioning in 
additional subcellular compartments. Notably, although considered to be a 
predominantly axonal protein, tau is known to mislocalise to the somatodendritic 
compartment of neurons in AD (Hoover et al., 2010; Zempel et al., 2010; Zempel and 
Mandelkow, 2014).  
The appearance of tau pathology in Alzheimer’s disease is initially observed in the 
entorhinal cortex, from where it spreads to anatomically connected regions (Braak and 
Del Tredici, 2011; Braak et al., 2011). It was previously suggested that the spread of tau 
pathology could be a passive process due to the death of neurons and subsequent 
release of toxic pathology-causing tau species (Gómez-Ramos et al., 2006; Simón et 
al., 2012b). However, several groups have now shown that tau pathology spreads 
through anatomically-connected regions of the brain, but the underlying mechanisms of 
this propagation has thus far been unclear (de Calignon et al., 2012; Liu et al., 2012; 
Clavaguera et al., 2013; Ahmed et al., 2014; Peeraer et al., 2014). Restricting 
expression of FTDP-17T-associated P301L tau to the entorhinal cortex in a transgenic 
mouse model showed trans-synaptic propagation of tau pathology (de Calignon et al., 
2012; Liu et al., 2012). As the P301L tau mice aged, mutant tau pathology developed in 
an anterograde fashion through synaptically connected regions from the entorhinal 
cortex to the dentate gyrus. Initially it was proposed that tau pathology spread via tau 
release upon cell death and uptake by neighbouring cells (Gómez-Ramos et al., 2006; 
Frost et al., 2009; Simón et al., 2012b). However, evidence from cell studies now 
shows that tau can be found extracellularly, even in the absence of disease or cell 
death (Chai et al., 2012; Simón et al., 2012a; Pooler et al., 2013a). Taken together, 
these studies suggest that synaptic activity, rather than diffusion, may be involved in 
the transmission of tau pathology. Furthermore, in vivo microdialysis detected tau in the 
interstitial fluid of mice expressing either WT or P301L tau, further suggesting that tau 
may be released from neurons under both physiological and pathological conditions 
(Yamada et al., 2014). Taken together, these studies suggest that synaptic activity may 
be involved in the transmission of tau pathology, rather than tau spread occurring 
passively by the diffusion of mutant tau. 
Several groups have shown that tau can be released from non-neuronal cells 
overexpressing tau, induced pluripotent stem cell-derived neurons, lamprey neurons, 
and mouse primary cortical neurons (Karch et al., 2012; Lee et al., 2012; Plouffe et al., 
2012; Saman et al., 2012; Simón et al., 2012a; Pooler et al., 2013a; Mohamed et al., 
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2014). These reports include studies from this laboratory showing that tau can be 
released from cultured primary cortical neurons following stimulation of neuronal 
activity by KCl or AMPA receptor agonists. Importantly, this secretion of tau is not 
accompanied by cell death, suggesting that tau release is a physiological process in 
healthy neurons that can be regulated by neuronal activity (Pooler et al., 2013a). Since 
tau spreads trans-synaptically in mouse brain (de Calignon et al., 2012; Liu et al., 
2012), and tau release from neurons is activity-dependent and stopped upon blockade 
of pre-synaptic vesicle release (Pooler et al., 2013a), this suggests that synaptic 
activity may modulate release of physiological and pathogenic tau.   
The mechanisms controlling the secretion of tau from neuronal cells remain to be 
elucidated. The phosphorylation state of tau can modify several tau functions, such as 
microtubule binding and association with membranes (Lindwall and Cole, 1984; Pooler 
et al., 2012). However, it is unclear whether tau phosphorylation and the activity of 
protein kinases affect tau release. This laboratory reported previously that fyn, a non-
receptor-associated tyrosine kinase, was necessary for the phosphorylation-dependent 
movement of tau from the cytosol to the membrane (Pooler et al., 2012). Since fyn is 
required for trafficking of intracellular tau to the membrane, it is possible that fyn may 
also play a role in regulating the secretion of tau from healthy neurons. 
Furthermore, the role of Aβ in tau propagation is unknown. The spread of tau pathology 
does not require the presence of toxic Aβ oligomers, as seen from several transgenic 
mouse models that harbour tau mutations (de Calignon et al., 2012; Liu et al., 2012; 
Michel et al., 2014). However, since Aβ exerts toxic effects on synapses, both indirectly 
and directly, and tau release is regulated by synaptic activity, it is important to 
determine whether Aβ can also alter tau release, as this could have implications for 
disease (Shankar et al., 2008; Ittner et al., 2010; Ripoli et al., 2014). Although soluble 
Aβ oligomers applied to primary cortical neurons did not appear to affect  activity-
dependent tau release (Pooler et al., 2013a), it is important to test the effects of Aβ in a 
more physiologically relevant system to better inform studies of potential synergistic 
effects between  tau and Aβ. 
In vivo studies using animal models are invariably the most physiologically relevant 
system available, but this requires extensive use of animals and high cost. Therefore 
culture of non-neuronal cells and primary neurons is frequently used to mitigate some 
of the disadvantages of using animal models. Despite their widespread use, primary 
neurons remain an imperfect in vitro model of a living animal. However, the use of non-
neuronal cells to investigate mechanisms of disease is questionable, as this usually 
involves overexpression of exogenous target protein which could generate artifactual 
99 
 
data. Primary neurons are typically maintained as a monolayer and other components 
of the neuronal system are missing, such as glial cells and the complex connectivity 
that exists between neural cell types in vivo (Duff et al., 2002).  
Long-term organotypic brain slice cultures are an attractive alternative to primary 
neurons and mouse models, as they retain synaptic plasticity and the cytoarchitecture 
of the brain in vivo, including a good representation of physiological neural cell 
composition (Gähwiler et al., 1997). Large numbers of brain slices can be prepared 
from a single animal, lessening the impact of animal use in research (Figure 3.1) (Duff 
et al., 2002).  
 
 
Figure 3.1 Schematic of organotypic brain slice preparation. 
Organotypic brain slices are prepared from postnatal mouse pups. (A) The cortex is 
first bisected (B) and sliced into 350 μm sections (C) before plating on a cell culture 
plate lined with membrane inserts (D). Medium exchange of brain slices is carried out 




It has been shown that organotypic hippocampal slices prepared from rat brain are 
developmentally comparable with acute hippocampal slices, when analysing synaptic 
transmission and morphology of spines (De Simoni et al., 2003). In contrast to acute 
slices, organotypic brain slices are also able to survive in long-term culture, which is 
advantageous for studies of neurodegeneration as this is usually a long-term process 
that cannot be replicated in acute slice cultures (Cho et al., 2007). Organotypic brain 
slices also offer an advantage over acute slices in that organotypic cultures recover 
from the slicing procedure and cells that have been damaged during dissection are 
removed after adaptation to the culture environment within 2-3 weeks (Gähwiler, 1981). 
Indeed, cultures of organotypic brain slices have previously been generated from 
P301S transgenic mice as a model of tauopathy (Mewes et al., 2012). Organotypic 
brain slices have also been used to evaluate drugs targeting tau aggregation (Congdon 
et al., 2012; Messing et al., 2013). Moreover, organotypic brain slices have been used 
to study a variety of other processes such as white matter injury, axonal regeneration, 
and epilepsy (Stoppini et al., 1997; Dean et al., 2011; Morin-Brureau et al., 2013). Once 
optimized, this technique provides a more physiological system than cell lines and 
primary neurons in which to model interactions between tau and fyn in normal and 
pathogenic conditions. 
In the work described herein, we sought to further investigate neuronal tau release 
from organotypic brain slices prepared from WT and fyn-/- mice. The aims of this 
chapter were to establish whether (1) tau is secreted by organotypic brain slices under 
basal conditions and following stimulation of neuronal activity, (2) fyn is involved in this 




3.1.1 Characterisation of wild-type and fyn-/- organotypic brain slices 
The mechanisms underlying the release of tau are not clear, although they have been 
studied in various model systems. Mounting evidence supports the hypothesis that tau 
release from neurons is regulated by synaptic activity. Therefore, in order to ensure that 
tau release could be investigated in organotypic brain slices, these were initially 
characterised to investigate the expression of tau protein and synaptic proteins. 
Organotypic brain slices were also examined by immunocytochemistry to analyse the 
cytoarchitecture and arrangement of neurons and glia. 
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WT organotypic brain slices prepared from P9-10 mouse pups were prepared and 
cultured for 28 DIV before being harvested and fixed with PFA. Several studies report 
the presence of a ‘glial scar’ either on top or beneath brain slices maintained in long-
term culture (del Rio and Soriano, 2010). In order to verify this, slices were stained with 
MAP2, a neuron-specific dendritic marker, GFAP, an astrocytic marker, and Hoescht 
33342 to indicate nuclei. Double immunostaining with GFAP and MAP2 for astrocytic 
and neuronal cells shows the retained cytoarchitecture of the cortex by epifluorescence 
microscopy (Figure 3.2A). Slices were also labelled with tau and GFAP antibodies. 
Using confocal microscopy, representative images taken from the top, middle, and 
bottom of the slice show a higher density of GFAP-positive cells clustered on the top 
and bottom layers of the slice (Figure 3.2B). In contrast, tau-positive cells appear 
primarily between these layers of astrocytes, suggesting the presence of a ‘glial scar’ in 





Figure 3.2 Immunocytochemistry of organotypic brain slices 
Characterisation of 28 DIV wild-type organotypic brain slices by immunocytochemistry. 
(A) Slice stained with MAP2 (green), GFAP (red), and Hoescht 33342 nuclear marker 
(blue) shows that brain slices retain much cytoarchitecture of the intact brain. (B) Z-
stack images from a confocal microscope showing image of a slice stained for tau 
(green) and GFAP (red). Top (left panel) and bottom (right panel) images show intense 
staining of GFAP-positive astrocytes. (C) Diagram of transverse view of brain slice 
(orange) in culture. Dashed lines (blue) indicate approximate planes of confocal images 




It was next important to examine any differences between WT and fyn-/- organotypic 
brain slices. These were cultured for 14, 28, and 42 DIV before being harvested. Some 
brain slices did not remain viable for 42 DIV and, in these cases, only the earlier time 
points were investigated. Slices from each time point were lysed and processed 
together in order to reduce variability between experimental conditions. Slice lysates 
were analysed on western blots and quantified data were normalised to values for WT 
14 DIV samples within each experimental repeat. The results show that there was no 
difference in the amount of tau present between WT and fyn-/- brain slices. 
Furthermore, increasing the time in culture from 14 to 42 DIV did not result in any 
change in the amount of tau present in either WT or fyn-/- brain slices (Figure 3.3A). 
Immunoblots probed with an antibody against dephosphorylated tau at S199/S202 
(Tau-1) showed similar results to those obtained for total tau and there were no 
apparent changes in phosphorylation at this epitope over time in either WT or fyn-/- 
brain slices (Figure 3.3B). In contrast, an antibody against tau phosphorylated at 
S396/S404 (PHF-1) revealed significantly less PHF-1 tau, relative to total tau, present 
in fyn-/- brain slices at both 14 and 28 DIV compared to WT brain slices (Figure 3.3C). 
However, by 42 DIV, the amount of PHF-1 was similar in both WT and fyn-/- brain slices. 
These results show that whilst the amount of total tau and tau dephosphorylated at 
S199/S202 in WT and fyn-/- brain slices is similar for culture periods up to 42 DIV, tau 
phosphorylated at S396/S404 is decreased in fyn-/- brain slices, at least up to 28 DIV.  
In order to investigate expression of synaptic proteins, western blots were probed with 
antibodies against pre-synaptic (synaptophysin) and post-synaptic (drebrin and PSD-
95) proteins. Drebrin was present in WT brain slices at each of the three ages 
examined, but the amount of drebrin present was diminished at 42 DIV, although this 
did not reach significance when compared to 14 DIV (Figure 3.3D). This is consistent 
with previous reports of changes in developmental drebrin expression in rat brain tissue 
(Shirao et al., 1989). There are two isoforms in the rat, drebrin-E (embryonic) and 
drebrin-A (adult) which run at 130 and 140 kDa, respectively (Shirao et al., 1989). As 
the two bands may not be distinguishable on western blots, reduced density of drebrin 
bands in older slices may reflect loss of the embryonic drebrin band. The amount of 
drebrin in fyn-/- brain slices was significantly reduced at 28 DIV in fyn-/- compared to WT 
brain slices, indicating a possible difference in the development of dendritic spines 
between WT and fyn-/- brain slices maintained in long-term culture (Figure 3.3D). At 42 
DIV, fyn-/- brain slices did not express any drebrin, indicating potential loss of viability in 





Figure 3.3 Characterisation of organotypic brain slice cultures 
Quantification of (A) total tau, (B) tau-1 (tau dephosphorylated at S199/S202), (C) PHF-
1 (tau pS396/S404), (D) drebrin, (E) PSD-95, (F) synaptophysin, and (G) fyn in WT 
(light grey bars) and fyn-/- (dark grey bars) cultured brain slices at 14, 28, and 42 days 
in vitro (DIV). Values represent mean ± SEM, n = 3-12. Two-way ANOVA with post-hoc 




The amount of PSD-95, a post-synaptic scaffolding protein, was approximately 
equivalent in 14 DIV WT and fyn-/- slices, but it was significantly reduced in fyn-/- brain 
slices at 28 and 42 DIV compared to WT brain slices cultured for the same amount of 
time (Figure 3.3E). In contrast, synaptophysin was detected in similar amounts at all 
ages in WT brain slices and synaptophysin expression was not significantly different 
between WT and fyn-/- brain slices at 14 and 28 DIV (Figure 3.3F). However, 
synaptophysin was not detectable in fyn-/- slices at 42 DIV, which could indicate loss of 
cell viability at this age. 
WT slices were also probed with an antibody against fyn, which showed that the 
amount of fyn remained stable at 14 and 28 DIV, but this increased approximately two-
fold at 42 DIV (Figure 3.3G). The relative stability of synaptophysin and PSD-95 
expression over time from 14 to 42 DIV suggests that the synaptic machinery such as 
synaptic vesicle scaffolding has been developed by 14 DIV and that slices are mature, 
at least for WT slices. Relative to WT brain slices, these results indicate that fyn-/- brain 
slices may have less developed dendritic spines as reflected by the decreased 
expression of drebrin and PSD-95 compared to WT. However, synaptophysin was not 
significantly different from WT brain slices. As the following experiments required use of 
reagents that would affect synaptic activity, such as KCl and Aβ, it was important to 
examine the expression of synaptic markers over time to select an appropriate age of 
slices for subsequent experiments. Based on these findings, slices cultured for periods 




3.1.2  Tau is secreted upon stimulation of neuronal activity in organotypic 
brain slices 
Stimulation of neuronal activity by treatment with KCl and AMPA receptor agonists has 
been shown to induce the release of tau in primary neurons without affecting cell 
viability (Pooler et al., 2013a). As organotypic brain slices are a more physiologically 
relevant model than primary neurons in culture, basal and stimulated tau release was 
investigated in organotypic brain slices. 
Organotypic brain slices exhibit relatively stable expression of synaptophysin and PSD-
95 between 14 to 42 DIV, hence organotypic brain slices between 28-42 DIV were used 
to investigate tau release in this model system. Slices were washed with Hank’s 
buffered saline solution (HBSS) to remove all traces of protein in the media before 
being treated with vehicle or 50 mM KCl for 30 minutes in HBSS containing calcium 
and magnesium. This concentration of KCl was selected because it has been shown to 
induce neuronal activity in primary neurons without affecting cell viability (Toescu, 
1999; Zhou et al., 2009). In addition, concentrations up to 100 mM KCl have been used 
to stimulate neuronal activity for in vivo microdialysis studies for periods up to one hour 
without loss of neuronal viability (Yamada et al., 2014). 
 After exposure of slices to 50 mM KCl for 30 minutes, the conditioned medium was 
collected and analysed using a sandwich ELISA. This ELISA is optimised for detection 
of tau, using DA31 as the coating antibody, and tau (DAKO, Cambridgeshire, UK) as 
the capture antibody. Medium that did not come into contact with cells (unconditioned 
medium), but which was incubated for the same length of time in a humidified incubator 
with 5% CO2, was used as a negative control and as a blank for the ELISA. Slices were 
harvested, lysed in hypotonic buffer, and the protein concentration of the slice lysates 
were determined by BCA assay (Section 2.2.3). 
The intracellular compartment from which extracellular tau is derived is currently 
unknown. Studies have shown that in addition to cytosolic tau, a small proportion of tau 
localises to the plasma membrane. We found previously that the presence of fyn is 
required for trafficking of tau from the cytosol to the plasma membrane (Pooler et al., 
2012). Thus, one possibility is that part of the pool of membrane-associated tau may be 
released into culture medium. Since fyn is necessary for the movement of tau from the 
cytosol to the membrane, it is reasonable to propose that fyn may also be involved in 
the release of membrane-associated tau. Therefore, organotypic brain slices from WT 
and fyn-/- mice were treated with vehicle or KCl for 30 minutes and the amount of tau 
released into the medium was measured using the sandwich ELISA.  
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In order to measure cell death, a lactate dehydrogenase (LDH) assay was used. LDH 
is a stable enzyme that is released from cells following damage to the plasma 
membrane, allowing for a quantitative assay in which LDH release is coupled to an 
enzymatic, colorimetric reaction. The amount of LDH released into the medium is 
compared to the total (intracellular and extracellular) amount of LDH present, to provide 
an indicator of the degree of cell death. 
The amount of tau released from slices in the presence or absence of KCl was 
standardised to the protein concentration of the corresponding slice lysate. The amount 
of tau released into the medium from unstimulated WT brain slices was used to 
normalise the amount of tau release under different experimental conditions. Following 
KCl treatment, there was a statistically significant increase in tau release of 
approximately ten-fold in WT slices compared to unstimulated WT brain slices (Figure 
3.4A). The proportion of LDH released increased from 2% to 4% of total LDH in KCl-
treated slices, indicating that the release of tau was not due to the disintegration of the 
plasma membrane, but instead represents a physiological process in healthy brain 
slices (Figure 3.4B). There was no statistically significant difference between the 
amount of tau released from WT and fyn-/- slices not exposed to KCl (Figure 3.4A, p > 
0.05). When fyn-/- slices were exposed to KCl, there was an approximate eight-fold 
increase in tau release compared to unstimulated fyn-/- slices (Figure 3.4A), which was 
similar to that observed in WT slices exposed to KCl. Similarly, the amount of LDH 
released was not significantly altered by the lack of fyn in the presence or absence of 
KCl (Figure 3.4B). These results show that KCl stimulates tau release in organotypic 
brain slices as well as in primary neurons and that the presence of fyn does not appear 
to affect this process. This suggests that, while fyn is necessary for phosphorylation-
dependent translocation of tau to the membrane, it is not required for tau release, 





Figure 3.4 Tau release from organotypic brain slices from WT and fyn-/- mice 
Tau release into culture medium from WT (light grey bars) or fyn-/- (dark grey bars) 
organotypic brain slices, with or without exposure to 50 mM KCl for 30 min, was 
quantified by sandwich ELISA, n = 16-27 (A). (B) The amount of LDH released was not 
significantly increased in KCl-treated slices compared to control, n = 10-13. Values 
represent mean ± SEM. One-way ANOVA with post-hoc Tukey’s test, ***p < 0.001, NS 
= not significant. 
 
 
Whole cell lysates of control and KCl-treated WT and fyn-/- organotypic brain slices 
were analysed on western blots to determine if KCl might affect the amount of 
intracellular tau. These results show that there was no difference in the amount of 
intracellular tau present in KCl-treated slices compared to untreated controls in either 
WT or fyn-/- slices (Figure 3.5). This suggests that the amount of tau released 
extracellularly is a small proportion of the total amount of intracellular tau. 
Taken together, these results show that tau can be released into the extracellular space 
and that this is dependent on neuronal activity. The absence of fyn does not appear to 





Figure 3.5 No detectable change in intracellular tau following exposure to KCl  
Representative western blots of whole cell lysates of (A) WT or (B) fyn-/- organotypic 
brain slices treated with 50 mM KCl or vehicle. Molecular weight markers are shown on 




3.1.3 Investigating the uptake of extracellular tau 
The spreading of tau pathology is of great interest for the tauopathies, but the 
mechanisms of transmission are currently unclear. It has been shown that pathological 
tau may propagate between neurons in a manner dependent on synaptic connectivity. 
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Therefore, it is important to determine whether tau secreted in response to neuronal 
stimulation can be taken up by connected neurons, as a possible pathogenic 
mechanism. To do this, brain slices were prepared from tau-/- mice to see whether tau 
could be detected in these slices following exposure to extracellular tau derived from 
KCl-stimulated WT brain slices.  
WT brain slices were treated with vehicle or 50 mM KCl for 30 min in HBSS containing 
calcium and magnesium to stimulate tau release. In parallel, a negative control 
comprising cell-free HBSS containing calcium and magnesium was incubated for 30 
min at 37°C in a humidified incubator. After 30 min, conditioned (vehicle-treated and 
KCl-treated) medium and cell-free (unconditioned) medium was collected and 
centrifuged to remove debris. Separately maintained tau-/- slices were washed and 
exposed to vehicle-treated, KCl-treated, or unconditioned medium collected from the 
stimulated WT slices. The tau-/- slices were then incubated for 4 hours at 37°C in a 
humidified incubator before being harvested in hypotonic buffer. Tau-/- slices were then 
fractionated into membrane and cytosolic fractions to determine whether exogenous 
tau was membrane-associated or internalised into the cytosol. All fractions were run on 
western blots and probed with antibodies against tau to detect any uptake of tau. 
Lysates of WT brain slices were included as a positive control. 
Probing the tau-/- slices exposed to tau-containing medium with an antibody against tau 
showed that no tau was detectable in any of the three conditions used (KCl, control, 
and unconditioned) in either total slice lysates or in membrane or cytosolic fractions, 
even at higher exposures (Figure 3.6). It had been determined previously that full-
length, intact tau was amongst the tau species released upon stimulation of neuronal 
activity in primary neurons (Pooler et al., 2013a). However, in this experiment, there 
was no evidence of full-length, intact tau of the expected, molecular weight (~50 kDa), 
nor were any smaller cleaved fragments of tau detectable on western blots following 
exposure of tau-/- slices to tau-containing medium (Figure 3.6). The positive control of 
WT brain slice lysate shows that the tau antibody is able to detect tau, and sufficient 
protein loading was determined by probing with an antibody against β-actin. Membrane 
fractions were loaded in equivalent protein proportions to cytosolic fractions, so the 
decreased amount of β-actin in the membrane fraction reflects the greater abundance 
of β-actin in the cytosol relative to the membrane. Therefore, these results suggest that 
the absence of detectable tau in these preparations is not due to a lack of binding with 
tau antibody but rather that there is an insufficient amount of tau protein present in the 





Figure 3.6 Tau uptake by tau-/- organotypic brain slices  
Western blots of tau-/- organotypic brain slices treated with conditioned culture medium 
from WT slices exposed to 50 mM KCl or vehicle (Ctrl). Cell-free unconditioned 
medium (Uncond) was used as a negative control. Tau at the expected size (50 kDa) 
was not observed in membrane, cytosol, or total fractions. Whole cell lysate from WT 
slices was used as a positive control for tau. Molecular weight markers are shown on 




3.1.4 Characterisation of soluble Aβ oligomers 
The aim of the following experiments was to determine whether soluble Aβ oligomers 
would have any effect on the release of tau from organotypic brain slices. First it was 
necessary to characterise the species of Aβ present in the preparation of soluble Aβ 
oligomers.  
Human Aβ1-42 peptide was used to prepare soluble Aβ by dissolving Aβ1-42 peptide in 
autoclaved DI water, as this has been shown to reliably produce predominantly soluble 
Aβ species of oligomers and monomers (Town et al., 2002; Garwood et al., 2011; 
Atherton et al., 2014). In order to determine the species of soluble Aβ present in this 
preparation, 5 μg of freshly prepared 250 µM soluble Aβ was mixed with 2x Novex® 
Tricine SDS sample buffer (Life Technologies, Paisley, UK), heated for 5 min at 100°C 
before resolving on a 16% Tricine gel (Life Technologies, Paisley, UK). Western blots 
were incubated with the 4G8 antibody, which recognises amino acids 17-24 of Aβ and 
labels low molecular weight Aβ oligomers. Figure 3.7A shows that 4G8 recognises a 
predominant Aβ species of ~4-5 kDa, equivalent to monomeric Aβ, with a smaller 
proportion of the sample being composed of low molecular weight oligomers of 13 and 
16 kDa, indicating the presence of Aβ trimers and tetramers. A minor proportion of this 
soluble Aβ preparation is comprised of 8 kDa dimers of Aβ (Figure 3.7A). It is possible 
that Aβ oligomers of higher molecular weight than the tetrameric forms are present in 
small amounts that are undetectable by 4G8, but the ratio of monomeric and oligomeric 
species of Aβ is similar to that reported previously by others (Town et al., 2002). 
Therefore, as this preparation is largely monomeric, concentrations of 10 μM Aβ or 
below should not contain significant amounts of toxic oligomeric species of Aβ. 
Prior to treating organotypic brain slices with Aβ, each individual batch of Aβ was tested 
on cultures of primary rat cortical neurons to ensure the effectiveness of each Aβ 
preparation at inducing neuronal death and the expected changes in intracellular 
proteins, such as increased tau phosphorylation. 12 DIV primary rat cortical neurons 
were treated with 10 μM Aβ in Neurobasal® medium containing B27 and L-glutamine. 
Phenol red has previously been shown to interfere with the effects of Aβ and thus 
phenol red-free medium was used for these experiments (Ono et al., 2003; Porat et al., 
2004; Necula et al., 2007). Neurons were treated with 0.5 μM staurosporine, which 
activates caspase-dependent apoptotic pathways (Yue et al., 1998; Zhang et al., 2004), 
as a positive control for cell death. Neurons were exposed to Aβ, vehicle (H2O), or 





Figure 3.7 Characterisation of the soluble Aβ oligomeric preparation 
 (A) Western blot of 5 µg soluble Aβ oligomers at low and high exposures with an 
antibody against Aβ (4G8). Molecular weight markers are shown on the left (kDa). (B) 
Primary rat cortical neurons were treated with vehicle, 0.5 μM staurosporine (STS), or 
10 µM soluble Aβ for 48 hours to assess neurotoxicity. Quantification of LIVE/DEAD, 
normalised to β-actin, shows significantly increased labelling of LIVE/DEAD in Aβ- and 
STS-treated neurons compared to control (C). Values represent mean ± SEM, n = 4-6. 
One-way ANOVA with post-hoc Dunnett’s test, **p < 0.01. 
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Cell toxicity was measured using a LIVE/DEAD assay, which enables quantitation of 
fluorescent ethidium homodimer-1 in cells with compromised membrane integrity. After 
incubating neurons with LIVE/DEAD according to the manufacturer’s instructions, 
neurons were fixed and stained with β-actin as an internal control, before quantifying 
the ratio of LIVE/DEAD to β-actin staining using the Odyssey scanner. Under these 
conditions, Aβ induced cell death to a degree that was 1.3-fold higher than that of 





3.1.5  Effects of soluble Aβ treatment on organotypic brain slices 
As discussed above, the effects of Aβ, and potential interactions between Aβ, tau and 
fyn on tau release and propagation are not well understood. To determine if the effects 
of Aβ on tau release could be investigated in organotypic brain slice cultures, it was first 
necessary to determine the activity of Aβ in this model. The aim of this study was 
therefore to determine the effects of Aβ on tau phosphorylation and trafficking, and 
whether fyn could mediate the toxic effects of Aβ in organotypic brain slices. 
The cytoskeletal protein α-spectrin undergoes calpain- and caspase-3-mediated 
cleavage in human post-mortem AD brain tissue (Atherton et al., 2014). α-Spectrin is a 
protein of 240 kDa, which is cleaved by calpain-1 and caspase-3, to generate 145-150 
kDa fragments, or  a 120 kDa fragment, respectively (Bahr et al., 1995; Martin et al., 
1995). Exposure to Aβ has been shown to induce cleavage of α-spectrin in cultured 
primary neurons (Lee et al., 2000; Nicholson and Ferreira, 2009). Therefore, α-spectrin 
cleavage was examined following Aβ treatment in 21 DIV organotypic brain slices 
treated with 10 μM soluble Aβ for 24 or 48 hours. Slices were harvested and soluble 
proteins were extracted for protein analysis on western blots.  
In contrast to previously reported findings in human AD brain, there were no significant 
changes in α-spectrin in Aβ-treated slices compared to vehicle-treated control slices. 
The amount of 140-150 kDa cleaved α-spectrin fragments as a proportion of total α-
spectrin was equivalent in Aβ-treated and control slices, indicating that calpain 
cleavage was minimal under these conditions (Figure 3.8A,C). Similarly, there was no 
significant change in the amount of the 120 kDa caspase-cleaved product induced by 
Aβ as a proportion of total α-spectrin (Figure 3.8B,C). To further investigate changes in 
caspase-3 activity, blots of Aβ-treated slices were probed with an antibody that 
specifically recognises the active form (cleaved) of caspase-3. In both vehicle-treated 
control and Aβ-treated slices, there were no bands at the expected size (17 and 19 
kDa) for cleaved caspase-3 (Figure 3.8D). This may be due to batch-dependent 
variability of the antibody, as the same antibody has previously been shown to label 





Figure 3.8 Aβ treatment of WT organotypic brain slice cultures 
WT organotypic brain slices were treated with 10 µM soluble Aβ for 24, 48, or 72 hours 
and analysed on western blots, n = 6. WT slices were analysed for (A) calpain-cleaved 
α-spectrin and (B) caspase-3-cleaved α-spectrin. (C) Representative western blots of 
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brain slices treated with Aβ for 24h or 48h, probed with α-spectrin antibody. 145-150 
kDa calpain-cleaved and 120 kDa caspase-3-cleaved bands are indicated. β-actin was 
used as a loading control. (D) Representative western blot of brain slices treated with 
Aβ for 72h, probed with cleaved caspase-3 antibody. β-actin was used as a loading 
control. WT slices were further analysed for (E) tau-1 (tau dephosphorylated at 
S199/202), (F) CP13 (tau pS202), (G) PHF-1 (tau pS396/404), and (H) GFAP 
expression. (I) LDH release was not significantly increased in 48 hour Aβ-treated slices 
compared to control, n = 3. Values represent mean ± SEM. One-way ANOVA, **p < 





Brain slices (21 DIV) were then analysed for tau phosphorylation, as this has previously 
been shown to increase at specific epitopes in rat primary cortical neurons treated 
under the same conditions of Aβ (Garwood et al., 2011). All western blots quantified for 
tau phosphorylation were normalised to total tau. In contrast to previous results found 
in rat primary cortical neurons, the antibody against tau dephosphorylated at 
S199/S202 (Tau-1) revealed a statistically significant increase at 24 hours, but not at 48 
hours of Aβ treatment, compared to control (Figure 3.8E). Accordingly, probing with 
CP13 (tau phosphorylated at S202) showed a parallel decrease in phosphorylation at 
this epitope after 24 and 48 hours of Aβ treatment, although the 48 hours treatment 
resulted in a lesser degree of S202 dephosphorylation (Figure 3.8F). Tau 
phosphorylated at the PHF-1 epitope (S396/S404) was also reduced at 24 hours, but 
not after 48 hours of Aβ treatment compared to control (Figure 3.8G). To investigate 
whether Aβ treatment affects the activity of astrocytes, immunoblots from treated and 
untreated slices were incubated with an antibody against glial fibrillary acidic protein 
(GFAP). These results show that there are no changes in the amount of GFAP in Aβ-
treated slices compared to control, when normalised to β-actin (Figure 3.8H). 
In conjunction with western blotting, the toxicity of soluble Aβ preparation was 
determined by LDH release as described above. Aβ treatment did not result in a 
statistically significant increase in LDH release (Figure 3.8I). These results show that 
WT organotypic brain slices are resistant to toxicity induced by this preparation of 
soluble Aβ oligomers at the concentration tested, which is sufficient to induce toxicity in 
primary neurons (Figure 3.7C). Taken together, these findings do not support the use of 
organotypic brain slice cultures for investigating the effects of Aβ on tau release, at 





In this chapter, organotypic brain slices were used as a model system in which to 
investigate tau release from neurons. Organotypic brain slice cultures were chosen as 
a more physiologically relevant system than cultured primary cortical neurons because 
the slices maintain the normal cytoarchitecture of the cortex and hippocampus, which 
allows retention of synaptic connectivity. These slices also contain more physiologically 
proportionate ratios of neurons to glia, and they are synaptically functional (De Simoni 
et al., 2003; Cho et al., 2007). Taken together, these reasons support the use of 
organotypic brain slices to study physiological, synaptic activity-dependent processes 
such as tau release. 
Initial studies were carried out to examine the presence of tau and the abundance of 
key synaptic proteins in WT and fyn-/- brain slices. The results described here show that 
tau is secreted from both WT and fyn-/- organotypic brain slices when neuronal 
activation is induced by KCl. Notably, the release of tau from brain slices is not 
accompanied by significant cell death, further suggesting that this is a physiological 
phenomenon that is observed in healthy neurons, as we previously reported (Pooler et 
al., 2013a). Interestingly, there was no significant difference in the amount of tau 
released in basal conditions, or following KCl stimulation, in the absence of fyn, 
suggesting that the fyn-dependent positioning of tau at plasma membranes is not an 
important criterion for tau release, at least not in this model.   
A key question remains, however: what is the source of the activity-dependent 
extracellular tau? As the results above show, the release of neuronal tau is not due to 
the death of neurons, excluding the possibility of tau being released due to loss of 
membrane integrity. Although tau is mainly localised to the cytoplasm where it is found 
in abundance, both in the free state and bound to microtubules (Weingarten et al., 
1975), tau is also associated with components of the plasma membrane (Brandt et al., 
1995; Pooler et al., 2012). Additionally, tau is also found in detergent-resistant 
microdomains in neurons, to where it appears to be recruited by a fyn-dependent 
mechanism (Williamson et al., 2008). Furthermore, fyn is required for phosphorylation-
dependent trafficking of tau to the plasma membrane (Pooler et al., 2012). Therefore, it 
is plausible that this pool of membrane-associated tau is a likely subcellular location 
from where tau can be released. Since fyn is necessary for tau translocation from the 
cytosol to the plasma membrane when tau is dephosphorylated, it was hypothesised 
that fyn may also play a regulatory role in tau secretion. 
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In support of this hypothesis, fyn has an established role as a membrane-associated 
protein that plays a role in trafficking of binding partners to the plasma membrane. 
Expression of fyn in COS7 cells results in increased cell surface expression of APP 
through tyrosine phosphorylation (Hoe et al., 2008). Moreover, fyn was shown to 
promote the recruitment of APP and Dab1 into lipid rafts (Minami et al., 2011). During 
signal transduction events in endothelial cells, activation of fyn is involved in the 
pathway regulating the transcytosis of albumin (Tiruppathi et al., 1997). In contrast to 
regulation of APP and Dab1, activation of fyn negatively regulates expression of ephrin-
A at the cell surface (Baba et al., 2009). Thus, there is a wide body of evidence that fyn 
is involved in a variety of roles in trafficking intracellular proteins between the cytosol 
and the plasma membrane. 
However, in opposition to the proposed hypothesis, the results in this chapter suggest 
that fyn does not play a major role in regulation of the spread of extracellular tau. There 
is currently no evidence indicating that fyn directly regulates the secretion of any 
intracellular protein from neurons; however, in mast cells, fyn does play a role in 
regulating secretion of inflammatory leukotrienes, cytokines, and chemokines, as well 
as vascular endothelial growth factor (Gomez et al., 2005; García-Román et al., 2010).  
Changes in the amount of intracellular tau was not detected following stimulation of 
neuronal activity with KCl, though it has been reported previously that synaptic activity  
increases tau expression in the post-synaptic density fraction of primary cortical 
neurons (Frandemiche et al., 2014). However, the amount of total tau was not 
measured in that report. One possibility is that neuronal activity stimulates the 
translocation of tau from the cytosol to the plasma membrane immediately prior to tau 
secretion, without affecting the total amount of tau in the neuron. Another possibility is 
the limitation of the technique used because the amount of tau released may have 
been too low to be detected on western blots, as it is likely that the amount of secreted 
tau is a minor proportion of endogenous tau. Thus, a more sensitive method, such as 
ELISA, may have allowed detection of subtle changes in the amount of intracellular tau 
following stimulation of its release from neurons. 
The spread of tau from cell to cell raises questions on the mechanism of uptake as well 
as its release. If tau does act as a signalling molecule in healthy neurons, it is logical to 
assume that it must be taken up by neighbouring neurons. The mechanism of tau 
uptake has been suggested to be by bulk endocytosis in neurons, but only tau 
aggregates and not endogenous extracellular tau were investigated in these studies 
(Frost et al., 2009; Kfoury et al., 2012; Wu et al., 2013). 
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In this chapter, uptake of extracellular tau was investigated in tau-/- organotypic brain 
slices exposed to conditioned medium from WT slices treated with KCl to stimulate tau 
release. Tau protein was absent from both membrane and cytosolic fractions of treated 
tau-/- slices. Despite the lack of tau seen in either fraction in slices treated with tau-
containing medium, it cannot be concluded definitively that extracellular tau is not taken 
up by neurons since there are important limitations to this experiment.  First of all, the 
amount of tau secreted is believed to be very low. For example, the amount of tau  in 
the interstitial fluid of WT mice is in the range of 40-50 ng/ml (Yamada et al., 2011), and 
although KCl would have induced an increase in tau release of several-fold, the total 
amount of tau released from neurons may have been insufficient for detection in the 
recipient neurons. Column concentration of tau in the medium would have increased 
the amount of extracellular tau and should be considered for future studies. 
Furthermore, despite subcellular fractionation of the recipient neurons, the samples 
may not have been sufficiently concentrated to detect tau. Further subcellular 
fractionation into synaptosomes may be beneficial in concentrating the samples so that 
more protein can be loaded. Moreover, if the amount of extracellular tau taken up by 
recipient brain slices was too low to detect on western blots, immunocytochemistry 
could indicate whether individual neurons have taken up extracellular tau. Finally, it is 
possible that the duration of exposure to tau in the medium applied to the slices may 
not have been long enough for tau to become internalised in amounts large enough to 
be detectable on western blots. In contrast, exogenous tau aggregates have been 
shown to be taken up by neurons after 6 hours exposure, although this uptake is likely 
through a different mechanism from that required for uptake of soluble tau (Wu et al., 
2013).  
The final aim for this chapter was to investigate the effects of Aβ on tau release in 
organotypic brain slices, and it was necessary to first characterise the nature of the Aβ 
species present in the synthetic Aβ peptide preparation as well as its toxicity to 
neurons. Here, the results show that soluble Aβ is comprised primarily of monomeric 
Aβ, but that it also contains smaller amounts of Aβ dimers, trimers, and tetramers. To 
assess neuronal toxicity, primary cortical neurons were treated with 10 μM Aβ for 48 
hours and medium was collected to quantify LDH release as a measure of cell death. 
Aβ treatment significantly increased LDH release into the culture medium compared to 
control cultures, indicating that under these conditions, Aβ is toxic to cultured primary 
neurons. Based on these results, the same conditions and preparation of Aβ was used 
to treat organotypic brain slices. However, extensive analysis on western blots to 
examine the effects of Aβ showed that Aβ treatment did not alter astrocytic activity, 
levels of phosphorylated tau, cleavage of α-spectrin, or activation of caspase-3 in 
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organotypic brain slices. This is in contrast to previous reports where, in primary 
neurons, soluble Aβ treatment was shown to increase tau phosphorylated at the PHF-1 
epitope (S396/S404), and to decrease the amount of tau dephosphorylated at the Tau-
1 epitope (S199/S202) (De Felice et al., 2008; Garwood et al., 2011). It was expected 
that phosphorylation at the CP13 epitope (S202) would increase correspondingly, but 
this was not observed here. Likewise, activation of caspase-3 in response to soluble Aβ 
has been shown in primary neurons and hippocampal slices, as well as calpain-
mediated cleavage of α-spectrin (Garwood et al., 2011; Chen et al., 2013; Atherton et 
al., 2014). Again, these changes were not observed in organotypic brain slices. Indeed, 
Aβ did not appear to increase LDH release in organotypic brain slices, despite the 
same treatment eliciting an effect on primary neurons as shown earlier in this chapter 
(Figure 3.7). 
It was also expected that Aβ treatment, under the same conditions, might have greater 
toxicity and an enhanced capacity to induce pathological changes in tau in brain slices 
compared to primary neurons, because it has been shown that astrocytes mediate Aβ-
induced neurotoxicity and tau phosphorylation (Garwood et al., 2011). 
Immunocytochemistry has revealed a layer of astrocytes on both the upper and lower 
surfaces of the cultured brain slices, as previously reported by others (del Rio et al., 
1991; Stoppini et al., 1991; del Rio and Soriano, 2010; Mewes et al., 2012). This “glial 
scar” that forms on brain slices in culture could also explain why Aβ treatment may not 
have induced toxicity. Thus, the abundant presence of astrocytes on top of and 
underneath the cultured brain slices, as shown earlier, could have hindered the access 
of Aβ to neurons in brain slices. In future, it may be necessary to directly inject the slice 
with Aβ preparations to enable it to penetrate through the layer of astrocytes. Another 
possibility would be to prepare brain slices from transgenic mouse models of AD, such 
as APP/Swe mice, and to compare these with WT brain slices, as APP/Swe mice 
secrete elevated levels of Aβ and develop progressive Aβ pathology with age 
(Savonenko et al., 2003). 
Taken together, these results show that tau is released under basal and activity-
stimulated conditions in WT and fyn-/- organotypic brain slices. The presence of fyn is 
not required for tau release, and the amount of tau released is a small proportion of 
total intracellular tau. Further work will be needed to determine the mechanisms of tau 
uptake, and the effects of Aβ on the physiological release and uptake of tau. 
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Chapter 4 Fyn binds to PXXP motifs in the proline-
rich region of tau 
The interaction between tau and fyn has drawn much attention due to the potential 
implications that tau-fyn interactions could have for the function of tau, both in normal 
and pathological conditions (Lee et al., 1998). In AD brain, fyn expression is increased 
in a subset of neurons that contain abnormally phosphorylated tau (Shirazi and Wood, 
1993). Increased levels of activated fyn are also observed in AD brain (Larson et al., 
2012). In parallel, tau phosphorylated at residue Y18, which is a fyn phosphorylation 
site, is found in neurofibrillary tangles in AD brain (Lee et al., 2004). 
Mounting evidence supports the hypothesis that tau-fyn interactions play a role at the 
dendrite and thereby modulate synaptic function. An aberrant increase of interactions 
between tau and fyn caused by Aβ may result in synaptic dysfunction in AD. Tau has 
been reported to target fyn to the dendrite, where fyn stabilises the interaction of N-
methyl-D-aspartate (NMDA) receptors with the postsynaptic density 95 protein (PSD-
95). Fyn phosphorylates subunit 2 of the NMDA receptor (NR2b) at Y1472 (Nakazawa 
et al., 2001). The importance of these interactions for AD was revealed in an elegant 
series of experiments using several different transgenic mouse models (Ittner et al., 
2010). In this paper it was shown that tau is required for the positioning of fyn in 
dendrites and that missorting of tau and fyn to the cell soma reduces the interaction of 
the fyn-dependent interaction of the NMDA receptor with PSD-95, suggesting that tau-
fyn binding facilitates stabilisation of the NMDA receptor complex at the postsynaptic 
density (Ittner et al., 2010).  
In addition, dephosphorylation of tau through inhibition of casein kinase Iδ (CK1δ) 
caused dynamic translocation of cytosolic tau to the plasma membrane, which was 
abolished in fyn-deficient neurons (Pooler et al., 2012). Inhibiting CK1δ also increased 
the association of tau with the SH3 domain of fyn, leading to the hypothesis that 
dephosphorylated tau moves to the membrane, possibly via a serine/threonine 
phosphorylation-dependent increased interaction of tau with the SH3 domain of fyn 
(Pooler et al., 2012). 
Synaptic activity also triggers translocation of tau and synaptic markers such as fyn 
and PSD-95 from the dendritic shaft to the postsynaptic compartment (Frandemiche et 
al., 2014). Exposure to Aβ oligomers results in the same translocation but, in 
conjunction with synaptic activity, Aβ impairs the recruitment of tau to the postsynaptic 
compartment (Frandemiche et al., 2014). In addition, a signalling pathway that couples 
Aβ with fyn and tau via cellular prion protein (PrPC) has also been proposed (Larson et 
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al., 2012). PrPC co-immunoprecipitates with fyn and soluble Aβ dimers, which also co-
localise at dendritic spines in AD brain (Larson et al., 2012). Aβ oligomer treatment 
induces activation of fyn, which is abolished in neurons lacking PrPC (Um et al., 2012). 
PrPC-deficient neurons also lacked the downstream phosphorylation of NR2b by fyn 
when treated with Aβ oligomers (Um et al., 2012). Likewise, deletion of PrPC in APP 
mutant mice resulted in reduced amounts of active fyn, reduced levels of 
phosphorylated Y18 tau, and reduced tau missorting (Larson et al., 2012). NMDA 
receptor activation also increases the association of fyn with phosphorylated tau in 
synapses (Mondragon-Rodriguez et al., 2012). These data provide support for the 
hypothesis that interactions between tau and fyn may be impaired in AD and cause 
synaptic dysfunction. 
Given that Aβ appears to exert synaptotoxicity that is mediated by tau and fyn, a 
rational option for therapy in AD might be to target fyn. Reduction of fyn has been 
shown to reduce Aβ-induced synaptotoxicity and early mortality in transgenic mice 
overexpressing mutant APP (Chin et al., 2004). However, mice lacking fyn exhibit 
impaired long-term potentiation and deficits in spatial learning (Grant et al., 1992). 
However, in apparent contrast to the study by Chin et al. (2004), reduction of striatal-
enriched phosphatase 61 (STEP61), which normally dephosphorylates and inhibits fyn 
activity, improved cognitive deficits in a mouse model of AD (Zhang et al., 2010). 
Moreover, in a subsequent study, genetic reduction of fyn in 3xTg mice, which express 
mutations in APP, presenilin-1, and tau, resulted in increased phosphorylation of tau 
compared to 3xTg controls. Reduction of fyn also resulted in impaired spatial learning 
in the Morris water maze task compared to control 3xTg mice (Minami et al., 2012).  
Additionally, global tau reduction may not be an optimum therapeutic strategy, as 
genetic ablation of tau results in mice with complex and sometimes inconsistent 
phenotypes. For example, tau knockout mice are reported to display motor deficits 
(Ikegami et al., 2000; Lei et al., 2012; Ma et al., 2014) and cognitive deficits (Lei et al., 
2014) although reports of the latter phenotype is inconsistent since it is not consistently 
reported (Morris et al., 2013; Li et al., 2014). Given the complexity that lies with the 
therapeutic approach of reducing levels of tau or fyn, it may be more prudent to 
investigate alternative options such as disrupting the interactions between tau and fyn.  
Previous efforts to determine the molecular specifications of the tau-fyn interaction 
suggested that tau could bind to the SH3 domains of src family kinases, including fyn 
(Lee et al., 1998; Reynolds et al., 2008). However, src family kinases also contain other 
SH domains, such as SH2 domains which bind to tyrosine phosphorylated residues, 
suggesting that proteins harbouring tyrosine residues could also be potential binding 
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candidates for fyn-SH2 (Boggon and Eck, 2004). Indeed, tau was previously shown to 
interact with fyn-SH2, in a manner modulated by tyrosine phosphorylation of tau 
(Usardi et al., 2011). 
Tau has a proline-rich region within its projection domain that contains several PXXP 
motifs (where P is a proline and X is any amino acid). SH3 domains recognise PXXP 
motifs on interacting proteins (Boggon and Eck, 2004). Earlier efforts to identify the 
binding site on tau for fyn in vitro demonstrated that truncated constructs with a 
deletion of 223-PXXP-236 and the C-terminal half of tau abolished the binding of tau to 
fyn-SH3 (Lee et al., 1998). More recently, using CHO cells expressing full length tau 
with PXXP-containing mutations, it was shown that mutation of proline 216 to alanine, 
but not proline 233 to alanine, reduced the amount of tau bound to fyn-SH3 (Usardi et 
al., 2011).  
The discrepancy of the results obtained by Lee et al. (1998) and Usardi et al. (2011) 
may be due to differences in the methods employed. In the first study, truncated tau 
constructs (residues 1-221) were used for GST pull-down with fyn-SH3. As this 
construct excluded the seventh PXXP motif (233-236), Lee et al. (1998) suggested that 
the seventh PXXP motif was critical for tau-fyn binding. Additionally, a construct that 
contained the 233-PXXP-236 motif but lacked PXXP motifs N-terminal to P233 
exhibited reduced binding to fyn-SH3 (Lee et al., 1998). Moreover, tau with an internal 
deletion at 228-236 was still able to bind fyn-SH3, suggesting that motifs N-terminal to 
P233 of tau are also important for tau-fyn binding (Lee et al., 1998). It is possible that 
the truncated tau fragments used by Lee et al. (1998) may result in a conformation of 
tau that is inaccessible to fyn-SH3, rendering it impossible for binding to occur in vitro, 
hence affecting the results of this study. Importantly, full-length intact tau was used in 
the studies carried out by Usardi et al. (2011). This approach is less likely to cause 
structural changes due to truncation of tau protein. Finally, the studies of Lee et al. 
(1998) were carried out with 0N3R tau, whereas Usardi et al. (2011) used 2N4R (full-
length) tau. Interestingly, 3R tau was shown to bind with higher affinity to fyn-SH3 than 
4R tau in surface plasmon resonance experiments, which may have also influenced the 
binding capacity of these tau fragments in these two different studies (Bhaskar et al., 
2005). In a separate study, it was reported that fyn-SH3 preferentially interacts with two 
tandem PXXP motifs at residues 213-219, but not the seventh PXXP motif at 233-236 
(Reynolds et al., 2008), contradicting those results from Lee et al. (1998) but in 
agreement with Usardi et al. (2011).  
Additional studies have investigated the binding of tau and fyn-SH3 further. Using 293T 
cells co-expressing fyn and 2N4R tau, or truncated tau constructs (residues 1-221, and 
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1-196), full-length tau co-immunoprecipitates with fyn (Ittner et al., 2010). Tau 1-221, 
which excludes the seventh PXXP motif (233-236), was still shown to bind to fyn, 
whereas tau 1-196, which only includes the first two PXXP motifs, does not bind to fyn 
(Ittner et al., 2010). This work suggests that the PXXP motif at 233-236 is not the only 
critical motif for tau-fyn binding, further supporting the idea that PXXP motifs N-terminal 
to P233 are also important. More recently, a separate study demonstrated inhibition of 
binding to fyn-SH3 when proline 216, but not 233, of tau was mutated to alanine 
(Cochran et al., 2014), adding further support to the findings of Usardi et al. (2011). 
However, the remaining four PXXP motifs in tau have yet to be formally tested for their 
ability to bind to fyn-SH3, in experiments designed to avoid potential modifications to 
tau structure. It is important to identify the binding site between tau and fyn so that the 
functional implications of disrupting this interaction can be elucidated.  Downstream 
consequences of disrupting the tau-fyn interaction could include altered localisation of 
tau or fyn, changes in fyn kinase activity, or could impact on the spread of tau in normal 
and pathological conditions. 
The aims of this chapter were therefore to characterise the interaction between tau and 
fyn and to investigate any downstream consequences of disrupting the interaction, by 
1) confirming the binding of tau to fyn in primary neurons; 2) identifying the critical 
PXXP motif(s) for tau-fyn binding; and 3) exploring downstream consequences for tau 
function when tau-fyn interactions are modulated following disruption of key PXXP 
motif(s) in organotypic brain slices. 
 
4.1 Results 
4.1.1 Tau binds to both SH2 and SH3 domains of fyn in vitro 
In order to confirm the interaction of tau with the SH2 and SH3 domains of fyn, primary 
neuronal lysates were subjected to glutathione S transferase (GST) pull-down assays. 
Recombinantly produced fyn-SH2 or fyn-SH3 were adsorbed onto glutathione agarose 
beads (GST-fyn-SH2 and GST-fyn-SH3, or GST alone) and were used in GST pull-
down experiments (Section 2.2.7). To assess the GST proteins bound to the beads, 
samples collected from different stages of GST fusion bead preparation were run on 
10% SDS-PAGE gels and stained with Coomassie blue to visualise the resolved 
proteins (Figure 4.1). Following induction of protein expression with IPTG, the presence 
of GST or GST-fyn-SH3 protein in the bacterial lysate was confirmed (Figure 4.1, lanes 
IPTG). Removal of the bacterial pellet also showed retention of GST proteins in the 
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supernatant (Figure 4.1, lanes Binding S/N). After coupling GST proteins to glutathione 
beads, the supernatant remaining following removal of GST beads showed a depletion 
of proteins corresponding to the sizes of GST and GST-fyn-SH3 (27 and 36 kDa, 
respectively) (Figure 4.1, lanes Beads S/N). As expected, GST and GST-fyn-SH3 
bound to glutathione beads did not bind non-specifically to other proteins, as shown by 
single bands at the expected sizes (~27 kDa and 36 kDa, respectively). Similar results 




Figure 4.1 Preparation and purification of GST fusion proteins 
Coomassie blue-stained 10% SDS-PAGE shows samples from different stages of 
preparation of GST fusion proteins. Bacterial lysates after induction of protein 
expression (IPTG) and cleared supernatants (Binding S/N) show GST or GST-fyn-SH3 
at the expected sizes (27 and 36 kDa, respectively). Supernatant retained following 
protein-bead coupling (Beads S/N) and proteins bound to the glutathione beads 
(Beads) show specific coupling of GST or GST-fyn-SH3 to glutathione beads. 




Primary rat cortical neuronal lysates were subjected to pull-down with glutathione 
beads fused to GST-fyn-SH2, GST-fyn-SH3, or GST-only (Figure 4.2A). Bound 
proteins were resolved on SDS-PAGE and western blots were probed with an antibody 
against total tau (Figure 4.2B). Whole cell lysates were run alongside as a positive 
control, confirming that tau was expressed in the neurons at the time of harvest. As 
expected, GST-only beads did not pull-down tau protein. Tau was bound to GST-fyn-
SH2 and GST-fyn-SH3 beads, as shown by bands at ~50 kDa. Tau was more abundant 
in the GST-fyn-SH3 beads, suggesting that tau binds with stronger affinity to fyn-SH3 
than it does to fyn-SH2. These results agree with previously published reports using 
cultured neurons and CHO cells showing that tau binds to both SH2 and SH3 domains 
of fyn in rodent neurons (Usardi et al., 2011; Pooler et al., 2012). 
 
Figure 4.2 Tau from primary cortical neurons binds to fyn-SH2 and fyn-SH3  
 (A) Diagram illustrating constructs expressing SH2 and SH3 domains of fyn fused to 
GST. (B) Western blot shows binding of endogenous tau protein to fyn-SH2 and fyn-
SH3. Primary cortical neurons were subjected to GST pull-down with GST, GST-fyn-
SH2, or GST-fyn-SH3. Supernatants containing bound proteins, along with total lysate, 
were separated on 10% SDS-PAGE gels and western blots were probed with an 




4.1.2 Site-directed mutagenesis of PXXP motifs in full-length tau 
As the SH3 domain, rather than SH2 domain, of fyn is the predominant region for tau 
binding, further experiments were designed to investigate the precise binding site of tau 
to fyn-SH3. To identify which specific PXXP motif is important for binding of tau to the 
SH3 domain of fyn, tau constructs were made in which individual proline residues in 
each of the PXXP motifs were mutated to alanine (Figure 4.3). A total of eight 
constructs were generated by site-directed mutagenesis and these were used to 
identify the binding site between tau and fyn. Each proline (P) to alanine (A) 
substitution is marked by an asterisk in Figure 4.3. 
V5-His-tagged 2N4R wild-type (WT) human tau cDNA was used as a template, and 
forward and reverse primers were designed to include the proline to alanine mutation 
for each individual construct. The P216A and P233A tau mutants had been generated 
previously (Usardi et al., 2011). All seven PXXP motifs were targeted individually, with 
the exception of the P216A tau construct (Usardi et al., 2011) which targets two PXXP 
motifs as the proline to alanine substitution overlaps two tandem motifs. The resulting 





Figure 4.3 PXXP motifs in the proline-rich region of full-length tau  
(A) Diagram illustrating the amino acid sequence of full-length tau, with the PXXP 
sequences highlighted in yellow. Individual PXXP motifs are numbered in red from 1 to 
7. Individual proline to alanine mutations are indicated by an asterisk above each 
proline in blue, generating a total of eight constructs. (B) Asterisks indicate the sites of 
individual PA mutations in the proline-rich region of tau for each construct. 
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Initial attempts using the standard PCR parameters as recommended by the 
manufacturer, using an annealing temperature of 60°C, resulted in successful 
generation only of the P182A tau construct with an expected size of 6.9 kbp (Figure 
4.4A). A successful mutagenesis product should yield a single band; however, P176A, 
P200A, P206A, P213A, and P219A tau constructs resulted in multiple bands when 
separated on a 1% agarose gel (Figure 4.4A). This may have been due to mis-priming 
or to secondary structure formation. In order to increase the stringency of the reaction, 
the annealing temperature was increased to 68°C, which resulted in successful 
generation of P206A, P213A, and P219A tau mutants (Figure 4.4B). 
The failure to generate products for the P176A and P200A tau constructs could be due 
to the high G-C content in the primers (58.6% and 73.9%, respectively), which could 
result in secondary structure formation. Therefore, new primers were designed for 
P176A and P200A tau. In particular, the P176A tau primers introduced a silent mutation 
(GCT instead of GCG) into the codon for alanine 176 to reduce the G-C content, and 
this resulted in successful generation of the P176A tau construct (Figure 4.4C). Primers 
for P200A tau were also re-designed to reduce G-C content and to lower the melting 
temperature, which also resulted in successful generation of PCR product (Figure 
4.4D). 
The tau mutant PCR products were each used to transform XL1-Blue competent E.coli, 
after which transformed cells were plated onto agar plates containing the appropriate 
antibiotic and incubated overnight. Transformed colonies were cultured in LB broth 
containing antibiotic and plasmids were purified and verified by sequencing (Eurofins 





Figure 4.4 Preparation and verification of mutant PXXP tau constructs 
Agarose gels of PCR products generated following site-directed mutagenesis of V5-
His-tagged 2N4R wild-type human tau cDNA (V5-tau) and PCR to generate mutant 
P→A tau constructs. Following site-directed mutagenesis, samples were amplified by 
PCR and resolved on 1% agarose gels to confirm the correct proline to alanine 
substitution, as indicated by a single band at the expected size (6.9 kbp). (A) With a 
60°C annealing temperature, P182A tau resulted in a single band of the correct size. 
(B) Increase of annealing temperature to 68°C resulted in successful generation of 
P206A, P213A, and P219A. Primers were re-designed for (C) P176A and (D) P200A 
which resulted in successful generation of constructs. Molecular weight markers are 
shown on the left (kbp).  
133 
 
4.1.3 P213-219 of tau is important for tau binding to the SH3 domain of 
fyn 
To determine whether any of P→A mutant tau constructs altered binding between tau 
and fyn, constructs were expressed in CHO cells, the lysates of which were then 
subjected to a GST pull-down assay with GST-fyn-SH3 beads. GST-only beads served 
as a negative control, to account for any non-specific binding between tau and GST 
beads. CHO cell lysates were analysed on western blots probed with an antibody 
against tau and this confirmed that tau protein was correctly synthesised and 
expressed by all of the tau mutants (Figure 4.5A, lower panel). The amount of tau 
bound to the GST-fyn-SH3 beads was quantified and standardised against the amount 
of tau expressed in the equivalent CHO cell lysate for each tau construct (Figure 4.5A). 
Western blots were also probed with an antibody against GST to normalise for equal 
amounts of GST protein (Figure 4.5A). 
Compared to WT tau, expression of P213A, P216A, and P219A tau each resulted in 
altered amount of tau bound to fyn-SH3 (Figure 4.5B). The expression of P216A tau 
impaired binding of tau to fyn-SH3, which agreed with previously reported results 
(Usardi et al., 2011; Cochran et al., 2014). Substitution of P219 by A219 also 
significantly reduced the amount of tau bound to fyn-SH3 to a similar extent as P216A 
tau. Conversely, tau in which P213 was mutated to alanine resulted in a significant 
increase in the amount of tau bound to fyn-SH3. Binding of fyn-SH3 to tau mutated at 
P176, P182, P200, P206, or P233 to alanine was unchanged compared to WT tau 
(Figure 4.5B). 
These results indicate that the sequence of amino acids between 213-219 of tau is 
important for binding between fyn-SH3 and tau. Importantly, the sixth PXXP motif at 
216-219 of tau plays a critical role for allowing tau binding to fyn-SH3, while the 
mutation at P213A of tau increased binding between tau and fyn-SH3 by 50% 
compared to WT tau. As expected, binding of P233A tau to fyn-SH3 was unchanged 
compared to WT tau, which agrees with previous reports (Usardi et al., 2011; Cochran 
et al., 2014). Although others have reported that deletion of the motif at 233-236 of tau 
disrupts binding to fyn-SH3 (Lee et al., 1998), mounting evidence, including data 
presented here, supports the idea that PXXP motifs N-terminal to P233 of tau are more 
important for tau-fyn binding. Furthermore, regions of tau other than the PXXP motifs 
may be important in tau binding to fyn-SH3, as neither P216A or P219A mutations 
completely abolished the interaction, but rather binding was reduced to only 0.65-fold 




Figure 4.5 Identification of PXXP motifs critical for tau binding to fyn-SH3 
Representative western blots of GST pull-downs of tau in lysates from  CHO cells 
expressing WT or mutant P→A tau with GST-fyn-SH3 beads. CHO cells transiently 
transfected with WT tau or mutant P→A tau were subjected to GST pull-down with GST 
or GST-fyn-SH3. (A) Western blots of proteins bound to GST-fyn-SH3 were probed 
with antibodies against tau (upper panel) and GST (middle panel). Western blots of 
CHO cell lysates were probed with an antibody against tau for standardisation (lower 
panel). Molecular weight markers are shown on the left (kDa). (B) Bar chart showing 
the amount of tau immunoreactivity pulled down by GST-fyn-SH3, as a proportion of 
WT tau, following standardisation to total tau in the corresponding lysate. Values 
represent mean ± SEM, n=6-22. One-way ANOVA with post-hoc Dunnett’s test, **p < 
0.01, ***p < 0.001.  
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4.1.4 Generation of lentiviral plasmids expressing wild-type and PXXP 
mutant tau 
CHO cells are widely used for expression studies as they are a convenient system in 
which to express large amounts of target proteins. However, to examine the functional 
relevance of tau-fyn binding, such as downstream implications for tau release, a more 
physiologically relevant system was required.  
Therefore, lentiviruses containing the expression constructs for wild-type and mutant 
PXXP tau were designed to transduce organotypic brain slices. This model enables 
expression of WT and mutant tau in a more physiological system. In addition to WT tau, 
the P213A, P216A, and P219A tau constructs were selected for further investigation 
because the results obtained previously indicated that these mutations were the most 
likely to induce significant alterations in tau-fyn interactions. 
The lentivirus constructs required a neuron-specific promoter for tau expression only in 
neurons in the transduced organotypic slices. Furthermore, a fluorescent reporter was 
needed to verify the presence of the plasmid in transduced cells. Previous reports have 
shown that GFP fusion proteins can alter the localisation and/or metabolism of the 
proteins. Therefore, to circumvent this problem, an internal ribosome entry site (IRES) 
vector was used in these experiments. An alternative method of co-expressing two 
heterologous transcripts would be to use two independent promoters; however, 
promoter interference can occur and this could result in transcription from one promoter 
inhibiting transcription by the second promoter (Emerman and Temin, 1984). Using an 
IRES eliminates this problem, although it has been shown that IRES-dependent gene 
expression can vary from 6%-100% relative to the first gene expression (Mizuguchi et 
al., 2000). This potential lack of equivalent gene expression efficiency is not a problem 
for the planned experiments because it would be used solely for indicating successful 
lentivirus transduction. 
The steps required to generate the PXXP tau lentiviruses are illustrated in Figure 4.6. 
This protocol utilised the existing plasmids (WT, P213A, P216A, P219A tau) generated 
by site-directed mutagenesis in Section 4.1.2, which were subsequently cloned into 
lentivirus expression vectors containing a neuron-specific promoter and IRES-





Figure 4.6 Schematic of protocol used to generate WT and mutant PXXP tau 
lentiviral constructs 
The steps taken to generate WT and mutant PXXP tau lentiviral constructs are 
illustrated. Expression vectors are listed above each plasmid. Restriction enzyme sites 
are indicated by dashed lines and the position of cut is indicated in parentheses. (A) 
WT and mutant PXXP tau in pcDNA3.1-V5-His-TOPO vector were used as templates 
for PCR. Forward (fwd) and reverse (rev) primers to amplify a fragment to substitute 
one base pair to insert a stop codon are indicated (left). Insert and V5-tau were 
digested with BsRGI and EcoRV (right) and ligated to generate pcDNA3.1-tau-stop (B). 
(B) pcDNA3.1-tau-stop was digested with EcoRI and EcoRV (left) and was ligated to 
pIRES2-EGFP digested with EcoRI and SmaI (right) to generate tau-IRES (C). (C) Tau-
IRES was digested with AfeI (left) and ligated to Lenti-GFP digested with SpeI and NotI 





First, a stop codon was introduced after the tau coding sequence in WT, P213A, 
P216A, and P219A tau to prevent translation of V5 and His from the pcDNA3.1 vector. 
Primers were designed to substitute the A at nucleotide 2297 with T, introducing the 
stop codon (AGATGA): 
Forward primer: 5’-TGACCTTCCGCGAGAACGCCAAAGCCAAG-3’ 
Reverse primer: 5’-GTGCTGGATATCTGCAGAATTGCCCTTTGATCACAAACC-3’ 
The AT replacement is underlined. 
These primers were used to PCR amplify a 230 bp sequence of pcDNA3.1-V5-His 
plasmid containing the tau sequence (V5-tau) flanking the stop codon (Figure 4.6A, left 
panel). The PCR product was separated on a 1.5% agarose gel and the 230 bp 
fragment (insert) was extracted and purified. The insert was digested with BsrGI and 
EcoRV and separated on a 1.5% agarose gel from which the 169 bp fragment 
containing the stop codon was extracted (Figure 4.6A, left panel). V5-tau was digested 
with BsrGI and EcoRV, and the 6650 bp tau-encoding fragment was extracted from a 
0.7% agarose gel (6.7 kb) and ligated to the BsrGI-EcoRV insert containing the stop 
codon (Figure 4.6A, right panel). The ligated DNA was transformed into DH5α E.coli 
cells, and plasmid DNA was purified (Section 2.2.12). This resulted in generation of WT 
and mutant PXXP tau in the pcDNA3.1-V5-His vector, containing a stop codon 
(pcDNA3.1-tau-stop) (Figure 4.6B, left panel). 
The pIRES2-EGFP plasmid was kindly provided by Dr Nina Balthasar (University of 
Bristol, UK). pcDNA3.1-tau-stop was digested with EcoRI and EcoRV (Figure 4.6B, left 
panel). pIRES-EGFP vector was digested with EcoRI and SmaI (Figure 4.6B, right 
panel). As EcoRV and SmaI leave blunt ends after digestion, the 3’ cut ends are 
compatible for ligation. Double-digested pcDNA3.1-tau-stop and pIRES-EGFP 
plasmids were separated on a 0.7% agarose gel. The 1.37 kb fragment encoding tau 
containing a stop codon (insert) and 5.3 kb-digested pIRES-EGFP (vector) were 
extracted and ligated overnight to produce Tau-IRES (Figure 4.6C, left panel) (Section 
2.2.12). Ligated DNA was transformed and plasmid DNA was isolated as above.  
To confirm that tau protein was correctly expressed, Tau-IRES was transiently 
transfected into CHO cells. Lysed transfected CHO cells were analysed on western 
blots with antibodies against tau and GFP, which verified that tau and EGFP were 
translated (Figure 4.7A). CHO cells were also transfected with WT V5-tau and Lenti-
GFP, the backbone for the lentiviral tau plasmids, as controls. Probing CHO cells 
expressing pcDNA3.1-tau-stop with an antibody against V5 showed that V5 was not 
translated from this plasmid and hence the stop codon was present (Figure 4.7A). β-




Figure 4.7 Transfection of tau-IRES and LV-tau in CHO cells  
Western blots of CHO cells expressing Tau-IRES and LV-tau. WT and mutant PXXP 
Tau-IRES (A) and LV-tau (B) plasmids were transiently transfected in CHO cells to 
verify correct translation of tau. CHO cell lysates were separated on a 10% SDS-PAGE 
gel and western blots were probed with antibodies against tau and V5 to ensure the 
insertion of stop codon, GFP to ensure expression of EGFP under the IRES, and β-
actin to visualise equal protein loading. CHO cells transfected with WT V5-tau and 




Finally, Tau-IRES was inserted into a lentiviral construct containing a human synapsin I 
promoter (Lenti-GFP), also provided by Dr Nina Balthasar (University of Bristol, UK). 
Tau-IRES was digested with AfeI and NotI (Figure 4.6C, left panel), separated on a 
0.8% agarose gel, and the 2.7 kb tau-encoding insert was extracted. Lenti-GFP was 
digested with SpeI and NotI (Figure 4.6C, right panel). As AfeI (for Tau-IRES) is a blunt 
cutter, Lenti-GFP was blunted at the 5’ SpeI site and the fragments were 
electrophoresed on a 0.8% agarose gel to separate the 8.2 kb cut vector (Section 
2.2.12). AfeI-NotI Tau-IRES was ligated (Section 2.2.12) with SpeI-NotI Lenti-GFP 
overnight to generate LV-tau (Figure 4.6D), a lentiviral construct containing the 
synapsin promoter, WT or mutant tau, and IRES-EGFP. 
Due to the instability and large size of the final construct (10.8 kb), SURE2 cells, which 
are deficient in the E.coli genes involved in DNA recombination, were used to transform 
LV-tau. Plasmid DNA was isolated as detailed in Section 2.2.12. The presence of each 
component of LV-tau was verified by sequencing. To confirm tau expression in the 
lentiviral plasmid, LV-tau was transiently transfected into CHO cells and cell lysates 
were analysed on western blots 24 hours later. Probing with an antibody against tau 
confirmed that the protein was translated in transfected CHO cells (Figure 4.7B). CHO 
cells were transfected with V5-tau and Lenti-GFP as controls. Probing with an antibody 
against V5 showed that V5 was not translated in LV-tau, due to the presence of the 
newly introduced stop codon (Figure 4.7B). GFP antibody recognised barely detectable 
expression of EGFP in the Lenti-GFP control but not in CHO cells expressing LV-tau or 
V5-tau, indicating a potential lack of sensitivity with this antibody (Figure 4.7B). β-actin 




4.1.5 Expression of wild-type and PXXP mutant tau in organotypic brain 
slices and primary neurons 
The aim of generating lentiviruses was to investigate the downstream consequences of 
expressing WT and mutant PXXP tau in neurons in organotypic brain slices, therefore 
optimisation of lentiviral transduction was carried out. Lentiviral plasmids expressing 
tau were used to produce lentiviral particles (Penn Vector Core, University of 
Pennsylvania, PA, USA). 
To determine whether the lentiviruses were able to express tau, 8 DIV rat hippocampal 
neurons were transduced with lentiviruses equivalent to 10, 20, or 50 multiplicities of 
infection (MOI). An MOI of 10-20 is recommended for transduction of primary neurons, 
and 50 MOI has been found to result in neuronal death (Zhang et al., 2006; Castellani 
et al., 2010; Hutson et al., 2012). 10 days post-transduction, neurons were harvested 
and neuronal lysates were separated on a 10% SDS-PAGE gel and analysed on 
western blots. Probing blots with a rabbit polyclonal antibody that recognised mouse 
and human tau (total tau) together with a mouse monoclonal antibody specific for 
human tau (Tau-13) resulted in a positive signal at 70 kDa which was not detected in 
non-transduced neurons (NT) (Figure 4.8). The total tau antibody also recognised 
endogenous tau in the cultured neurons. However, probing transduced neurons with an 
antibody against GFP did not result in a positive signal (Figure 4.8), although EGFP 





Figure 4.8 Optimisation of LV-tau transduction in rat primary cortical neurons  
Western blots of primary rat hippocampal neurons transduced with LV-tau. Lentiviral 
particles were applied to the culture medium at 5, 10, or 20 multiplicities of infection 
(MOI) for 10 days prior to separating lysed neurons on a 10% SDS-PAGE gel. 
Neuronal lysates were probed with Tau-13, total tau, and GFP antibodies. Non-
transduced (NT) neurons were included as a control. Molecular weight markers are 
shown on the left (kDa). 
 
 
Delivery of lentivirus to primary neurons has been shown to be effective when lentiviral 
particles are added to the culture medium. However, because organotypic brain slices 
are cultured on an insert in wells containing 1 ml medium, this results in a substantial 
dilution of the lentiviruses, or the use of prohibitively large amounts of virus transducing 
units. Therefore, three different methods of lentiviral application were tested to 
determine the most efficient route of lentivirus administration. The first method applied 
lentivirus directly onto the top of the slice, the second method used injection of 
lentiviruses directly into the slice, and the third method involved addition of lentiviruses 
to the culture medium underneath the slice insert. 
Organotypic brain slices were prepared from WT and tau-/- mice. Tau-/- brain slices were 
used so that endogenous tau would not compete with expression of lentiviral tau for 
binding to fyn-SH3 in functional experiments. Previous studies have demonstrated 
successful lentiviral transduction when viral particles are added on the day of plating 
the slices, prior to the growth of the glial layer surrounding the slice (Chapter 3) 
(Teschemacher et al., 2005a).  Therefore, on the day of plating the slices, lentiviruses 
were diluted to 109 transducing units (TU)/ml in slice culture medium, and 
approximately 107 TU were applied directly to the upper surface of each slice. As 
previous reports indicate that lentiviral expression peaks eight days post-infection and 
remains stable for at least a further six days (Ehrengruber et al., 2001; Teschemacher 
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et al., 2005b; Hioki et al., 2007), brain slices were harvested two weeks post-
transduction (14 DIV). Slice lysates, including non-transduced brain slices as a 
negative control, were resolved on western blots to detect expression of lentiviral-
encoded tau (Figure 4.9A). Probing with the human tau-specific antibody (Tau-13) and 
the total tau antibody did not reveal any tau bands of the expected size for either 
endogenous tau (~50 kDa) or transduced tau (~70 kDa) (Figure 4.9A). The 42 kDa 
band visible in the Tau-13 blot does not appear to be tau, as it is also visible in the non-
transduced tau-/- slice lysate. As the band is approximately the same molecular weight 
as β-actin, the Tau-13 bands could indicate non-specific binding to β-actin. 
The second method was to inject the lentiviruses directly into the brain slices after they 
had attached to the insert. Two weeks after plating (14 DIV), approximately 107 TU 
were injected into WT and tau-/- brain slices at three equally spaced locations using a 
Hamilton syringe. Slices were harvested two weeks post-injection (28 DIV) and 
analysed on western blots as above. Probing with Tau-13 and total tau antibodies did 
not reveal tau bands of the expected size (Figure 4.9B). Injection of LV-tau into brain 
slices from WT mice did not reveal any expression of EGFP on western blots probed 
with antibodies against GFP (Figure 4.9C). β-actin antibody demonstrated equal 
protein loading.  
A third approach was tested in 42 DIV WT brain slices. Slices were transduced at 20 
MOI (approximately 107 TU) by addition to the medium underneath the slice culture 
insert for 48 hours before changing the medium at 44 DIV. Slices were cultured for a 
further four weeks before harvesting at 70 DIV to explore whether a longer duration 
post-transduction might improve lentiviral tau expression. Western blots of slice lysates 
probed with total tau antibody did not reveal any detectable tau at 70 kDa, nor any 
bands in the Tau-13 blot, despite the presence of endogenous mouse tau at ~50 kDa 
(Figure 4.9D). 
Taken together, these results suggest that while the lentiviruses are able to translate 
tau protein that is detectable with an antibody recognising human tau, this has only 
been successfully transduced in primary neurons and not in organotypic brain slices. 
Despite attempting three different methods of transduction in slices, none of these 
approaches resulted in significant tau expression from the lentiviruses in neurons. As 
lentiviral expression of tau was successful in primary neurons, this indicates that the 
problem of lack of lentiviral tau expression may be a technical issue relating to the 
introduction of lentivirus into neurons in slice culture.  
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Figure 4.9 Optimisation of LV-tau transduction in organotypic brain slices 
Western blots of total lysates from WT and tau-/- organotypic brain slices transduced 
with LV-tau. Different methods of transduction were used to test the expression of LV-
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tau in WT and tau-/- organotypic brain slices. (A) Lentiviruses were applied directly to 
the surface of each slice on the day of plating and incubated for 2 weeks before 
harvesting. Total slice lysates were probed with antibodies against Tau-13 (recognises 
human tau), total tau, and β-actin to ensure equal protein loading. (B) Lentiviruses were 
injected into 14 DIV tau-/- brain slices and harvested 2 weeks post-transduction. Total 
slice lysates were probed with Tau-13, total tau, and β-actin. (C) Lentiviruses were 
injected into 14 DIV WT slices and total slice lysates were probed with antibodies 
against GFP and β-actin. (D) 42 DIV WT slices were transduced with 20 MOI and 
harvested at 70 DIV. Western blots of total slice lysates were probed with antibodies 
against Tau-13 and total tau. β-actin antibody was used to ensure equal protein 
loading. Non-transduced slices (NT) were included in all blots as a control. Molecular 




4.2.1 Discussion and summary of results 
These results show that tau can bind to both the SH2 and the SH3 domains of fyn in 
neurons. Tau preferentially binds to the SH3 domain of fyn relative to fyn-SH2, and 
further experiments were carried out to identify the critical binding site of tau with fyn-
SH3. In this study, all seven PXXP motifs of tau were tested for their ability to bind to 
the SH3 domain of fyn. In transfected CHO cells, GST pull-downs showed that the 
P216A and P219A mutations of tau reduce its binding to fyn-SH3, while P213A 
increases the association between tau and fyn. This indicates that fyn-SH3 binds to the 
sixth PXXP motif of tau at residues 216-219, and that the fifth PXXP motif of tau at 213-
216 also appears to play a role in regulating the association between tau and fyn-SH3.  
PXXP ligands are classified as either class I or class II and the binding domains are 
usually flanked by positively charged amino acids. The localisation of the flanking 
amino acids at the N or C terminus of the motif determines its categorisation into class I 
or II. Class I ligands are characterised by a consensus sequence of RPLPPXP and 
class II ligands by XXXPXXPXR, where X denotes any amino acid (Alexandropoulos et 
al., 1995). The classification of the PXXP ligand defines the orientation by which it 
binds to the SH3 domain, and SH3 domains may exhibit a preference for either class of 
ligand. In the case of fyn, the SH3 domain can bind to both class I and II PXXP ligands 
(Alexandropoulos et al., 1995). In contrast to previous reports in which the seventh 
PXXP motif of tau at 233-236 appeared to be important for binding to fyn-SH3 (Lee et 
al., 1998; Ittner et al., 2010), the data shown here suggest instead that tau residues 
213-219 (fifth and sixth PXXP motifs) are involved in this interaction, with the sixth motif 
enabling the binding between tau and fyn-SH3. The sequence surrounding the sixth 
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PXXP motif in tau is 211-RTPSLPTPPTREP-223, whilst that surrounding the seventh 
PXXP motif is 228-VVRTPPKSPSSAK-240. Comparing the amino acid sequences 
around these two PXXP motifs suggests that the sixth PXXP motif fits the consensus 
for a class II ligand, whereas the seventh PXXP motif conforms better to a class I 
ligand, and the fifth PXXP motif conforms to neither class of ligand. Even though fyn-
SH3 can bind to both class I and II ligands, the conformation of tau could define the 
orientation with which it binds to fyn-SH3, which could mean that fyn-SH3 favours 
binding to the sixth PXXP motif as a class II ligand. However, this has not been 
examined and the functional implications of SH3 domain binding to class I or II PXXP 
ligands remains to be properly defined. 
A previous study from this laboratory using truncated tau peptides to investigate tau-
fyn-SH3 binding showed that inclusion of K224 and K225 in tau resulted in improved 
binding between fyn-SH3 and tau containing the fifth and sixth PXXP motifs, when 
compared to a peptide lacking residues K224 and K225 (Reynolds et al., 2008). The 
study by Lee et al. (1998), that identified tau residues 233-236 as important for tau-fyn-
SH3 binding, used truncated tau constructs that excluded both the seventh PXXP motif 
and the lysine residues at 224 and 225, therefore the absence of K224 and K225 could 
also explain the lack of binding of this construct to fyn-SH3. It is also possible that fyn-
SH3 can bind to different PXXP motifs depending on the experimental conditions used. 
This idea is supported by data shown in this chapter that the mutations at P216A and 
P219A did not completely abolish the interaction between tau and fyn-SH3. This 
suggests that tau can still bind to fyn-SH3 through another binding site, and it may be 
that other PXXP motifs, including the seventh motif, may also facilitate binding between 
tau and fyn-SH3. Further support for this conclusion comes from a study by Ittner et al. 
(2010) who reported that a truncated construct containing the N-terminus of tau and the 
first two PXXP motifs could not bind to fyn in co-transfected 293T cells, whereas 
another truncated N-terminal tau construct that included the sixth PXXP motif exhibited 
reduced binding to fyn compared to full-length tau. Therefore, the exclusion of the 
seventh PXXP motif in the Ittner et al. (2010) study was insufficient to completely 
abolish tau-fyn-SH3 binding. The contributions of other PXXP motifs on the binding 
between tau 216-219 and fyn-SH3 would have to undergo further investigation by 
double mutations, in particular at P219A/P233A.  
Interestingly, we found that the P213A tau mutation resulted in an increased binding to 
fyn-SH3. The reasons for this are unclear. However, one possibility is that the alanine 
substitution at P213 results in an altered tau conformation that is favourable for binding 
to fyn-SH3, given the presence of the intact sixth PXXP motif. It has been shown that 
specific residues outside the core PXXP motif can contribute to the binding between 
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PXXP motifs and SH3 domains (Mayer, 2001), which could explain the increased 
affinity between tau P213A and fyn-SH3. For example, the serine residue downstream 
of the PXXP motif is important for binding to the SH3 domain of the protein Nck (Zhao 
et al., 2000). Residues C-terminal to PXXP ligands are also shown to modulate binding 
to fyn-SH3, although flanking residues N-terminal to PXXP have not been examined 
(Rickles et al., 1995). Thus, if fyn-SH3 binds to tau at residues 216-219, the proline to 
alanine substitution at residue 213 of tau upstream of the sixth PXXP motif could result 
in increased binding affinity with fyn-SH3. Another possibility is that the P213A mutation 
alters tau phosphorylation around this PXXP motif, which could enhance tau-fyn 
binding at the SH3 domain. The phosphorylation state of tau at S199/S202 has been 
shown to influence tau binding to fyn-SH3 (Pooler et al., 2012), but the precise 
residues and the effects of phosphorylation on tau-fyn binding have not been clearly 
identified. There is also no effect of tyrosine phosphorylation on tau binding to fyn-SH3, 
although phosphorylation at Y18 of tau was shown to regulate the interaction between 
tau and the SH2 domain of fyn (Usardi et al., 2011). The PXXP motifs of tau are located 
in a region that has a high density of phosphorylatable serine/threonine residues 
(Hanger et al., 2009). Therefore, it is likely that phosphorylation, or other post-
translational modifications at residues surrounding the sixth PXXP motif of tau could 
influence its binding to fyn-SH3. In support of this idea, substitution of 18 serine and 
threonine residues to glutamate in the N-terminal half of tau, which mimics 
phosphorylation, inhibited binding between tau and fyn-SH3 (Reynolds et al., 2008). 
These mutations include residues S198, S199, S202, T205, S208, S210, T212, S214, 
T217, T220, and S235, which are located within the proline-rich region of tau. Fyn-SH3 
was also unable to bind to Tau-Glu10, a construct that mimics phosphorylation at 10 
serine/threonine sites throughout the sequence of tau, including 5 in the proline-rich 
region (S198, S199, S202, T231, S235) (Reynolds et al., 2008). Additionally, fyn-SH3 
was unable to bind to highly phosphorylated tau isolated from AD brain (Reynolds et 
al., 2008). Thus it appears that phosphorylation of tau influences its binding to fyn-SH3, 
and much of this phosphorylation occurs around the PXXP motifs identified here as 
being important for tau-fyn-SH3 binding.  
Lentiviruses were generated to express WT, P213A, P216A, and P219A tau constructs 
in order to investigate the effects of disrupting these PXXP motifs on downstream tau 
functions in organotypic brain slices. However, although these lentiviruses expressed 




4.2.2 Limitations of lentiviruses expressing tau 
In order to troubleshoot the problems with transduction of lentivirally-encoded tau in 
organotypic brain slices, the DNA and amino acid sequences of the lentiviral constructs 
were re-assessed. During this analysis, it became apparent that although the DNA and 
protein sequence of tau in LV-tau was correct, insertion of Tau-IRES into the lentiviral 
plasmid had resulted in the removal of a single base pair at the SpeI-blunt/AfeI 
insertion site. This change resulted in utilisation of a different ATG start codon at base 
pair 211, rather than at base pair 735. This use of an ATG at a more 5’ position in the 
lentiviral vector resulted in translation of full-length tau with an additional 145 amino 
acids fused to the N-terminus of tau, giving a protein with a predicted molecular weight 
of 70 kDa. It is apparent therefore that the 70 kDa exogenous tau species detected in 
neurons corresponded to this tau fusion protein. The 5’ sequence that formed the 
fusion protein was translated from part of the synapsin promoter. Despite the truncation 
of the synapsin promoter, and the additional encoded amino acids, full-length tau was 
translated, although the effect on the promoter may have resulted in reduced 
expression of lentiviral tau, compared to endogenous tau in primary neurons. However, 
the lack of lentiviral tau expression in organotypic brain slices does not appear to be 
caused by the additional amino acids fused to the N-terminus of tau. Rather, this 
suggests that the techniques used to deliver the lentivirus particles to organotypic brain 
slices were inefficient. In the future, it will be necessary to implement alternative 
lentiviral delivery techniques, such as direct injection into the brains of tau-/- mice prior 
to preparation of brain slices.  
 
In summary, the results presented in this chapter has identified mechanisms by which 
tau interacts with fyn. Further investigation is required into whether phosphorylation at 
individual serine/threonine residues within the proline-rich region are critical regulators 
of tau-fyn interactions. This may provide additional insight as to whether inhibiting tau-
fyn interactions would be a good target as a therapeutic strategy for AD. For example, if 
phosphorylation at a specific residue inhibits tau-fyn interactions, targeting kinase 
inhibition could be a viable option for treatment.  
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Chapter 5 Investigating interactions between tau 
and fyn in brain tissue 
The first study which implicated fyn in the pathogenesis of AD was reported by Shirazi 
and Wood (1993). These authors observed increased fyn immunoreactivity in a subset 
of neurons containing abnormally phosphorylated tau in AD brain (Shirazi and Wood, 
1993). In vitro studies demonstrating that oligomeric Aβ can upregulate fyn activity 
(Lambert et al., 1998; Williamson et al., 2002; Um et al., 2012) have further implicated 
fyn and its downstream signalling partners in the underlying mechanisms of AD. 
During the progression of AD, the ratio of soluble to insoluble fyn in the brain decreases 
substantially, without any significant change to the total amount of fyn (Ho et al., 2005). 
Immunohistochemical analysis showed that fyn was mislocalised from its normal 
synaptic localisation to the neuronal cell body in AD, and this change became more 
prominent with disease severity (Ho et al., 2005). A proportion of neurons containing 
mislocalised fyn in the cell body also showed increased co-localisation with tau-
containing tangles (Ho et al., 2005). Furthermore, the amount of soluble fyn correlated 
positively with a decrease in the mini mental state examination (MMSE) (Ho et al., 
2005), which is a common clinical test used to determine cognitive ability (Folstein et 
al., 1975). In the same study, soluble fyn was inversely correlated with the cerebral 
load of tau-containing neurofibrillary tangles, but neither soluble nor insoluble fyn 
correlated with amyloid plaques (Ho et al., 2005). Nonetheless, these reported changes 
in fyn expression in AD brain need to be replicated independently in a larger cohort of 
individuals since the study by Ho et al. (2005) was limited by the small number of 
replicates of each group (n = 3-8 for each group). 
In a larger cohort of subjects (n = 24-26 for each group), Larson et al. (2012) showed 
that the total amount of fyn was unchanged in AD patients compared to non-demented 
controls and individuals with mild cognitive impairment (MCI). However, although there 
was no relationship between levels of fyn and severity of dementia, a strong correlation 
was found between total fyn and cellular prion protein (PrPC), regardless of the 
cognitive status of each individual (Larson et al., 2012). These authors also reported 
that the amount of active fyn, assessed by immunoprecipitation of fyn followed by 
western blotting with an antibody against the active form of fyn, was increased in AD 
brain compared to controls, and that in AD brain, but not in controls, the amount of 
active fyn was also significantly correlated with that of PrPC (Larson et al., 2012). These 
data strengthen the hypothesis that Aβ signals through PrPC and fyn to mediate 
synaptotoxicity and this could be an important mechanism underlying the development 
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of AD. However, to date, the relationship between tau and fyn has not been explored 
extensively in human brain tissue, which was the aim of this study.  
Interactions between tau and fyn in rodents and in cell lines, however, have been 
observed in several studies. The first in vitro studies showed that tau could directly 
interact with the SH3 domain of fyn (Lee et al., 1998; Bhaskar et al., 2005; Pooler et al., 
2012), which was confirmed by the results presented in Chapter 4 of this thesis. 
Subsequently it was demonstrated that tau also associates directly with the SH2 
domain of fyn (Usardi et al., 2011). However, a greater challenge is to validate this 
binding in vivo in a physiologically relevant system.  
Interaction assays pose a challenge because the nature of the interaction can interfere 
with the assay and there are many variables that can determine whether the assay is 
successful or not. For example, weak or transient interactions can be difficult to verify 
in an in vivo system using endogenous proteins. One of the most common methods of 
investigating interactions in a more physiologically relevant system is the co-
immunoprecipitation assay (Berggård et al., 2007). It has recently been reported that 
tau and fyn can be co-immunoprecipitated in rodent brain tissue and synaptosomes 
using either tau or fyn antibodies for immunoprecipitation (Ittner et al., 2010; 
Mondragon-Rodriguez et al., 2012). However, in both of these previous studies, 
negative controls for co-immunoprecipitation experiments were not shown, and 
therefore the observed apparent interactions of tau and fyn could conceivably have 
been due to detection of non-specific bands. The necessary controls for this type of 
experiment usually include samples of lysates incubated with agarose beads in the 
absence of primary antibody, and/or the inclusion of an irrelevant antibody that does 
not bind either protein to determine whether the target protein is binding non-
specifically to immunoglobulins present in the immunoprecipitate. In another study, 
using transgenic mice overexpressing both wild-type human tau and mutant APP, co-
immunoprecipitation also revealed associations between tau and fyn (Chabrier et al., 
2012). It should be noted, however, that this experiment was performed under 
conditions in which one of the target proteins was overexpressed. Therefore, although 
tau and fyn binding has been demonstrated in rodent brain tissue, it is important that 
this interaction is reproduced in an independent study examining the endogenous 
proteins, and with the inclusion of appropriate negative controls. 
It is currently unclear whether tau and fyn are associated only at the dendrite, or 
whether these proteins can also interact in different subcellular locations. In addition, 
the relationship between tau phosphorylation and expression of fyn has not been well 
explored, particularly in the case of human brain. Therefore, the aims of this chapter 
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were 1) to determine whether an interaction of endogenously expressed tau and fyn in 
rodent brain could be detected, and if so, 2) to identify the subcellular localisation of 
this interaction, and 3) to investigate the relationship between tau phosphorylation and 
fyn in human AD post-mortem brain tissue.  
 
5.1 Results 
5.1.1 Optimisation of tau-fyn co-immunoprecipitation assays using 
lysates from primary neurons and brain tissue 
A range of different conditions was tested to verify the tau-fyn interaction in lysates 
prepared from primary neurons and rodent brain tissue by co-immunoprecipitation. 
Several factors affect the success of co-immunoprecipitation experiments, including 
buffer composition, antibody-antigen accessibility, concentration of target proteins, and 
the nature of the interaction between the target proteins. A summary of all the 
conditions tested is shown in Table 5.1. 
Different buffers containing a range of detergent types and concentrations were tested 
to find the optimal conditions for co-immunoprecipitation (see Section 2.1.4 for details 
of lysis buffers). Radioimmunoprecipitation assay (RIPA) buffer was used in the first 
instance, because fyn is a membrane-bound protein and we hypothesised that the 
additional ionic detergents SDS and sodium deoxycholate present in this buffer would 
aid in the disruption of membranes. Facilitating fyn solubilisation could hence provide 
more opportunity for its interaction with soluble tau. Due to concerns that RIPA buffer 
could also have the effect of disrupting tau-fyn interactions, lysis buffers containing 
non-ionic detergents were also tested. HEPES buffer containing the non-ionic 
detergent Triton X-100 was used to successfully demonstrate co-immunoprecipitation 
between tau and fyn in a previous study (Ittner et al., 2010), while NETF buffer contains 
a non-ionic detergent, Nonidet P-40, and has also been used in successful co-
immunoprecipitation of V5-tagged tau (Derkinderen et al., 2005). 
Primary antibodies directed against either tau or fyn were used to investigate the 
interaction in both directions. Since it is known that the SH3 domain of fyn binds to the 
proline-rich region of tau in vitro, efforts were made to find antibodies for 
immunoprecipitation with epitopes that did not bind to these identified binding regions.  
The sources used were rat primary cortical neurons, mouse brain tissue, and CHO 
cells co-expressing tau (V5-His-tagged) and fyn. In some cases, primary neurons were 
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treated with IC261, an inhibitor of casein kinases 1δ and ε (CK1δ and CK1ε, 
respectively), as this has been shown to increase the association between tau and fyn-
SH3 in vitro (Pooler et al., 2012). Another approach was to crosslink proteins using 
Dithiobis[succinimidyl propionate] (DSP), since this can aid in detecting weak or 
transient protein-protein interactions. Mouse brain tissue was separated into membrane 
and cytosolic fractions because fyn is predominantly found in association with 
membranes. Finally, CHO cells expressing tau and fyn were treated with sodium 
pervanadate, a tyrosine phosphatase inhibitor, because a previous study showed that 
pervanadate increases the association between tau and fyn-SH2 in vitro (Usardi et al., 
2011). 
Regardless of the type of sample (primary neurons, brain tissue, or cultured non-
neuronal cells), treatment, lysis buffer, or primary antibody used, the co-
immunoprecipitation protocol remained the same (Section 2.2.8). Prepared samples 
were pre-incubated with washed protein A agarose beads to clear endogenous 
immunoglobulins, and the pre-cleared samples were incubated with primary antibody 
overnight to allow binding to antigen. Lysates containing antibody-antigen complexes 
were bound to protein A agarose beads, and bound proteins were eluted and analysed 
on western blots with antibodies against tau or fyn to verify the presence of co-
immunoprecipitated proteins. Lysates without primary antibody, or incubated with an 
irrelevant antibody raised in the same species as the tau or fyn antibody, were bound to 
beads and eluates were included on western blots as controls. Total lysates were also 
run on western blots as a positive control for the target proteins and to ensure that the 
amount of antigen input was detectable.  
Western blots were probed with antibodies raised in a different species than the 
primary antibody used for immunoprecipitation, to avoid detection of the heavy-chain 
IgG proteins immunoprecipitated with the antibody-antigen-bead complex. Because tau 
is ~50 kDa, and fyn is 59 kDa, the heavy chain IgG (50 kDa) interferes with the 
detection of tau and fyn. Since preliminary studies had shown that commercial mouse 
monoclonal antibodies did not specifically detect fyn with much sensitivity, and 
therefore the best option was to use a rabbit polyclonal antibody, the combinations of 
binding and detection antibodies were necessarily limited for these studies. 
To identify an association between tau and fyn in cultured neurons, rat primary cortical 
neurons were subjected to immunoprecipitation of fyn in RIPA, HEPES, or NETF buffer 
with the following antibodies: polyclonal fyn (Sigma), monoclonal fyn (BD Biosciences), 
polyclonal fyn (Cell Signalling Technologies; CST), polyclonal fyn sc-16 (Santa Cruz 
Biotechnology), monoclonal fyn sc-434 (Santa Cruz Biotechnology), and monoclonal 
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fyn 1S (Abcam). A representative western blot of co-immunoprecipitation of fyn using 
the polyclonal fyn (Sigma) antibody from rat cortical neurons is shown in Figure 5.1. 
Rat cortical neurons were also subjected to tau immunoprecipitation in RIPA buffer with 
a monoclonal tau antibody (Tau-5) and the following polyclonal antibodies: tau (DAKO), 
C-terminal epitope of tau (TP70), and N-terminal epitope of tau (TP007). In addition, rat 
cortical neurons were treated with IC261 to inhibit CK1δ/ε, or DSP to cross-link 
proteins. IC261 treatment was followed by immunoprecipitation with fyn (Sigma), fyn 
(BD Biosciences), fyn (CST), or total tau (DAKO) antibodies. DSP treatment was 
followed by immunoprecipitation with the following antibodies: fyn (CST), fyn sc-16, fyn 
1S (Abcam), tau (DAKO), and tau-5. Western blots of immunoprecipitates from 
monoclonal antibodies were probed with polyclonal antibodies against tau and fyn, and 





Figure 5.1 Co-immunoprecipitation of fyn from rat cortical neurons  
Western blot of co-immunoprecipitation from rat cortical neurons. Fyn was 
immunoprecipitated from rat cortical neurons with the polyclonal fyn (Sigma) antibody. 
As negative controls, neuronal lysates were incubated without primary antibody 
(beads), or an with an irrelevant polyclonal antibody (IgG). Western blots of neuronal 
lysate, immunoprecipitates, and negative controls were probed with a monoclonal 
antibody against tau (upper panel) and the same polyclonal fyn (Sigma) antibody used 
for immunoprecipitation (lower panel). The 50 kDa heavy chain band is indicated 
(arrow) and is distinct from the 59 kDa fyn band (lower panel). Molecular weight 
markers are shown on the left (kDa). 
 
 
Whole brain mouse homogenates were subjected to fyn immunoprecipitation in RIPA, 
HEPES, or NETF buffer as above, and analysed on western blots. In addition, 
membrane and cytosolic fractions of mouse brain tissue were immunoprecipitated with 
fyn (CST), tau (TP70), or tau (TP007) antibodies. Western blots were probed with tau 
and fyn antibodies as above. 
Finally, CHO cells co-expressing tau (V5-His-tagged) and fyn were treated with 
pervanadate and subjected to immunoprecipitation with fyn (CST) and V5 antibodies. 
Western blots were probed with tau and fyn antibodies as above.  
In all the conditions tested (Table 5.1), western blots showed that tau and fyn were both 
present in the total lysate. Samples immunoprecipitated with tau or fyn antibody were 
all strongly positive for tau or fyn, respectively, showing that the immunoprecipitation of 








immunoprecipitates and neither was fyn detected in any of the tau immunoprecipitates 
under any of the conditions tested in these studies. These results are in contrast to the 
study by Ittner and colleagues (2010), in which the authors used fyn antibodies sc-434 
and sc-16 (both from Santa Cruz Biotechnology) to successfully demonstrate co-
immunoprecipitation in both directions. It is unclear which antibody was used for 
immunoprecipitation and which for determining the co-immunoprecipitation, but both 
antibodies were tested here (Table 5.1). Through personal communication with the 
authors of the study (Ittner et al., 2010), it appeared that fyn antibodies obtained from 
Santa Cruz Biotechnology demonstrated considerable batch to batch variability. It was 
subsequently determined that the batch number used in the studies reported herein 
differed from that used by Ittner et al. (2010), which could provide a possible 
explanation for the discrepancy between the results obtained from each laboratory.  
It remains possible that the tau-fyn interaction is weak or transient and that successful 
co-immunoprecipitation requires a precisely optimised combination of factors to detect 
tau or fyn in the co-immunoprecipitates. The stoichiometry of the tau-fyn interaction is 
also unclear. It is not known how much tau is normally bound to fyn, and vice versa. 
The absence of follow-up studies that reproduce an endogenous tau-fyn interaction in 
vivo, in contrast to the abundance of in vitro studies using recombinant or 
overexpressed tau or fyn proteins, suggests that the tau-fyn interaction may not be a 
robust, stable association, at least under normal conditions. Further methods to 
concentrate the target proteins, such as additional fractionation into synaptosomes 
where the tau-fyn interaction is thought to occur, may be necessary to facilitate 
detection of their binding by co-immunoprecipitation. Alternatively, assays such as 
Duolink may be capable of detecting transient interactions within cells. Duolink is a 
proximity ligation assay which detects protein-protein interactions by utilising probes 
that bind to primary antibodies in fixed cells or tissues. If the target proteins are in close 
enough proximity (<40 nm), the probes ligate to elicit a reaction that can be visualised 
under a fluorescent microscope. This approach would also allow visualisation of the 




5.1.2 Fyn expression in the human brain 
To investigate fyn expression in human brain, antibodies against fyn were first 
optimised for use in human post-mortem brain tissue. Brain homogenates from WT and 
fyn-/- mouse brain tissue were used as controls. Human brain tissue from a control 
individual without AD that had previously been shown to contain undegraded protein 
was used as the optimisation sample. Human and mouse brain tissue were separated 
on 10% SDS-PAGE gels and western blots were probed with antibodies targeting fyn, 
with β-actin antibody as a loading control. 
The polyclonal fyn (Sigma) antibody detected a single, prominent band at 59 kDa in all 
samples except for fyn-/- mouse brain (Figure 5.2A). Fyn antibodies from Abcam, 
Invitrogen, and Santa Cruz Biotechnology (sc-434) did not reveal any positive signal in 
human brain tissue (Figure 5.2A). A second antibody from Santa Cruz Biotechnology 
(sc-16) did recognise a 59 kDa band in both human and WT mouse brain tissue, but 
not in fyn-/- brain tissue (Figure 5.2A). However, sc-16 also recognised a non-specific 
band at 50 kDa in all brain samples. The antibody from Cell Signalling Technologies 
(CST) also recognised fyn at 59 kDa in human brain tissue. However, the best signal 
was obtained using the polyclonal fyn (Sigma) antibody which provided a clear fyn 
band at 59 kDa in both mouse and human brain tissue in the absence of non-specific 
bands (Figure 5.2A). 
An antibody directed against the active form of fyn was also tested for immunoreactivity 
in mouse and human brain tissue. The src pY420 antibody (CST) recognises fyn and 
cross-reacts with other src family members only when they are phosphorylated at 
Y420, which indicates an active conformation. As controls, CHO cells expressing tau 
and fyn with and without pervanadate treatment were used. Pervanadate inhibits 
tyrosine phosphatases, resulting in increased tyrosine phosphorylation and increased 
association of recombinant tau with fyn-SH3 (Usardi et al., 2011). As expected, probing 
western blots with the fyn (Sigma) antibody revealed a 59 kDa band in all samples 
except for fyn-/- mouse brain tissue (Figure 5.2B). Conversely, the pY420 antibody only 
recognised active fyn in CHO cells expressing fyn (Figure 5.2B). This could have been 
due to the relatively small amount of endogenous fyn in human and mouse brain tissue 
compared to CHO cells that were overexpressing fyn, or that little of the fyn protein 






Figure 5.2 Optimisation of antibodies against fyn 
Western blots of wild-type (WT) and fyn-/- mouse brain tissue, CHO cells expressing 
V5-His-tagged tau and fyn, and post-mortem human brain tissue. (A) A panel of 
polyclonal and monoclonal antibodies directed against fyn were tested in lysates 
prepared from WT and fyn-/- mouse brain tissue, and human brain tissue (Hum). β-actin 
antibody was used as a loading control. CST, Cell Signalling Technologies. BD, BD 
Biosciences. (B) An antibody directed against src phosphorylated at Y420, which cross-
reacts with active fyn, was tested in human brain tissue, WT and fyn-/- mouse brain 
tissue, and CHO cells expressing tau and fyn treated with (Pervan) to increase tyrosine 
phosphorylation, and vehicle-treated (Ctrl) cells. Pervanadate treatment of CHO cells 
decreases the mobility of fyn on SDS-PAGE. Molecular weight markers are shown on 




To concentrate the amount of fyn in samples, immunoprecipitation of fyn would 
facilitate a greater chance of detecting phosphorylation at Y420. This approach would 
also specifically indicate the amount of active fyn, rather than Y420 detected in other 
src family members. Therefore, fyn was immunoprecipitated with a monoclonal 
antibody against fyn (BD Biosciences), using control and AD human brain tissue. 
Samples were also immunoprecipitated without the addition of a primary antibody as a 
negative control. Western blots of immunoprecipitated fyn and total brain homogenates 
(input) were probed with the polyclonal antibodies fyn (Sigma) and src pY420, to avoid 
cross-reaction with immunoglobulin bands. Probing with the total fyn antibody (Sigma) 
showed that fyn was present in human brain tissue, but there was considerably less fyn 
protein immunoprecipitated with the monoclonal fyn (BD Biosciences) antibody (Figure 
5.3). The pY420 blot showed the absence of a band at the expected size (59 kDa) in 
the immunoprecipitates and total lysates, but there appeared to be some cross-reaction 
with the fyn immunoprecipitation antibody as a band corresponding to the size of the 
immunoglobulin heavy chain (50 kDa) was recognised (Figure 5.3A). This was likely 
due to the relatively low amount of fyn that was immunoprecipitated from the brain. A 
potential cause of the weak immunoprecipitation is the monoclonal antibody used. Its 
ability to recognise fyn in total lysates is apparent, but its epitope may not be easily 
accessible in the native form of fyn. To determine whether this is the case, an 
alternative fyn antibody could be used for immunoprecipitation. However, time 
constraints meant that optimisation of fyn immunoprecipitation in these samples was 





Figure 5.3 Immunoprecipitation of fyn in human post-mortem brain tissue  
Western blots of total lysates (input) and immunoprecipitates from human post-mortem 
brain tissue. (A) Fyn was immunoprecipitated from control (C) and Alzheimer’s disease 
(AD) human brain tissue using a monoclonal fyn antibody. (B) Beads-only 
immunoprecipitates were included as negative controls. Western blots were probed 
with polyclonal antibodies against fyn and src phosphorylated at Y420. The 50 kDa 





5.1.3 Alterations in tau and fyn expression during the progression of AD 
To investigate any disease-related changes in tau and fyn expression in AD, age-
matched human cortical post-mortem brain tissue from control and individuals with 
sporadic AD (Braak stages I-VI) was homogenised in extra strong lysis buffer (Section 
2.1.4) and separated on 10% SDS-PAGE gels. Phosphorylation of tau at several 
epitopes was investigated by probing western blots with the following tau antibodies: 
PHF-1 (recognises tau phosphorylated at S396/S404), Tau-1 (tau dephosphorylated at 
S199/S202), CP13 (tau phosphorylated at S202), pS214, and pS262. All 
phosphorylated tau species are expressed relative to the total amount of tau. The 
cohort of brain samples investigated here included brains classified as normal aging 
controls and Braak stages I-VI (AD). Due to the low numbers of available samples at 
each Braak stage, the brains were grouped into controls, Braak stages I-II, III-IV, and 
V-VI. 
The amount of total tau was initially measured, relative to neuron-specific enolase 
(NSE) expression, to determine whether there were any differences in the amount of 
total tau present in neurons in control and AD brain. NSE was used for normalisation 
since this neuron-specific protein allows standardisation of samples whilst taking into 
account neuron loss and gliosis that occurs during the progression of AD. There was 
wide variation in the total amount of tau relative to NSE in AD brain (Figure 5.4A), 
although the amount of tau present in control brain appeared to be considerably less 
than that of AD brains at all Braak stages. Quantification of the western blots showed 
that tau was significantly increased at Braak stages I-II and Braak stages V-VI, 
compared to controls (Figure 5.4A).  
Tau phosphorylated at the PHF-1 and CP13 epitopes (S396/S404 and S202, 
respectively) was detectable at Braak stages V-VI, but not in controls or during Braak 
stages I-IV brain tissues (Figure 5.4B, C). However, the wide variation in 
phosphorylated tau at Braak stages V-VI meant that no statistically significant 
difference from controls was determined. Interestingly, the amount of tau 
phosphorylated at S396/S404 appeared to be significantly increased at Braak stages 
V-VI compared to earlier Braak stages I-II. However, the significant difference between 
Braak stages I-II, but not control or Braak stages III-IV, and Braak stages V-VI is not 
reflected on the western blots as the presence of PHF-1 immunoreactivity is only 
observed in Braak stages V-VI. Therefore the statistical difference is likely caused by 








Figure 5.4 Changes in tau phosphorylation over time in AD 
Representative western blots of control and AD (Braak stages I-VI) human post-
mortem brain tissue. Western blots were probed for (A) total tau, or phosphorylated tau 
with (B) PHF-1, (C) CP13, (D) tau pS262, (E) Tau-1, and (F) tau pS214. Quantification 
of total tau is shown in graphs following normalisation to neuron-specific enolase (NSE) 
amounts in each sample. Quantification of phosphorylated tau is shown in graphs to 
the right of each western blot following normalisation to total tau amounts in each 
sample. (G) Western blots were also probed with an antibody against fyn and 
quantification of fyn was normalised to NSE. Molecular weight markers are shown on 
the left (kDa). Values represent mean ± SEM, n=6-7 per group. Kruskal-Wallis with 
post-hoc Dunn’s test, *p < 0.05, **p < 0.01.  
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In addition, phosphorylation of tau at the CP13 epitope (S202) appeared to be reduced 
at Braak stages I-IV compared to control brain (Figure 5.4C), but this is likely due to the 
variation in total tau (Figure 5.4C) rather than any reduction in tau phosphorylation at 
S202 at Braak stages I-IV.  
Phosphorylation of tau at S262 and S214 was detected in control and AD brain of all 
Braak stages, but the amount of tau phosphorylation at these epitopes, relative to total 
tau, was not significantly different between controls and AD samples of all stages 
(Figure 5.4D, F). However, tau species phosphorylated at S262 and S214 appeared to 
have a higher molecular weight in a subset of Braak stage V-VI AD brain, indicating 
increased phosphorylation, but this did not reach statistical significance when 
compared to control brain (Figure 5.4D, F). Nevertheless, this suggests the presence of 
highly phosphorylated species that are recognised by the pS214 and pS262 tau 
antibodies in late stage AD brain. The Tau-1 antibody, which recognises tau 
dephosphorylated at S199/S202, detected tau in both control and AD brain in all 
samples tested. Notably, tau dephosphorylated at S199/S202 was significantly 
decreased at Braak stages V-VI compared to control brain (Figure 5.4E), indicating an 
increase of tau phosphorylated at the S199/S202 in late stage AD brain. 
Probing with an antibody against fyn showed that it was present as a 59 kDa band in 
both control and AD brain (Figure 5.4G).  There appeared to be a slight trend towards 
decreased fyn in subjects in AD brain homogenates of increasing Braak stage (Figure 
5.4G). However, this did not reach statistical significance. Levels of fyn protein were 
normalised to NSE to account for any potential variations in neuronal loss between the 
different brain samples (Figure 5.4G). 
Taken together, these results suggest that increased tau phosphorylation, at least at 
the epitopes examined here, can be observed in late stage AD brain (Braak V-VI). 
There appears to be a wide range in the total amount of tau in different AD brains, but 
these data suggest an accumulation of tau with increasing Braak stage. 
Phosphorylation of tau at several epitopes (S214, S202, S262, S396/S404) increases 
with progression of AD as defined by the Braak stage, but some of these results were 
only shown qualitatively by western blot. The lack of statistical significance apparent 
following quantification of some of these data is likely caused by the large variations in 
the total amount of tau present, compounded by the relatively small number of AD brain 




5.1.4 Tau and fyn expression in the soluble fraction of human brain 
It was previously reported that fyn is decreased in the soluble fraction of AD brain and 
that the increased fyn in the insoluble fraction is correlated with progression of disease 
(Ho et al., 2005). There is also substantial evidence that tau pathology correlates with 
the severity of disease (Augustinack et al., 2002). To investigate the relationship 
between soluble tau and fyn in AD, human post-mortem brain tissue from controls and 
sporadic AD patients (Braak stages II-VI) were homogenised in detergent-free lysis 
buffer (Section 2.1.4). Since there are no denaturing or reducing agents in the lysis 
buffer, insoluble components in the sample are retained in the pellet after 
centrifugation. The supernatant of homogenised brain tissue was separated on 10% 
SDS-PAGE gels, analysed on western blots and probed with antibodies targeting tau 
and fyn. 
Samples were grouped into controls, Braak stages II, III-IV, and V-VI, due to a low 
number of replicates available for each Braak stage. AD brain tissue at Braak stage I 
was unavailable at this time. Quantification of western blots showed that total tau in AD 
brain was significantly increased in AD brain at Braak stages V-VI compared to control 
brain tissue after normalisation to NSE to account for variations in neuronal loss 
between control and AD brain (Figure 5.5A). However, soluble fyn was unchanged 
between controls and AD brain across all Braak stages (Figure 5.5B). Interestingly, the 
bands recognised by the fyn antibody in human brain tissue did not appear as a single 
prominent band of 59 kDa, but up to four bands ranging from ~48-62 kDa were visible 
(Figure 5.5B). It is unclear whether these bands are modified species of fyn, or whether 
they represent different isoforms of fyn. It is possible that the preparation of these 
samples resulted in protein degradation, reflecting the presence of the lower molecular 
weight bands of fyn. In addition, the buffer used to prepare these samples does not 
contain detergent, which may not have been effective at lysis of fyn, a membrane-
associated protein. Therefore, this may represent a different pool of fyn which could 
comprise of different fyn species as compared to membrane-associated fyn. Thus, 
although the increase in total tau in the soluble fraction of AD brain reflects the previous 
results using total brain homogenate, the amount of soluble fyn was unchanged in AD 





Figure 5.5 Tau and fyn expression in soluble fractions of AD brain 
Representative western blots of soluble fractions of control and AD (Braak stages II-VI) 
post-mortem human brain tissue were probed with antibodies against (A) total tau and 
(B) fyn. Molecular weight markers are shown on the left (kDa). Quantification of 
western blots normalised to neuron-specific enolase (NSE) is shown on the right. 
Values represent mean ± SEM, n=4-7 per group, Kruskal-Wallis with post-hoc Dunn’s 




5.1.5 Disease-related changes in tau and fyn in the human brain 
The number of independent replicates used in the previous experiments shown above 
is low because samples from early and mid-Braak stages were not readily available. 
The low replicate number combined with high variability within groups is likely to have 
influenced the statistical analyses performed. We hypothesised that alterations of fyn 
levels and tau phosphorylation would be most prominent in the late stages of AD where 
severe tau pathology is observed. Hence, tau and fyn expression were investigated 
further in a larger cohort of control and Braak stages V-VI AD brain to increase the 
statistical power of the experiments. 
All samples showed prominent tau staining with the distinctive banding pattern of 
human tau (Figure 5.6A). After normalisation to NSE to account for variability in 
neuronal loss, the total amount of tau was shown to be significantly increased in AD 
brain (Braak stages V-VI) compared to control brain (Figure 5.6A). The total amount of 
tau also appears to have wide variation in AD brain, which is not seen in control brain, 
in agreement with previous results shown earlier in this chapter (Figure 5.6A). Western 
blots showed barely any immunoreactivity to PHF-1 antibody in control brain, as shown 
previously (Figure 5.6B). Quantification of PHF-1 bands showed a significant increase 
of PHF-1 immunoreactive tau in AD brains at Braak stages V-VI compared to control 
(Figure 5.6B), suggesting that phosphorylation of tau at this site is a feature of AD 
brain. Likewise, tau immunoreactivity to CP13 antibody was barely detectable in control 
samples but higher molecular weight bands at ~65-70 kDa were recognised by this 
antibody in AD brain (Figure 5.6C). Quantification of these tau species relative to total 
tau revealed that CP13 immunoreactivity was significantly increased in AD brains 
compared to control (Figure 5.6C). The pS262 tau antibody revealed higher molecular 
weight bands (65-70 kDa) in AD, but not control, samples, and these species were also 
found to be significantly increased in AD (Figure 5.6D). Phosphorylation of tau at S214, 
which is located close to the PXXP motifs important for tau-fyn binding (Chapter 4), 
was also investigated in human brain tissue. pS214 tau antibody revealed a 50 kDa 
band present in all brain samples, which co-localised with tau (Figure 5.6E). However, 
quantification showed that tau phosphorylated at S214 relative to total tau was not 
significantly different between AD and control brains (Figure 5.6E). Tau-1, an antibody 
which recognises dephosphorylated tau at S199/S202, revealed prominent bands in all 
samples tested (Figure 5.6F). Quantification of Tau-1 bands relative to total tau showed 
a significant decrease of Tau-1 immunoreactivity in AD samples compared to control, 
indicating phosphorylation at S199/S202 is increased in AD (Figure 5.6F). This reflects 
the increase of CP13-immunoreactive bands in AD samples, as CP13 recognises 







Figure 5.6 Altered tau and fyn expression at late stages of AD (Braak stages V-VI) 
Representative western blots of control and AD (Braak stages V-VI) post-mortem 
human brain tissue were probed with antibodies against (A) total tau and 
phosphorylated tau. Tau phosphorylation was detected with antibodies (B) PHF-1, (C) 
CP13, (D) tau pS262, (E) Tau-1, and (F) tau pS214. Quantification of total tau was 
normalised to neuron-specific enolase (NSE). Quantification of phosphorylated tau is 
shown to the right of each western blot and normalised to total tau. (G) Western blots 
were also probed with an antibody against fyn and quantification of fyn was normalised 
to NSE. Molecular weight markers are shown on the left (kDa). Values represent mean 
± SEM, n=13-16 per group. Mann-Whitney non-parametric test, *p < 0.05, **p < 0.01, 
NS = not significant.   
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To determine whether any changes in the amount of fyn protein could be observed in 
AD, western blots of human brain tissue were probed with an antibody against fyn. The 
amount of fyn protein was normalised to NSE to ensure any alterations in fyn protein 
were not due to neuronal loss. Quantification of fyn bands showed that levels of fyn 
protein, relative to NSE, appeared to be slightly decreased in AD compared to control 
brains, but this decrease did not reach significance (Figure 5.6G). A summary of the 
statistical significance between control and AD brains for phosphorylated tau and total 
fyn is shown in Table 5.2. 
 
Table 5.2 Summary of significance values from western blots of tau and fyn in 
control and AD brain tissue  
  Antibody 












0.0099 0.0017 0.1281 
0.066
8 
Control vs I-II * NS * NS NS NS NS 
Control vs III-
IV NS NS * NS NS NS NS 
Control vs V-
VI * NS NS NS ** NS NS 
I-II vs III-IV NS NS NS NS NS NS NS 
I-II vs V-VI NS ** NS NS NS NS NS 
III-IV vs V-VI NS NS NS NS NS NS NS 
Table 5.2 shows the significance values obtained following statistical analysis of total 
tau relative to NSE, tau phosphorylation at the epitopes PHF-1, CP13, pS262, Tau-1, 
and pS214 normalised to total tau, and fyn levels normalised to NSE, in controls and 
AD post-mortem human brain tissue. Mann-Whitney test was carried out to determine 
the difference between means of controls and late-stage AD (Braak stages V-VI, Figure 
5.6), while the Kruskal-Wallis with post-hoc Dunn’s test was carried out to determine 
the difference between means of controls and AD groups (Braak stages I-II, III-IV, V-VI, 




To determine if there was any correlation between levels of fyn protein in AD and tau 
phosphorylation at the epitopes above, non-parametric Spearman correlation analysis 
was carried out. Correlation between tau and fyn was first investigated in the cohort of 
control and late-stage (Braak V-VI) AD patients as a combined group, to investigate 
whether there was any association irrespective of the neuropathological status (Figure 
5.7). Notably, fyn was significantly correlated with pS214 tau in both control and AD 
brain (Figure 5.7F). When the control and AD groups were combined, the amount of fyn 
was not associated with that of total tau (Figure 5.7A), phosphorylated tau at 
S396/S404 (Figure 5.7B), S202 (Figure 5.7C), S262 (Figure 5.7D), or S199/S202 
(Figure 5.7E). 




Figure 5.7 Correlation between disease-related changes in tau and fyn in AD 
brain  
Spearman’s rank correlation analysis of the (A) total amount of tau, phosphorylated tau 
at (B) PHF-1, (C) CP13, (D) pS262, (E) tau-1 (F) pS214 epitopes relative to fyn in post-
mortem control and AD human brain. See Table 5.3 for details of significant 




To investigate whether the correlation between fyn and tau was altered due to 
neuropathological AD status, the cohort was separated into controls and AD samples 
and re-analysed for correlation. A summary of Spearman’s rank correlation coefficients 
and significance levels for correlation between fyn and tau in control and AD brain is 
shown in Table 5.3. Statistically significant results are highlighted in purple. 
Interestingly, this analysis showed that the amount of fyn was positively correlated with 
tau phosphorylated at S202 (CP13) and S214 in control brain, but not in AD brain 
(Table 5.3). There appeared to be a negative correlation between the amount of total 
tau and fyn in control brain, but this was not statistically significant (Table 5.3). Tau 
phosphorylated at S396/S404 (PHF-1) appeared to be positively correlated with the 
amount of fyn in control brain, but this did not reach statistical significance (Table 5.3).  
 
Table 5.3 Analysis of correlation between the amounts of tau and fyn in control 
and AD brain  
  Control AD 
Fyn vs r p r p 
Total tau -0.5257 0.065 0.156 0.5942 
PHF-1 0.5055 0.0812 0.1752 0.5293 
CP13 0.8741 0.0004 0.2857 0.3012 
Tau 
pS262 0.4670 0.1103 -0.1209 0.6806 
Tau-1 -0.1504 0.6238 -0.1198 0.6833 
Tau 
pS214 0.6099 0.0269 -0.0699 0.8045 
Spearman’s rank correlation coefficients (r) and significance values (p) corresponding 
to associations between fyn, and total and phosphorylated tau. Correlation analyses 
were carried out on brains from controls only or AD only. 
 
 
This suggests that tau phosphorylation at S202 and S214 correlates with the amount of 
fyn in normal brain, but that this correlation is lost in AD. These data support the 
hypothesis that tau and fyn are associated under normal conditions, but that 
pathological activation of fyn by Aβ or other alterations in fyn in AD may directly or 




In this chapter, co-immunoprecipitation was used to identify an interaction between tau 
and fyn in vivo. In addition, to investigate whether the expression levels of fyn is 
associated with the pathogenesis of AD, human post-mortem tissue of control and AD 
brain was analysed on western blots. Moreover, the accumulation of phosphorylated 
tau was investigated in controls and AD brain. Statistical analyses showed that the 
amount of fyn does not correlate with increased tau phosphorylation in AD.  
Both tau and fyn were successfully immunoprecipitated from mouse brain tissue, 
primary rat cortical neurons, and CHO cells expressing tau and fyn. However, the 
presence of fyn in tau immunoprecipitates and tau in fyn immunoprecipitates was not 
observed, suggesting that either these two proteins do not co-immunoprecipitate, that 
any binding is transient, or that the amounts of associated proteins were below the 
level of detection using these antibodies. A large number of different conditions were 
applied in order to optimise the co-immunoprecipitation. A decisive factor is likely the 
combination of binding and detection antibodies, although antibodies that did not 
overlap with the SH3 domain of fyn or the proline-rich region in tau were used for 
immunoprecipitation. Given that several studies have now confirmed that tau and fyn 
can directly interact in vitro (Lee et al., 1998; Bhaskar et al., 2005; Usardi et al., 2011; 
Pooler et al., 2012; Cochran et al., 2014), and two independent studies have verified 
the tau-fyn interaction using endogenous proteins in vivo by co-immunoprecipitation 
(Ittner et al., 2010; Mondragon-Rodriguez et al., 2012), it is likely that the tau-fyn 
interaction may well exist in vivo. It is probable that this interaction is transient, as the 
major function of tau is to bind to microtubules. In addition, only a small proportion of 
tau is bound to the plasma membrane (Maas et al., 2000; Pooler et al., 2012; Liu and 
Götz, 2013), and a similarly small pool of tau is found at the dendrite (Ittner et al., 2010; 
Mondragon-Rodriguez et al., 2012; Liu and Götz, 2013; Frandemiche et al., 2014). It is 
not clear what proportion of fyn is normally bound to tau. Therefore, the amount of tau 
bound to fyn may be only a very minor proportion of the total amount of tau in neurons. 
It is possible that for the studies with successful co-immunoprecipitation between tau 
and fyn, much larger amounts of protein were used as the starting material in order to 
concentrate the target proteins. However, in the experiments presented herein, a 
considerable amount of fyn and tau protein was immunoprecipitated from the starting 
material, suggesting that this is not the sole reason for the lack of co-
immunoprecipitation. 
An interesting question would be to identify the precise cellular localisation of the tau-
fyn interaction. Fyn is required for phosphorylation-dependent trafficking of tau to the 
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membrane, although the amount of tau at the membrane under basal conditions does 
not appear to be affected by the presence of fyn (Pooler et al., 2012). Fyn is also 
required for recruitment of tau to lipid rafts (Williamson et al., 2008; Usardi et al., 2011). 
In parallel, tau is required for the localisation of fyn at the dendrite. Does the interaction 
occur at the dendrite, as suggested by Ittner et al. (2010), or in the cytosol from where 
the complex is transported to dendrites? Further investigation is required to answer this 
question. One approach would be to utilise imaging methods such as Duolink, in which 
interaction of endogenous proteins can be detected and quantified in fixed cells. 
Identification of the tau-fyn localisation would aid in developing specific therapeutics for 
AD, if unique components of a pathological tau-fyn interaction can be targeted 
dependent on its subcellular localisation. 
Although there is now compelling evidence for a signalling cascade via fyn triggered by 
Aβ (Larson et al., 2012; Um et al., 2012; Rushworth et al., 2013), data from this chapter 
show that the amount of fyn is not altered in AD brain relative to control tissue. Thus, 
the role of fyn in the pathogenesis of AD does not appear to be related to the fyn 
expression. Fyn activity, as determined by immunoprecipitation of fyn followed by 
western blots with an antibody against the active form of fyn, has been shown to 
increase in AD patients compared to controls (Larson et al., 2012). The amount of fyn 
is also correlated with that of PrPC in both control and AD brains (Larson et al., 2012). 
However, the relationship of fyn with total tau or tau phosphorylation has not been 
investigated previously. Here, data from this chapter show that the amount of fyn does 
not correlate with tau phosphorylation in AD, suggesting that regulation of tau 
phosphorylation, at least at the serine/threonine residues examined here, is not the 
major pathogenic mechanism of fyn in AD. It will be interesting to determine whether 
the amount of fyn correlates with tau phosphorylation at tyrosine residues in human 
brain. However, in this study, fyn kinase activity was not examined and this would likely 
provide more accurate data as to the role of fyn in regulating downstream effects of tau 
phosphorylation. Further investigations to determine the relationship between fyn 
kinase activity and tau phosphorylation, including the tyrosine phosphorylation of tau, in 
human brains will be important in developing novel therapeutics for AD.  
Intriguingly, although no correlation was found between levels of fyn and tau 
phosphorylation at S199, S262, or S396/S404, there was a significant correlation 
between fyn and tau phosphorylated at S202 and S214 in control brain tissue. This 
correlation was not apparent in AD brain, suggesting that at least during the late stages 
of AD, underlying pathogenic mechanisms may result in disruption of the association 
between fyn and tau phosphorylated at these epitopes. Notably, inhibition of CK1δ, 
which results in increased tau dephosphorylated at S199/S202, increases the 
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association of tau with fyn-SH3, while okadaic acid, which induces tau phosphorylation 
at multiple sites, including S199/S202, decreases the tau-fyn association (Pooler et al., 
2012). Phosphomimics of tau at S202 have altered affinity for fyn in vitro dependent on 
the insertion of microtubule-binding repeats of tau (Bhaskar et al., 2005). 
Phosphorylation at S214 of tau has been shown to inhibit binding between tau and 
microtubules, as well as preventing aggregation of tau fibrils (Illenberger et al., 1998; 
Schneider et al., 1999). Detachment of tau from microtubules might increase the 
likelihood of tau associating with fyn. Interestingly, although tau phosphorylation at 
S262 is also important for microtubule binding with tau (Schneider et al., 1999), the 
amount of tau phosphorylated at S262 did not correlate with fyn in control or AD brain. 
It is possible that tau phosphorylated at S202 and S214 can bind to fyn normally, but at 
late stages of AD, tau becomes increasingly phosphorylated at other epitopes which 
might alter the subcellular localisation of tau and cause the loss of tau-fyn binding. The 
progressive accumulation of tau into aggregates in AD could also result in the loss of 
the association with fyn. However, it is important to note that correlation analyses do 
not imply causation. Hence, further investigation is required to fully understand the 
relationship between fyn and tau phosphorylation, in particular at the epitopes S214 
and S202, and to determine what relevance this has for AD.  
These data suggest that therapies targeting the expression level of fyn may not be 
beneficial to AD patients, but a fyn kinase inhibitor is currently being tested in phase IIa 
clinical trials as a therapy for AD (Nygaard et al., 2014). If successful, this will provide 
proof-of-concept evidence that reducing fyn kinase activity can be therapeutically 
beneficial for AD patients. It will be interesting to investigate whether fyn inhibition 
affects downstream targets such as tau phosphorylation at specific epitopes, tau 




Chapter 6 Discussion 
The primary aims of this thesis were to investigate and characterise the functional 
implications of interactions between tau and fyn in AD and how this association might 
contribute to mechanisms underlying the development of neurodegenerative disease.  
For several years, research into tau and Aβ-mediated neurodegeneration has 
dominated the field of AD research. The amyloid cascade hypothesis has been a 
leading guide for much of this research (Hardy and Higgins, 1992), although the 
original hypothesis has required significant modification over the years (Hardy, 2009; 
Karran et al., 2011). The amyloid cascade hypothesis posits that the accumulation of 
toxic Aβ peptide in the brain triggers downstream changes in tau, leading to 
synaptotoxicity and neurotoxicity. However, the mechanisms that link Aβ and tau have 
so far been unclear. Mounting evidence points to the tyrosine kinase fyn as an 
important mediator in the signalling cascade between Aβ and tau. Upregulation of fyn 
activity is induced by Aβ (Williamson et al., 2002; Um et al., 2012), and increased fyn 
activity is found in AD brain (Larson et al., 2012). Fyn is a known tau kinase (Lee et al., 
2004), and both tau and fyn co-localise in a subset of degenerating neurons in AD 
(Shirazi and Wood, 1993). The presence of fyn is also required for phosphorylation-
dependent trafficking of tau (Usardi et al., 2011; Pooler et al., 2012). Thus, identifying 
the mechanisms by which tau and fyn may contribute to neurodegeneration will aid in 
understanding the missing mechanisms that link the pathogenesis of Aβ and tau and 
lead to the development of AD. 
The primary findings of the work presented in this thesis are that: 
 Tau is released through activity-dependent mechanisms in organotypic brain 
slices, but this process does not appear to be regulated by fyn. 
 The PXXP motifs located between residues 213-219 of tau are critical for the 
interaction between tau and fyn. 
 The amount of fyn is not altered during the progression of AD, nor is it 
correlated with tau phosphorylation in AD, suggesting that fyn-dependent 





6.1 Regulation of extracellular tau release 
The presence of extracellular tau supports the hypothesis that tau pathology can 
spread in a stereotypic, trans-synaptic manner in the brain of some neurodegenerative 
diseases. Spreading of tau pathology via anatomically-connected pathways was first 
shown in 2009. Injection of brain extracts obtained from P301S tau transgenic mice into 
WT human tau-overexpressing mice resulted in the formation of  tau filaments and over 
time, tau pathology spread beyond the injection site, which could not be explained by 
diffusion alone (Clavaguera et al., 2009). Two further studies have since been 
published that confirm these findings in vivo in mice in which P301L tau expression is 
restricted to the entorhinal cortex. In these mice, tau pathology spreads progressively 
in an age-dependent manner along anatomical pathways to hippocampal neurons that 
do not express the transgene (de Calignon et al., 2012; Liu et al., 2012). Induction of 
tau fibrils was also observed when young P301S tau transgenic mice were injected 
with brain extract from aged P301S tau mice at a time when the recipients were pre-
symptomatic (Ahmed et al., 2014). Tau pathology spread to the contralateral side of the 
brain, as well as to other regions that are anatomically connected to the injection site, 
further supporting the conclusion that tau propagation is trans-synaptic. Taken together, 
these results suggest that rather than tau pathology being spread by diffusion of cell 
contents as a result of cell death, tau propagation is an active process. Notably, 
neurodegeneration or severe neuronal loss was not detected in any of these models, 
suggesting that mechanisms other than the toxic effects of abnormally folded and 
aggregated tau may lead to a loss of neurons in AD. This also indicates that the 
species of transmitted tau may not be solely responsible for neurodegeneration and 
that other toxic tau species are involved, or that propagation of tau pathology occurs at 
an earlier stage of disease prior to widespread neurodegeneration or neuronal loss. At 
a recent meeting, it was reported that mice expressing P301L tau restricted to the 
entorhinal cortex exhibit hypometabolism in the entorhinal cortex and hippocampus by 
two years of age, as determined by functional magnetic resonance imaging (Duff et al., 
2013). Even at two years of age, there is no change in cognitive function as assessed 
by the Morris water maze test (Duff et al., 2013). This is similar to AD patients with 
neuropathology classified as Braak stage I or II, as these individuals exhibit 
hypometabolism but without any overt cognitive symptoms (Duff et al., 2013). 
The mechanisms underlying the spread of tau pathology are not yet understood. If tau 
propagation is indeed trans-synaptic, it must exit the neuron in order to cross the 
synapse into the connected neuron. Hence, it is plausible that tau is normally released 
as a physiological process, and in pathological conditions, toxic species of tau are 
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transmitted, leading to the spread of tau pathology. Tau can be detected in the 
interstitial fluid and cerebrospinal fluid of WT and P301S tau-expressing mice at an age 
when no overt neurodegeneration is detected, suggesting that tau can be secreted into 
the extracellular space under physiological conditions in vivo (Yamada et al., 2011).  
In this thesis, organotypic brain slices were validated for use as a physiologically 
relevant ex vivo alternative to primary neurons, since brain slices express synaptic 
markers within two weeks of preparation and are cultured in the presence of astrocytes 
and glia. The data presented in Chapter 3 show that, similar to primary neurons, tau in 
organotypic brain slices is released into the extracellular medium in an activity-
dependent manner. Importantly, this release of tau is not associated with a significant 
increase in cell death, as measured by lactate dehydrogenase assay. These results 
confirm previous findings in primary rat cortical neurons that tau release can be 
stimulated by neuronal activity (Pooler et al., 2013a). In agreement with these findings, 
it was recently reported that an increase of endogenous tau in the interstitial fluid of WT 
mice could be observed following neuronal depolarisation by potassium chloride. This 
activity-dependent secretion of tau increased from 1-3 hours following stimulation, and 
tau in the interstitial fluid gradually returned to baseline within 5 hours after neuronal 
depolarisation (Yamada et al., 2014). In the studies presented in this thesis, 
extracellular tau in the medium was increased 10-fold following potassium chloride 
stimulation of neuronal activity in organotypic brain slices. Time points longer than 30 
minutes were not examined, although it could be anticipated that the rise in 
extracellular tau and subsequent return to baseline would mirror that observed in vivo 
by Yamada et al. (2014). Herein, the amount of intracellular tau was unchanged 
following activity-dependent secretion of tau, suggesting that the amount of both basal 
and stimulated tau release was very low when considered as a proportion of total 
endogenous tau. The total amount of tau released into the medium was not measured 
in this study, but extracellular tau has been reported to be approximately 40-50 ng/ml in 
the interstitial fluid of WT mice (Yamada et al., 2011). In primary mouse cortical 
neurons, the amount of extracellular tau present under resting conditions has been 
determined to be approximately 2-3% of intracellular tau (Karch et al., 2012). This 
estimate is likely to be similar to the organotypic brain slices used in this thesis, as the 
primary neurons used by Karch et al. (2012) were grown on an astrocyte monolayer, 
reflecting the mixed cell population in organotypic brain slice culture. Given that the 
concentration of neuronal tau is estimated to be 1-2 µM (Iqbal et al., 2010; Zempel and 
Mandelkow, 2014), if the proportion of extracellular tau is 2-3% of total tau, the 
concentration of tau would be approximately 20-60 nM in the culture medium.  
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6.1.1 The role of fyn in tau release 
To investigate the intracellular source from which extracellular tau might originate, we 
hypothesised that a pool of membrane-associated tau, which is a small proportion of 
the total amount of endogenous tau, is released upon stimulation of neuronal activity. 
Fyn is required for the phosphorylation-dependent trafficking of tau to the membrane 
(Pooler et al., 2012), leading to the hypothesis that fyn is required for tau release. 
Interestingly, the results in Chapter 3 show that organotypic brain slices prepared from 
fyn knockout mice did not exhibit a change in the amount of tau released compared to 
that released from WT brain slices. There was also no change in the amount of basal 
tau release in fyn-/- organotypic brain slices compared to WT. These results suggest 
that while fyn plays a role in trafficking proteins, such as tau, ephrin-A, Dab1, and APP, 
to the membrane (Hoe et al., 2008; Baba et al., 2009; Minami et al., 2011; Pooler et al., 
2012), fyn is not involved in the regulation of tau secretion. These results could also 
indicate that the extracellular tau does not originate from the membrane-associated 
pool of tau. It should be noted that the presence of fyn does not affect basal levels of 
membrane tau, so it is also possible that stimulation of neuronal activity would result in 
fyn-independent release of membrane tau. Because phosphorylation of tau changes its 
dynamic association with the membrane through a fyn-dependent mechanism (Pooler 
et al., 2012), another possibility is that phosphorylation of tau could alter tau release by 
a fyn-dependent mechanism. Although this idea was not examined here, the results 
obtained in this thesis suggest that there may be more than one mechanism underlying 
tau release, and that this could be triggered either by neuronal activity or tau 
phosphorylation. Further investigation is required to examine how phosphorylation of 
tau affects its release and whether or not this is a separate mechanism to activity-
stimulated tau release. If so, it will be important to determine whether fyn is involved in 
either mechanism of tau release. 
 
6.1.2 Implications of activity-dependent tau release for AD 
A worthy avenue of investigation is to examine how tau secretion is altered under 
pathological conditions because dysregulation of this process could have implications 
for the propagation of tau pathology in AD. Aggregates of truncated tau injected into the 
brains of mutant P301S tau transgenic mice resulted in decreased tau presence in the 
interstitial fluid in vivo compared to controls (Yamada et al., 2011). Moreover, P301S 
tau transgenic mice secrete reduced amounts of tau into the interstitial fluid over time 
from 6-12 months, whereas the amount of tau in the interstitial fluid remains stable in 
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WT mice over the same period of time (Yamada et al., 2011). As P301S tau mice 
accumulate tau tangles from 6 months of age, the reduction of tau in the interstitial fluid 
accompanies the accumulation of aggregated tau and the corresponding decrease in 
intracellular soluble tau, neither of which events occurs in WT mice (Yamada et al., 
2011). These results suggest that sequestration of soluble tau into aggregates results 
in decreased tau secretion and reduced levels of extracellular tau. In addition, 
destabilisation of microtubules with pseudolaric acid, a microtubule-destabilising agent, 
led to significantly increased extracellular tau amounts, indicating that loss of binding to 
microtubules, one of the major functions of tau, also has significant consequences for 
tau release (Karch et al., 2012). In addition, HEK293T cells expressing mutant P301S, 
P301L, or R406W tau produce less extracellular tau than WT tau-expressing cells 
under basal conditions, in the absence of any detectable changes in the amount of 
intracellular tau (Karch et al., 2012), indicating that some disease-relevant species of 
tau have altered capacity to be released. Activity-dependent tau secretion was also 
unchanged in the presence of soluble Aβ oligomers, nor did the level of basal tau 
decrease with Aβ treatment (Pooler et al., 2013a). Conversely, HeLa cells expressing a 
phospho-mutant of tau in which 12 residues were mutated to glutamate, to mimic a 
state of phosphorylation, secreted considerably more tau than cells expressing WT tau 
(Plouffe et al., 2012). In another study, tau secretion was investigated in primary 
cortical neurons under stress conditions (Mohamed et al., 2014). Nutrient deprivation 
and inhibition of lysosomal function resulted in increased stress and elevated basal tau 
secretion that was not associated with loss of cell viability (Mohamed et al., 2014). 
Hence, a wealth of published literature shows that conditions mimicking disease can 
not only alter intracellular tau function and phosphorylation, but also dysregulate tau 
release, all in the absence of neuronal death. 
Previous work showed that activity-dependent tau secretion, and intracellular tau 
amounts, were unchanged in the presence of soluble Aβ oligomers (Pooler et al., 
2013a). It was an intention of this study to investigate the effects of Aβ on tau release in 
a more physiologically relevant slice culture model. However, results presented in this 
thesis show that it was difficult to demonstrate any biological activity of soluble Aβ, 
including induction of synaptotoxicity, in organotypic brain slices as described in 
Chapter 3. Aβ is known to alter tau phosphorylation and localisation in cultured 
neurons, and therefore it would be of interest to determine whether the effects of Aβ 
also extend to extracellular tau. Further investigation into the effects of abnormal tau 
phosphorylation, excitotoxicity, and Aβ-induced synaptotoxicity will be important in 




6.1.3 Uptake of extracellular tau 
Since tau appears to be propagated between neurons via synapses, it follows that the 
released tau must be taken up by connecting neurons. Therefore, organotypic brain 
slices were examined for uptake of released tau. Medium from WT organotypic brain 
slices stimulated with potassium chloride were collected and used as the source of 
extracellular tau, since we previously found that depolarisation of neurons by 
potassium chloride induces a 10-fold increase of extracellular tau. The medium from 
stimulated neurons was used to treat tau-/- organotypic brain slices, so that the uptake 
of exogenous tau could be identified. Unfortunately, it was not possible to detect uptake 
of tau into neurons on western blots. It is likely that this apparent absence of tau 
internalisation may be due to methodological issues, and more sensitive methods such 
as ELISA should be used in future studies. In one study, exogenous low molecular 
weight tau aggregates, mainly comprised of dimers and trimers of tau, added to the 
culture medium of tau-/- primary neurons were internalised after six hours of incubation 
(Wu et al., 2013). It was also demonstrated that approximately 100 ng of tau 
aggregates per mg of total protein was taken up (Wu et al., 2013). Thus, if the ratio of 
internalised tau to total tau was similar in the experiments carried out in Chapter 3, 
given that the concentration of extracellular tau is likely to be very low, the minute 
amount of internalised tau may not be detectable by on western blots. In addition, the 
rate of extracellular tau uptake may be slow and, in the experiments carried out in 
Chapter 3, there may have been insufficient contact time (4 hours) with extracellular 
tau for internalisation. The characterisation of endogenous tau uptake in neurons 
should be further investigated, with increased incubation of tau-containing medium with 
the slices, in combination with a more sensitive detection method such as ELISA or 
immunofluorescence. The former method would allow for quantification of the ratio of 
internalised tau to total extracellular tau, and the latter method would enable 
identification of the subcellular localisation of internalised tau.  
Preliminary data by Karen Duff’s laboratory has shown that cyan fluorescent protein-
tagged tau is released by neurons prepared from rTg4510 mice expressing mutant 
P301L tau, and is subsequently taken up by tau knockout neurons. Once internalised, 
which can take up to six days, extracellular tau accumulates at dendritic spine-like 
structures. Uptake of endogenous tau was also investigated using conditioned media 
from neurons derived from induced pluripotent stem cells (iPSC). When conditioned 
media from WT iPSC-neurons was incubated with neurons prepared from tau knockout 
mice, human tau was also taken up by the mouse neurons, where it accumulated in 
lysosomes as determined by co-localisation with lysosomal-associated membrane 
protein 1 (Lamp1) (Karen Duff, personal communication). These preliminary results 
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indicate that endogenous, non-pathogenic tau can be transmitted between neurons. 
Nevertheless, it will be important to characterise endogenous tau uptake in organotypic 
brain slices, as the presence of glial cells may influence the uptake of extracellular tau. 
Several different mechanisms for neuronal uptake of tau have been proposed (Figure 
6.1). The precise mechanisms of tau uptake may be dependent on the form of secreted 
tau. Some groups have reported that extracellular tau could be associated with 
vesicular membranes, such as exosomes or ectosomes, which could lead to fusion of 
vesicle-associated tau with the plasma membrane of recipient neurons (Lee et al., 
2012; Saman et al., 2012; Simón et al., 2012b; Dujardin et al., 2014). However, we and 
others have reported that the majority of soluble full-length extracellular tau is not 
associated with exosomes, suggesting that tau is not secreted within a membranous 
structure (Karch et al., 2012; Pooler et al., 2013a). Non-exosomal tau could be taken 
up by endocytosis, or by direct penetration of the plasma membrane and this may 
depend on the conformation of extracellular tau. One study by Wu et al. (2013) 
suggests that pathological forms of tau are taken up by bulk endocytosis in neurons. 
Using a microfluidic chamber culture system that separates primary neurons into 
somatodendritic and axonal compartments, aggregated tau was added to the 
somatodendritic compartment (Wu et al., 2013). Tau aggregates bound to the neurons 
and were anterogradely transported to the axon, and tau was also internalised and 
transported retrogradely upon addition of tau aggregates to the axonal compartment 
(Wu et al., 2013). Internalised tau co-localised with dextran and was trafficked to 
lysosomes, indicating that tau aggregates were taken up by bulk endocytosis (Wu et 
al., 2013). Macropinocytosis, a form of bulk endocytosis, has also been proposed to 
underlie the uptake of aggregated tau (Holmes et al., 2013; Falcon et al., 2014). 
Alternatively, nanotubes, which are extracellular tunnel-like structures that connect two 
cells, have been proposed as a method for transmission of pathological forms of 
proteins, such as the pathogenic prion protein and mutant huntingtin, between neurons 
(Gousset et al., 2009; Costanzo et al., 2013). Thus transmission of pathological forms 
of neuronal tau could also involve nanotubes.  
The uptake of monomeric, physiological tau is less well-studied and recombinant 
monomeric tau has been reported to be rapidly internalised by human neuroblastoma 
cells within 1 hour (Michel et al., 2014). Receptor-mediated endocytosis has also been 
suggested to be responsible for uptake of monomeric tau. Addition of tau protein to 
COS-7 cells results in direct interaction of tau with M1 muscarinic receptors, leading to 
receptor activation and induction of intracellular calcium currents (Gómez-Ramos et al., 
2009). This suggests that soluble, monomeric tau could play a role in signalling 




Figure 6.1 Potential mechanisms of tau secretion and uptake in neurons 
Possible mechanisms underlying cell-to-cell transmission of neuronal tau. Tau can be 
released into the extracellular space as (1) vesicle-bound tau, such as in exosomes, or 
(2) free tau. (3) Tau could also be transferred between neurons through nanotubes. 
Uptake of tau could result from (4) bulk endocytosis, (5) exosomal fusion to the plasma 
membrane of the recipient cell, (6) direct penetration of tau into the plasma membrane, 




Acetylcholine, a muscarinic agonist, has been shown to potentiate NMDA receptor 
currents in response to NMDA and glutamate (Markram and Segal, 1990). The 
potentiating effect on NMDA receptor currents of carbachol, a muscarinic receptor 
agonist, was blocked by M1-toxin (Marino et al., 1998). As M1-toxin is a highly specific 
M1 muscarinic receptor antagonist, these data suggest that NMDA receptor currents 
can be mediated by M1 muscarinic receptor agonists. If extracellular tau can indeed 
bind to M1, and in fact tau has been shown to elicit greater calcium responses than 
acetylcholine alone (Gómez-Ramos et al., 2009), this would suggest that tau-mediated 
M1 receptor activation can modulate NMDA receptor currents. A proposed model that 
might explain this could involve the activation of M1 receptors by extracellular tau, 
eliciting an intracellular calcium response (Figure 6.2). In this model, extracellular tau 
could be internalised by M1 receptor-mediated endocytosis. While it remains at the 
post-synaptic density, endocytosed tau could bind to fyn, promoting its association with 
PSD-95 and the NR2b subunit of the NMDA receptor. This postsynaptic complex would 
stabilise the NMDA receptor, potentiating NMDA receptor-mediated activity, leading to 
increased intracellular calcium currents. If this model is correct, under pathological 
conditions, aberrant tau release could lead to increased intracellular calcium mediated 
by M1 and subsequently NMDA receptors. This would provide an explanation for the 





Figure 6.2 Model of extracellular tau binding on M1 and modulation of NMDA 
receptors  
This schematic illustrates a candidate role of extracellular tau in neuronal signalling. 
Dynamic phosphorylation of tau regulates its trafficking from the cytosol to the plasma 
membrane. Upon induction of neuronal activity, tau is released at the pre-synaptic 
terminal.  This pool of tau could originate from the cytosol, or from the membrane. 
Extracellular tau binds to and activates post-synaptic M1 muscarinic receptors. 
Internalised tau can then bind to dendritic fyn, and both proteins co-translocate to the 
NMDA receptors where fyn phosphorylates the NR2b subunit and forms a complex with 
PSD-95. This facilitates NMDA receptor signalling. In pathological conditions, aberrant 




6.1.4 Extracellular tau as a therapeutic target 
Extracellular tau makes an attractive target for therapy because it is more accessible to 
tau-targeted therapies than intracellular tau. The discovery that tau pathology can be 
transmitted from cell to cell suggests that targeting the extracellular tau may be able to 
stop or slow the progression of tau-mediated neurodegeneration. However, data 
presented in this thesis and elsewhere (Pooler et al., 2013b; Yamada et al., 2014) 
indicate that tau can be secreted from neurons under physiological conditions, in a 
process regulated by synaptic activity. For this reason, therapeutics that target 
extracellular tau should be designed to distinguish between physiological and 
pathological forms of extracellular tau, to avoid side effects originating from loss-of-
function of normal tau. It is therefore important to determine if the species of secreted 
tau differs in physiological and pathological conditions. In addition, AD-related 
excitotoxicity could also contribute to aberrant tau release.  In AD, tau becomes 
missorted to the somatodendritic area, where it normally interacts with fyn to stabilise 
the NMDA receptor complex with PSD-95, a postsynaptic scaffolding protein (Ittner et 
al., 2010).  Under pathological conditions, increased association of tau and fyn caused 
by mislocalisation of tau could lead to NMDA receptor-mediated excitotoxicity.  Since 
tau release is regulated by neuronal activity via AMPA and NMDA receptors (Pooler et 
al., 2013a; Yamada et al., 2014), this could lead to increased release of tau at the 
synapse due to  positive feedback mechanisms. Such a mechanism would induce local 
spreading of tau pathology, as it has been shown that tau pathology can spread in both 
anterograde and retrograde directions (Wu et al., 2013).  
Passive antibody immunisation is one strategy that can be used to target extracellular 
tau and the efficacy of such treatments has been demonstrated both in vitro and in 
vivo. A mouse monoclonal antibody raised against tau, HJ9.3, prevented tau 
aggregation in acceptor cells when co-cultured with donor cells expressing 
fluorescently-tagged tau (Kfoury et al., 2012). In this study, HEK293 cells were 
transfected with a tau fragment containing only microtubule repeat domains of tau, 
which leads to formation of fibrils when expressed in cultured cells. The donor cells 
expressed this truncated tau construct containing two aggregant-prone mutations 
within the repeat domain, while a form of tau containing only one mutation in the repeat 
domain was expressed in the acceptor cells. The tau constructs were tagged with 
yellow or cyan fluorescent protein, which enabled quantification of aggregate formation 
by fluorescence resonance energy transfer. This treatment was deemed to be specific 
for extracellular tau, because addition of antibody HJ9.3 did not prevent intracellular tau 
aggregation in a single cell population expressing the repeat domain of tau with 
aggregant-promoting mutations (Kfoury et al., 2012). Labelling with an anti-mouse 
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secondary antibody to detect HJ9.3 showed that tau fibrils bound to antibody 
complexes were mainly found at the cell surface, suggesting that HJ9.3 blocks uptake 
of extracellular tau by sequestration outside the cell (Kfoury et al., 2012). Passive and 
active immunisation targeting tau phosphorylated at S396/S404 has also been shown 
to effectively reduce insoluble tau aggregates and ameliorate some behavioural tests in 
P301L tau transgenic mice, although these studies did not determine whether the 
antibodies entered the cells and bound to intracellular tau (Boutajangout et al., 2011; 
Chai et al., 2011).  
Immunotherapy studies have also been carried out using antibodies that target different 
epitopes in 3xTg mice which express mutations in APP, tau, and presenilin (Walls et al., 
2014), htau mice overexpressing all six isoforms of human WT tau in the absence of 
mouse tau (Castillo-Carranza et al., 2014a), P301S tau mice (Yanamandra et al., 
2013), and P301L tau mice (Castillo-Carranza et al., 2014b). Immunisation of 3xTg 
mice with the AT8 antibody, which recognises phosphorylated tau at S202/T205, 
transiently decreased the amount of tau at the somatodendritic area and overall AT8 
immunoreactivity without affecting Aβ pathology from 7-14 days post-immunisation 
(Walls et al., 2014). In contrast, immunisation of 3xTg mice with the 4G8 antibody, 
which recognises Aβ, reduces both Aβ pathology and neurofibrillary tangles within a 
week (Walls et al., 2014). Chronic injection of a monoclonal antibody recognising 
oligomeric tau (TOMA) in htau mice resulted in improved cognitive function as 
assessed by the novel object recognition task, and reduced levels of oligomeric tau 
(Castillo-Carranza et al., 2014a). In addition, immunisation of P301S mice with anti-tau 
antibodies reduced AT8 tau-positive immunoreactivity as well as insoluble tau levels, 
and rescued deficits in contextual fear conditioning (Yanamandra et al., 2013). 
Furthermore, injection of the antibody TOMA into P301L mice improved deficits in the 
rotarod test, reduced the level of oligomeric tau, and reduced phosphorylation of tau at 
several epitopes (Castillo-Carranza et al., 2014b). Moreover, immunotherapy has been 
shown to be effective for clearance of other pathological proteins relevant to 
neurodegenerative disease, such as Aβ (Bard et al., 2000; Morgan et al., 2000; 
Sigurdsson et al., 2001), α-synuclein (Masliah et al., 2011; Bae et al., 2012; Tran et al., 
2014), and superoxide dismutase 1 (SOD1) (Gros-Louis et al., 2010). It remains to be 
seen whether the results from tau immunotherapy studies in animal models can 
translate to efficacy in humans. These studies are therefore proof-of-principle 
experiments that demonstrate the effectiveness of extracellular tau as a therapeutic 
target. Alternative approaches to further refine drug treatments that inhibit tau 
propagation without affecting physiological tau signalling should be encouraged. 
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6.2 Association between tau and fyn in AD 
Altered gene or protein expression, or altered localisation or structure of a protein in 
pathological conditions, points towards a mechanistic role for that protein in disease. 
Fyn expression, as well as the ratio of soluble to insoluble fyn, is altered in AD (Shirazi 
and Wood, 1993; Ho et al., 2005). The accumulation of insoluble fyn protein is 
associated with the progression of AD, when correlated with cognitive measures 
including the MMSE score, and with the progressive accumulation of neurofibrillary 
tangles (Ho et al., 2005). Moreover, fyn activity is increased in brains of AD patients 
compared to controls and individuals with MCI (mild cognitive impairment), whereas 
total levels of fyn remain unchanged over the course of disease (Larson et al., 2012). 
Fyn phosphorylates tau at Y18, and increased phosphorylation at this epitope can be 
observed in some neurofibrillary tangles in AD (Lee et al., 2004). Together, these data 
indicate that the relationship between fyn and tau is important in AD.  
To determine whether changes in the association of these proteins were apparent in 
AD brain, samples of brain tissue from AD and control individuals were analysed by 
western blot for tau and fyn expression. Statistical analyses were carried out in order to 
establish whether there is a relationship between tau and fyn expression. Total levels of 
fyn were unchanged between control and late-stage AD (Braak stages V-VI) samples, 
confirming previously reported findings (Ho et al., 2005; Larson et al., 2012). Fyn 
expression over the course of disease was also investigated in controls and AD 
samples ranging from Braak stages I-VI. There was no change in total fyn expression 
over time in AD compared with control whole brain homogenates.  In contrast to 
findings from Ho et al. (2005), levels of soluble fyn were also unchanged during the 
progression of disease, although this discrepancy may have been due to the low 
numbers of samples used here. Although total levels of fyn were unchanged throughout 
all stages of AD, we hypothesised that expression of fyn could correlate with tau 
phosphorylation, as it has been shown that fyn levels correlate with PrPC irrespective of 
AD status (Larson et al., 2012).  
This is the first study to investigate relationships between fyn expression and tau 
phosphorylation in AD. Although phosphorylation at several epitopes of tau (S199, 
S262, S396/S404) was increased at late stages of AD, there was no relationship 
between increases in the amount of tau phosphorylated at these epitopes and the 
amount of fyn present in the same brain samples. Interestingly, although tau 
phosphorylated at S214 was unchanged between control and AD samples, the amount 
of fyn was significantly correlated with tau phosphorylation at S214 in control samples, 
but not AD brain. Likewise, fyn was significantly correlated with phosphorylation at 
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S202 of tau in control, but not in AD brain. These results indicate that there is a 
relationship between fyn and tau phosphorylated at S202 and S214 under normal 
conditions, but this link is lost in AD, at least in Braak stages V-VI. 
It is apparent that one of the disease mechanisms underlying AD triggers the 
dissociation between tau pS202/pS214 and fyn. Phosphorylation at S202 of tau can 
increase its propensity to polymerise (Rankin et al., 2005), and as this epitope is 
increasingly phosphorylated in AD, the structural changes of tau that is caused by 
phosphorylation at this site may result in the inability of tau to bind to fyn during the late 
stages of AD. Phosphorylation at S214 regulates tau binding to microtubules. If tau 
S214 is increasingly phosphorylated in AD, and fyn levels are no longer correlated in 
pathogenic conditions, this could suggest that fyn is unable to associate with tau during 
late stage AD. Interestingly, mice expressing a constitutively active form of fyn have 
increased tau phosphorylation at S202/T205 (Xia and Gotz, 2014). This suggests that 
fyn has an indirect effect on phosphorylation at this epitope, which the results 
presented here suggest could be out-competed in AD as other kinases and 
phosphatases become dysregulated. 
Unexpectedly, given the wealth of data supporting a direct interaction between tau and 
fyn, we were unable to identify this interaction by co-immunoprecipitation of the 
endogenous rodent proteins, in contrast to other groups (Ittner et al., 2010; 
Mondragon-Rodriguez et al., 2012). Data presented in this thesis and previously 
published literature have demonstrated that tau and fyn can interact directly in neurons 
in vitro (Lee et al., 1998; Usardi et al., 2011; Pooler et al., 2012), although many of 
these studies involved the use of recombinant SH2 or SH3 domains of fyn. Taken 
together, these findings could suggest that the tau-fyn interaction is transient in vivo 
and requires very specific conditions in order to be detected biochemically. 
Furthermore, the stoichiometry of the tau-fyn interaction is not known. Of the total 
amount of tau present in neurons, it is likely that the majority of tau is bound to 
microtubules, and only a minor fraction of unbound tau is present at the dendrite. This 
small amount of tau may be sufficient to carry out its functions in neuronal signalling, in 
conjunction with fyn, but it may be insufficient for detection biochemically unless a large 
amount of starting material is available. To fully understand the interaction between tau 
and fyn, it will be important to determine the nature of the tau that is bound to fyn, and 
the temporal nature of fyn activation in relation to tau binding. This can be determined 
by immunofluorescence using specific antibodies recognising phosphorylated forms of 
tau to examine which species of tau co-localises with fyn. In addition, imaging methods, 
such as Duolink, enable detection of protein-protein interactions in neurons, using 
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proximity measures. These experiments could be used in conjunction with phospho-
specific antibodies to tau and fyn without resorting to over-expression of either protein. 
6.3 Identification of the binding site between tau and fyn 
The interaction of tau and fyn at dendritic spines in neurons has implications for AD, as 
mislocalisation of tau to the dendrite, in association with fyn, may facilitate increased 
NMDA receptor-mediated excitotoxicity (Ittner et al., 2010). This hypothesis is 
supported by data showing that exposure to Aβ induces translocation of tau and fyn 
from the dendritic shaft to the postsynaptic density, ensuring that these proteins are in 
the correct place to perform their function of stabilising NMDA receptors (Frandemiche 
et al., 2014). Increased NMDA receptor activity promotes association of fyn with 
phosphorylated tau at the synapse, which could result in a positive feedback cycle of 
NMDA receptor-mediated excitotoxicity (Mondragon-Rodriguez et al., 2012). Thus 
targeting tau or fyn, or inhibiting their interaction, is a rational target for AD therapy. 
To do that, it is critical to find the binding site between tau and fyn, which was one of 
the principal aims of Chapter 4. Fyn, like other members of the src kinase family, is 
comprised of four src homology (SH) domains. The binding between tau and fyn was 
first confirmed in primary neurons, where tau binds to both fyn-SH2 and fyn-SH3 
(Figure 6.3), confirming previous studies (Reynolds et al., 2008; Usardi et al., 2011; 
Pooler et al., 2012). As the dominant domain of interaction between tau and fyn 
appears to be fyn-SH3, the binding site between tau and fyn-SH3 was selected for 
further investigation.  SH3 domains are known to recognise and bind to PXXP 
sequences (proline-X-X-proline, where X is any amino acid) (Ren et al., 1993; Cheadle 
et al., 1994; Sparks et al., 1994). In its proline-rich region, tau contains seven PXXP 
motifs that are possible candidates for interacting with fyn-SH3. The studies carried out 
in Chapter 4 are the first to examine each PXXP motif in tau for their ability to bind to 
fyn-SH3 while conserving the structure of full-length intact tau in the experimental 
design. First, single proline residues within PXXP motifs of tau were substituted with 
alanine, generating tau constructs harbouring individual mutations in each PXXP motif. 
Using GST pull-down assays with fyn-SH3 beads and CHO cells expressing WT or tau 
containing mutant PXXP motifs, the sixth PXXP motif at 216-219 of tau was identified 
as a critical binding site for fyn-SH3. The residues surrounding 216-PXXP-219 of tau 
can also modulate the interaction of tau with fyn-SH3, as it was shown that substitution 
of proline 213 of tau with alanine enhanced the binding affinity between tau and fyn-
SH3.  Taken together, the work here shows that the sixth PXXP motif of tau is a major 
site for interaction with fyn-SH3, whereas modification of residues, particularly in close 




Figure 6.3 Interactions between tau and fyn-SH2 and SH3 domains  
Fyn contains 4 SH (src homology) domains (SH1-4), of which the SH2 domain 
recognises tyrosine residues, and the SH3 domain recognises PXXP motifs. Tau can 
bind to fyn at either the SH2 or SH3 domain. (A) The major binding site for tau-fyn 
interaction is located between PXXP motifs at residues 216-219 of tau and fyn-SH3. 
(B) Tau also binds to fyn-SH2 but with weaker affinity. The binding site on tau is not 
known, but phosphorylation at Y18 of tau regulates binding between tau and fyn-SH2. 
The microtubule binding repeats of tau are labelled as R1-4 and the N- and C-termini 
are indicated. Further information about the functions of the SH domains is discussed 




Previous in vitro studies undertaken to identify the binding site between tau and fyn-
SH3 utilised truncated tau constructs or tau peptides. The first of these studies 
proposed that the seventh PXXP motif at tau residues 233-236 was the major binding 
site for fyn-SH3 (Lee et al., 1998). In this report, tau peptides containing C-terminal 
deletions, generating truncated tau constructs with or without PXXP motifs, were 
incubated with fyn-SH3 in a GST pull-down assay. Deletion of tau 222-441 abolished 
binding with fyn-SH3, leading to the conclusion that the PXXP motif at 233-236 was 
required for tau-fyn binding (Lee et al., 1998). A subsequent in vitro binding assay 
showed that a recombinant tau peptide spanning the two tandem motifs at 213-219, but 
not 233-236, of tau could bind to fyn-SH3 (Reynolds et al., 2008). Further investigation 
by Ittner et al. (2010) revealed that deletion of the PXXP motif at 233-236 and the C-
terminal half of tau significantly decreased interaction of tau with fyn. However, binding 
was not completely abolished until PXXP constructs C-terminal to tau residue 196 were 
removed (Ittner et al., 2010). The nature of truncated tau peptides could lead to 
conformational changes in tau that could influence protein-protein interactions, which 
underscores the importance of using intact tau constructs for such experiments. More 
recently, two additional studies have attempted to identify the PXXP motif recognised 
by fyn-SH3 using intact full-length tau. In agreement with our findings, both studies 
conclude that of the PXXP motifs investigated, PXXP motifs in the region of 213-219 of 
tau are the most likely sites for binding with fyn-SH3 (Usardi et al., 2011; Cochran et 
al., 2014). 
The experiments presented in this thesis address many of the pitfalls of using truncated 
tau mentioned above by instead using intact full-length tau expressed in CHO cells for 
GST pull-down with fyn-SH3 beads. This allows examination of the tau-fyn interaction 
in a cellular system which is more physiologically relevant than testing the binding 
efficacy of recombinant peptides in vitro. Nevertheless, CHO cells are a non-neuronal 
cell line and hence these experiments in CHO cells were intended as preliminary 
experiments to identify the binding site for tau and fyn. In particular, the aims were to 
determine what the effects of PXXP mutations would have on tau release and on tau 
and fyn trafficking, and whether the PXXP mutations influenced the susceptibility of 
neurons to Aβ toxicity. Since both tau and fyn are reported to play roles in trafficking to 
the dendrite and the plasma membrane (Ittner et al., 2010; Pooler et al., 2012), 
inhibition of tau-fyn binding would be expected to sequester both proteins in the 
cytosol. Moreover, given that reduction of tau or fyn confers neuroprotection from Aβ 
toxicity (Lambert et al., 1998; Rapoport et al., 2002; Chin et al., 2004; Roberson et al., 
2007; Shipton et al., 2011), inhibiting the interaction between tau and fyn may also be 
sufficient for resistance to Aβ toxicity. Thus, the constructs containing mutations in 
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P213, P216, and P219 of tau were used to generate lentiviruses, as mutations at these 
sites had the most significant effects on tau-fyn binding. Lentiviruses were engineered 
to contain a synapsin promoter to enable neuron-specific expression of tau, along with 
an independently expressed fluorescent EGFP reporter protein. Subsequent 
generation of lentiviruses expressing tau with individual mutations in PXXP motifs were 
to be used to investigate functional downstream consequences on tau and fyn in 
organotypic brain slices. Expression of lentiviral tau was successful in primary neurons, 
but unfortunately this was not detectable following lentiviral transduction of organotypic 
brain slices. This lack of expression was likely due to methodological difficulties caused 
by inaccessibility of lentivirus particles to the neurons in slice cultures. It is possible 
that, with further optimisation, lentiviral expression of mutant PXXP tau in organotypic 
brain slices would have been sufficient to allow further functional experiments, but this 
remains to be determined experimentally. One alternative approach would be to inject 
lentivirus into the brains of tau-/- mice prior to the preparation of organotypic brain 
slices, to circumvent possible obstruction of virus internalisation by the glial scar that 
forms over cultured brain slices. Another approach could be to treat organotypic brain 
slices from WT mice with a peptide spanning the sixth PXXP motif to attempt to block 
the interaction of fyn with endogenous tau. 
 
6.3.1 Inhibition of tau-fyn interaction: a viable therapy? 
It is important to note that the substitution of proline with alanine at residues P216 and 
P219 in tau did not completely abolish its binding to fyn. Likewise, although neuronal 
tau preferentially binds to fyn-SH3 relative to fyn-SH2, data presented in Chapter 4 
demonstrate that tau can also bind to fyn-SH2 in neurons, in agreement with a previous 
report from this laboratory (Usardi et al., 2011). Therefore, although the majority of the 
tau-fyn interaction is likely mediated by the SH3 domain of fyn, it is possible that 
inhibition of binding between tau and fyn-SH3 may not entirely prevent the association 
of tau with fyn. It is possible, however, that the downstream functional effects on tau 
may differ according to which domain of fyn is bound to tau. Blocking the interaction 
between tau and fyn-SH2, as opposed to fyn-SH3, could confer different consequences 
for tau function and/or phosphorylation, and for mediating Aβ neurotoxicity. For 
example, Y18 was previously shown to mediate binding between tau and fyn-SH2, and 
altering the tyrosine phosphorylation of tau disrupts its trafficking to lipid rafts (Usardi et 
al., 2011). It is important to determine which binding site mediates the pathological 




More investigation is also needed to determine how modifications of tau affect its 
affinity with fyn. For example, 3R tau binds to fyn-SH3 with higher affinity than 4R tau 
(Bhaskar et al., 2005; Cochran et al., 2014). In addition, phosphorylation of tau at 
epitopes abnormally phosphorylated in AD has been shown to increase the association 
of tau with fyn-SH3 (Bhaskar et al., 2005; Cochran et al., 2014). Furthermore, 
pseudophosphorylation of tau by amino acid substitution of serine/threonine to 
glutamate at tau residues S199, S202, T205, S262, S293, S324, S356, or S404 
increases the association of 4R tau with fyn (Bhaskar et al., 2005; Cochran et al., 
2014). These data are in contrast to results from the study by Reynolds et al. (2008). In 
this study, the authors investigated binding of phosphorylated 2N4R tau to fyn-SH3 by 
using tau constructs that contained substitutions of 10 or 18 serine/threonine tau 
residues to glutamate to mimic phosphorylation (residues S198, S199, S202, T231, 
S235, S396, S404, S409, S413, S422; or residues S46, T50, T69, T111, T153, T175, 
T181, S198, S199, S202, T205, S208, S210, T212, S214, T217, T231, S235, 
respectively). It was reported that the pseudophosphorylated tau constructs exhibited 
reduced binding to fyn-SH3 compared to WT tau (Reynolds et al., 2008). Discrepancies 
of the results obtained from the tau-fyn binding assays could stem from the 
combination of phospho-epitopes that were mutated in the tau constructs in the 
Reynolds et al. (2008) study, as opposed to the individual glutamate substitutions in the 
two former studies. Nonetheless, further experiments are required to clarify the effect of 
tau phosphorylation on its association with fyn-SH3. Collectively, these studies suggest 
that modifications of tau that lead to structural or phosphorylation changes could 
regulate tau-fyn interactions. In AD, the oligomerisation and abnormal phosphorylation 
of tau could result in altered tau-fyn binding, leading to dysfunction in the stabilisation 
of NMDA receptors and possibly other downstream effects.  
One recently published study has suggested the use of small peptides to inhibit tau-fyn 
binding as a potential therapy for AD. A fluorescent cell-based assay (bioluminescence 
resonance energy transfer; BRET) has been developed to screen molecules for their 
ability to modify the interaction between tau and fyn-SH3 (Cochran et al., 2014). In this 
study, fyn-SH3 was tagged with click beetle green luciferase, while 2N4R tau was 
tagged with a far red fluorescent reporter. Upon association of tau with fyn-SH3, the 
donor luciferase fused to fyn-SH3 is in close proximity to the fluorescent acceptor-
tagged tau, leading to energy transfer that can be measured by fluorescence. Dozens 
of compounds were screened with the BRET assay and several hits were identified that 
could inhibit the tau-fyn interaction (Cochran et al., 2014). Using this assay, it will be 
possible to identify hits that can modify interactions between pseudophosphorylated tau 
and fyn-SH3, which may be of relevance for AD. Importantly, the results presented in 
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this thesis indicate that the effects of post-translational modification of residues 
surrounding the sixth PXXP motif at residues 216-219 of tau should be taken into 
account when screening for tau-fyn-SH3 small molecule inhibitors. Since the 
pathological conditions in AD induce aberrant tau phosphorylation and structural 
changes, kinases that phosphorylate residues surrounding the sixth PXXP motif may 
be putative candidates. In addition, it would be interesting to modify the BRET assay so 
that compounds that block tau and fyn-SH2 interactions can be screened, which would 
provide additional insight into the functional effects of tau-fyn-SH2 binding. 
 
6.4 Concluding remarks  
Research in AD has grown from focusing on the pathogenic roles of tau and Aβ in 
neurons to studying the involvement of many other proteins and cell types. Multiple 
proteins are dysregulated in AD, and several pathways have been identified that might 
contribute to AD pathogenesis. This thesis focuses on the roles of tau and fyn in AD 
and contributes novel findings to elucidate the relationship between tau and fyn in 
normal and pathogenic conditions. Thus, release of tau can be induced by neuronal 
activity in organotypic brain slices, but this process does not seem to be regulated by 
the presence of fyn. Moreover, tau binds to both fyn-SH2 and fyn-SH3 in neurons, but 
shows more preference for binding with fyn-SH3 compared to fyn-SH2. Interactions 
between tau and fyn-SH3 are mediated primarily by the sixth PXXP motif at residues 
216-219 of tau, and residues surrounding these motifs can also modulate the degree of 
binding between tau and fyn-SH3. In particular, phosphorylation of serine/threonine 
residues in close proximity to this PXXP motif such as S210, T212, S214, and T217 of 
tau, which are detected in AD brain, could regulate the interaction between tau and fyn-
SH3. Finally, a correlation was observed between tau phosphorylation at specific 
residues and fyn protein amounts in control, but not AD human brain tissue, suggesting 
that the functional associations between these two proteins could be dysregulated in 
AD. The work presented in this thesis paves the way for further research to address 
questions that remain unanswered concerning the physiological and pathological 
consequences of tau interactions with fyn. 
In particular, the role of extracellular tau remains to be elucidated. If tau is involved in 
normal neuronal signalling, then this is a novel role for tau that is not properly 
understood. Activation of muscarinic receptors by tau has been demonstrated (Gómez-
Ramos et al., 2009), but in a relatively artificial system and therefore this needs to be 
replicated with endogenous proteins in neurons. Additionally, the effects of 
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phosphorylation on tau release are unclear; in particular, evidence is needed to 
demonstrate whether tau phosphorylation regulates the amount and to identify the 
species of tau that is released from neurons. 
It is important to determine the effect of Aβ on tau-fyn interactions, and in particular 
whether Aβ potentiates or disrupts the tau-fyn interaction. Previous studies have shown 
that Aβ treatment causes translocation of tau to dendrites, activation of fyn, and 
phosphorylation of tau at Y18, but any functional effects of fyn-mediated Y18 
phosphorylation under pathological conditions have yet to be described. Y18 tau 
phosphorylation can regulate association of tau with fyn-SH2, but not fyn-SH3 (Usardi 
et al., 2011). Tyrosine phosphorylation of tau can also regulate its association with lipid 
rafts (Usardi et al., 2011). Because fyn is required for this process (Usardi et al., 2011; 
Pooler et al., 2012), it could mean that fyn-mediated phosphorylation of tau at Y18 
influences its association with membranes. It will be important to determine whether 
binding of tau with fyn-SH2 results in different downstream effects than interaction with 
fyn-SH3, since these effects appear to be differentially regulated by phosphorylation at 
serine, threonine, and tyrosine residues. Although the binding site between tau and fyn-
SH3 has been identified, SH2 domains do not recognise PXXP motifs. Thus the 
structural characteristics of interaction with tau and fyn-SH2 may differ, and 
experiments to block tau-fyn-SH2 binding will also be important to elucidate the 
functional consequences of tau-fyn interactions in pathological conditions.  
Collectively, results from this thesis show that further investigation into interaction 
between tau and fyn in AD will be important for further understanding the role of these 
proteins in AD pathogenesis and for developing future therapeutics that may be able to 
halt or slow disease progression. Furthermore, the work presented here also highlights 
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